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Preface 
Aortic stenosis is a major health problem with large personal and economic impact. In 
the last decades there has been a trend of worldwide aging, and diseases which are
common in elderly people will take an important place in clinical practice.  Aortic
stenosis affects 3-5 percent of persons older than 65 years and leads to greater 
morbidity and mortality than other cardiac valve diseases. Currently, aortic stenosis is
the most frequent heart valve disease in industrialized countries and its prevalence
increases with age. Thus with the prolongation of life expectancy, the population of
patients with aortic stenosis is expected to grow in the future. The etiology of this
disease is changing and is more precisely specified. Diagnostics is changing with new 
trends and technical developments in echocardiography. Guidelines and indications
for aortic valve replacement are changing thanks to new trends in anesthesiology, 
surgery and mini-invasive approaches. Patients previously considered too old or ill
are now indicated for aortic valve replacement procedures. 
The approach and management of isolated aortic valve stenosis between fetal life and
late adolescence is discussed in the first chapter. Bicuspid aortic valve as a most 
common form of congenital valve stenosis, is also described. Since approximately 2% 
of people over the age of 65, 3% of people over the age of 75, and 4% of people over
the age of 85 have the disorder, important geriatric aspects of aortic stenosis are 
discussed in the second chapter. Highly accurate indications are extremely important 
in future treatment decisions. Abnormal left ventricular response to exercise and
change in the hemodynamic severity of the valvular disease add to the prognostic 
value of clinical symptoms.  Therefore stress testing is debated in the third chapter. 
Successful valve replacement surgery in elderly and often polymorbid patients with 
congestive heart failure would not be possible without properly aimed modern 
anesthesia and monitoring. Patients formerly considered inoperable are now profiting 
from valve replacement procedures. Challenges in anesthesia and post-surgical care
are described in chapter four. The only mode of treatment of highly calcified 
degenerated native aortic valve is its replacement. In chapter five types of surgical 
approaches and valve prostheses are discussed. 
Currently, there is no artificial aortic valve prosthesis hemodynamically equal to 
native healthy aortic valve. The condition, where the prosthesis orifice is distinctly
smaller for a given patient than natively appropriate is defined as patient-prosthesis 
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mismatch. Clinical importance of this phenomenon is the subject of chapter six. Atrial 
fibrillation is the most common concurrent arrhythmia associated with heart valve 
diseases and is very poorly tolerated by patients. Sinus rhythm restitution contributes 
to hemodynamic heart output increase and clinical status improvement. Atrial 
fibrillation treatment modalities are debated in chapter seven. Despite increasing 
safeness of standard aortic valve replacement surgery, it is still greatly complex 
procedure connected with possible adverse complications especially in polymorbid 
elderly patients. Therefore an effort to decrease extensiveness of surgery has led to 
development of mini-invasive approaches and procedures. These principles and 
techniques, which are still evolving, are discussed in the final chapter. 
Limited volume of this book cannot substitute comprehensiveness of textbooks, but 
tries to depict current advances in aortic valve stenosis evaluation and treatment. 
 
Petr Šantavý, M.D., Ph.D. 
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Aortic valve stenosis is the obstruction to outflow from the left ventricle because of an 
abnormal aortic valve. The discharge restriction to the systemic ventricle may also be 
produced by an anomaly at a sub or supravalvar level. Nevertheless, the most common site 
of occurrence is by far the annulus (70%). Although congenital aortic stenosis is frequently 
associated with other significant cardiovascular lesions (20%) such as the hypoplastic left 
heart syndrome, mitral disease and coarctation of the aorta, we will mainly discuss the 
isolated congenital aortic valve stenosis in this chapter. 
Congenital aortic valve stenosis accounts for approximately 5% of all cases of congenital 
heart disease, with reported incidences ranging from 0.04 to 0.38 per 1000 live births (Botto 
et al., 2001; Hoffman & Kaplan, 2002). A clear male predominance (Wagner et al., 1977) has 
been reported, with a gender ratio of 4:1. There is recent evidence of familial predisposition 
for aortic valve anomalies (recurrence risk ~3% and ~15% in offspring of an affected father 
or mother respectively). This valvar defect occurs sporadically in most cases however. There 
is a controversy whether consanguinity has an influence on the incidence of congenital heart 
disease; while some studies emphasized the increased risk in the rate of congenital cardiac 
malformations (Badaruddoza et al., 1994; Bassili et al., 2000; Gatrad et al., 1984), others failed 
to show such association (Robida et al., 1997; Subramanyan et al., 2000). Recent large case 
series demonstrated that parental consanguinity increases the risk of valvar aortic stenosis 
as well as atrial septal defect and tetralogy of Fallot, wich supports the involvement of 
autosomal recessive genes in its bearing (Nabulsi et al., 2003; Chehab et al., 2007). Lately, 
aortic valvar anomaly in families with autosomal dominant transmission was found to be 
secondary to a mutation in the NOTCH1 gene (Garg et al., 2005). This apparent contradiction 
could be explained by the existence of many cases where a gene may be responsible for 
autosomal recessive and dominant inheritance, depending on the types of mutations. 
Turner syndrome, a congenital disease caused by structural and/or functional aberrations of 
the X chromosome, is associated with an increased risk of cardiovascular malformations 
(Bondy & Turner Syndrome Study Group, 2007). It has been reported that 17 to 59% of the 
patients carrying this chromosomal alteration are affected with at least one structural 
cardiovascular anomaly, mainly coarctation of the aorta and bicuspid aortic valve, but also 
mitral valve disease and dilatation of the aortic root (Landin-Wihelmsen et al., 2001; Sybert, 
1998). Although some authors have found no correlation between karyotype and heart 
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defects (Poprawski et al., 2009; Ruibal et al., 1997), others reported congenital cardiovascular 
malformations in 39% of patients with X chromosome monosomy, in 24% with mosaicism 
and in 12% with structural aberrations (Gravholt, 2001, 2004). The current guideline of the 
Turner syndrome Study Group (Bondy & Turner Syndrome Study Group, 2007) 
recommends cardiology assessment including echocardiography. They also recommend 
physical examination and echocardiography during adolescence and again every 3-5 years 
in adulthood even if cardiovascular abnormalities were not detected in childhood. Based on 
the increased risk of hypertension and aortic dissection of these patients, blood pressure 
should be measured at least twice a year. Girls with bicuspid aortic valve require periodical 
monitoring for future development of aortic stenosis, regurgitation, and aortic root 
dilatation. 
Bicuspid aortic valve disease is the most common congenital heart defect, with an estimated 
prevalence of 0.5-2% and male predominance (3:1) (Basso et al., 2004; Roberts, 1970; Ward, 
2000). A recent prospective echocardiographic study in newborns showed a high prevalence 
of 4.6 in 1000 live births (7.1 per 1000 male newborns versus 1.9 per 1000 female newborns) 
(Tutar et al., 2005). Nowadays, this condition is considered not only a valvar anomaly but a 
genetic disorder of the aorta and cardiac development (Siu & Silversides, 2010). It is often 
associated with coarctation of the aorta and dilatation of the thoracic aorta. About 50-75% of 
patients with coarctation have bicuspid aortic valve (Roos-Hesselink et al., 2003). Other 
congenital lesions such as ventricular septal defects, patent ductus arteriosus or atrial septal 
defects have been also associated with bicuspid aortic valve. There are few syndromes 
whose cardiac involvement includes bicuspid aortic valve and left-sided obstructive lesions: 
Shone syndrome (multiple left-sided anomalies), Williams syndrome (supravalvar stenosis) 
and Turner syndrome (coarctation of the aorta). The importance of this disease lies in the 
fact that valvar dysfunction may develop at any time during life span (stenosis or 
incompetence) as well as disturbances of the aortic wall. In children, 70-85% of stenotic 
aortic valves are found to be bicuspid (Mack & Silberbach, 2000). An autosomal dominant 
pattern of inheritance was suggested (Clementi, 1996; McDonald & Maurer, 1989) , and 
there are reports of 24% prevalence of bicuspid aortic valve in families with more than one 
affected member (Glick & Roberts, 1994). Recent research demonstrated that bicuspid aortic 
valve is likely due to mutations in different genes with dissimilar patterns of inheritance 
(Cripe et al., 2004). The 9% prevalence of bicuspid aortic valve in first-degree relatives of 
patients with this valvar disturbance supports the current guidelines of the American 
College of Cardiology/ American Heart Association suggesting echocardiographic 
screening for bicuspid aortic valve in first-degree relatives (Warnes & American College of 
Cardiology/ American Heart Association [ACC/AHA], 2008). 
2. Anatomical pathology 
The obstruction of the left ventricle outflow tract may occur at the subvalvar, valvar or 
supravalvar levels. Subvalvar stenosis can be produced by a fibrous membrane, a 
fibromuscular ridge or a diffuse fibromuscular tunnel. Supravalvar obstruction  can be a 
result of an external hourglass deformity with a corresponding luminal narrowing, a fibrous 
diaphragm or a diffuse narrowing (Edwards, 1965; Iwata et al., 2008). Nevertheles, we will 
only discuss the most common type at the valvar level, the focus of this chapter. The normal 
aortic valve is tricuspid, also refered to as trileaflet or trifoliate (3 comissures). The 3 cusps 
are typically designated as: left coronarian, right coronarian and noncoronarian. Aortic 
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valvar stenosis may be caused by unicuspid, bicuspid or tricuspid valves. Quadricuspid 
aortic valve is very rare in the exception of the truncus arteriosus malformation. 
Unicuspid valve is commonly found in neonates and infants but rare in children, adolescents 
or adults (Falcone et al., 1971; Mookadam et al., 2010; Roberts & Ko, 2007). All three cusps are 
fused, with a central opening (acomissural) or an eccentric orifice (unicomissural, with only 
one fully developed commissure, commonly in a posterior location). It has no attachement or a 
single lateral attachment to the aorta at the level of the orifice. It is usually observed as a 
primitive and myxomatous tissue with a pinhole opening, often associated with severe aortic 
arch obstruction, underdeveloped aortic valve ring, and hypoplastic left heart syndrome. In 
infants critical stenosis causes a low output syndrome.  
Bicuspid (or bileaflet) valve constitutes the most common aortic valve anomaly (Siu & 
Silversides, 2010). It is clasically formed by 2 unequal-sized leaflets. The larger leaflet has a 
central raphe resulting from commissural fusion (called “functional” or “fused” bicuspid 
valve). According to which commissures are fused, there are different morphologic patterns, 
the most frequent  involve fusion of the right and left cusps (60%). Less often, there is no raphe 
(“pure” or “truly” bicuspid valve). Dilatation of the thoracic aorta is commonly associated 
with aortic bicuspid valve. It was thought to be secondary to abnormal flow dynamics, but 
recent evidence indicates structural abnormalities at the cellular level (Niwa et al., 2001; 
Pachulski et al., 1991). These aberrations are independent of the hemodynamic alteration. They 
include decreased fibrillin-1, elastin fragmentation and apoptosis. They are thought to play a 
decisive role in thoracic aorta dilatation and subsequent dissection. These structural anomalies 
are also found in the main pulmonary artery of patients with bicuspid aortic valves, with 
unclear clinical significance (De Sa et al., 1999). Obstruction or incompetence of bicuspid aortic 
valves may develop at any age, mainly in relation to increasing adhesion of remaining 
commissure margins as well as leaflet thickening or calcification. 
Tricuspid valve is the least common cause of congenital aortic stenosis in the youth 
compared to the various forms of bicuspid valves which represent 70-85% in this age group. 
The obstruction may be produced by an incomplete leaflet opening and/or cusp thickening, 
and the stenosis may develop and/or progress over time. 
3. Physiopathology 
A compensatory left ventricular concentric hypertrophy results proportionally to the degree 
of the outflow obstruction. A mild stenosis usually produces minimal or no myocardial 
hypertrophy. The degree of obstruction tends to increase in relation to periods of rapid 
somatic growth (Wagner et al., 1977). Severe hypertrophy and valvar obstruction may cause 
myocardial ischemia from the combination of limited cardiac output, reduced coronary 
perfusion and increased myocardial oxygen consumption. Fibrosis may occur in areas of the 
myocardium damaged by ischemia (Alsoufi et al., 2007). Post-stenotic aortic root dilatation, 
defined as dilatation of the vessel wall distal to the area of a partial stenosis, may be caused 
by the hemodynamic abnormality, but also by intrinsic aortic parietal structural anomalies, 
especially in bicuspid aortic valve disease. A stenosed aortic valve may also develop valvar 
incompetence, with secondary left ventricular dilatation in case of significant regurgitation. 
During prenatal development, severe aortic stenosis causes increased left cardiac chambers 
pressures. The blood in the left atrium flows preferencially to the low-pressure right atrium 
(Alsoufi et al., 2007; Turner et al., 2009). The subsequent reduced antegrade flow through the 
left heart structures induces detention of left ventricular growth, with the potential 
development of a hypoplastic left heart syndrome. Occasionally the left ventricle is normal 
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in size, with depressed function of the damaged fibrotic myocardium. The increased 
afterload contributes to left ventricular hypertrophy and dysfunction. Ventricular 
hypertrophy and increased intracavitary pressure may lead to subendocardial ischemia with 
the development of endocardial fibroelastosis which further impairs the ventricular 
function. In fetuses with aortic stenosis and an intact or restrictive atrial septum, there is no 
low-pressure outlet for blood entering the left heart, so the left atrium and ventricle may 
become severely dilated. This may lead to severe mitral regurgitation due to mitral annular 
dilation, with the resultant elevated pressure and compression of the right heart causing 
right heart failure, fetal hydrops, and severe pulmonary vascular changes leading to 
pulmonary hypertension in the neonatal period (Rychik et al., 1999). 
4. Clinical manifestations 
Although severe stenosis may manifest as exercise induced thoracic pain, fainting, exercise 
intolerance or even sudden death during childhood, most of the children with valvar aortic 
stenosis are asymptomatic. The diagnosis is often made during the evaluation of an 
asymptomatic heart murmur. The typical auscultatory features (Fyler, 1992) consist on an early 
systolic ejection click followed by a crescendo-decrescendo systolic murmur that reaches peak 
intensity in mid-systole. In advanced aortic stenosis, the murmur is best heard at the second 
intercostal space in the right upper sternal border, it radiates to the neck and it is often 
associated with a systolic thrill in the suprasternal notch. The second sound aortic component 
is delayed secondary to the left ventricular systole extension, proportionate to the severity of 
the obstruction. This may result in a narrowly split second heart sound or even with the aortic 
closure appearing after pulmonary closure (reverse, or paradoxical splitting). The length but 
not the intensity of the murmur correlates with the degree of the stenosis. The murmur 
intensity of valvar aortic stenosis increases upon squatting and, in opposition to what happens 
in cases of hypertrophic obstructive cardiomyopathy, decreases with Valsalva maneuvers. An 
early diastolic regurgitant murmur may be heard when valvar insufficiency is also present. 
Bicuspid aortic valve disease is commonly assymptomatic in childhood; it is estimated that 
only 1 in 50 children present a clinically significant valve disease by adolescence (Bonow & 
ACC/AHA, 2008). Globally, only 10-15% of patients present clinical manifestations within 
the first 12 months of life (Brown et al., 2003; McCrindle et al., 2001). Newborns with critical 
aortic stenosis usually have a dramatic presentation soon after birth. As the ductus arteriosus 
starts closing, a decreased systemic and coronary perfusion is established. This situation 
carries a high morbidity and mortality, fatal within hours if left untreated. Neonates and 
infants with milder stenosis may present with failure to thrive, tachypnea and respiratory 
distress secondary to pulmonary vascular congestion. Prenatally, only critical stenosis may 
have clinical repercussion. As previously explained, when an intact or restrictive atrial 
septum is present, left chambers may become severely dilated leading to heart failure, fetal 
hydrops and demise. On the other hand, when a non-restrictive foramen ovale coexists with 
critical stenosis, left chambers may be underdeveloped. The myocardium may be damaged, 
but the systemic output is usually secured at least untill birth through the ductus arteriosus. 
5. Diagnostic tests 
5.1 Electrocardiography 
In mild cases there are no electrocardiographic changes. When the stenosis is at least 
moderate, abnormalities reflecting left ventricular hypertrophy may be observed with or 
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without strain pattern. These findings include increased left ventricular voltages, left 
bundle-branch block, decreased right anterior forces, T-wave inversion and ST-segment 
depression. Although electric changes are much more likely with severe stenosis, 
electrocardiography is not a reliable indicator of the degree of obstruction (Botto et al., 2001; 
Fowler et al., 1982). In neonates with critical obstruction, the electrocardiogram usually 
shows right ventricular dominance with evidence of diffuse T-wave and ST-changes 
secondary to left ventricular strain (Lofland et al., 2001). ACC/AHA guidelines  include: 
“An Electrocardiogram is recommended yearly in the asymptomatic adolescent or young 
adult with aortic stenosis who has a Doppler mean gradient greater than 30 mmHg or a 
peak velocity greater than 3.5 m/sec (peak gradient greater than 50 mmHg) and every 2 
years if the echocardiographic Doppler mean gradient is less than or equal to 30 mmHg or 
the peak velocity is less than or equal to 3.5 m/sec (peak gradient less than or equal to 50 
mmHg) (Class I; Level of Evidence C)” (Bonow & ACC/AHA, 2008). 
5.2 Chest X-ray 
The heart size is usually normal in children. A prominent ascending aorta is occasionally 
identifiable because of the dilatation of the ascending aorta, and it is observed as a bulge on 
the right upper mediastinum or a prominence of the aortic knob on the left upper 
mediastinum. Those newborns or infants in congestive heart failure due to a critical stenosis 
show cardiomegaly and pulmonary vascular congestion. 
5.3 Echocardiography  
Transthoracic echocardiography confirms the diagnosis. The degree of obstruction refers to 
pressure loss across the valve in systole. This gradient was historically measured by cardiac 
catheterization. Peak-to-peak gradients determined by cardiac catheterization have 
constituted the basis of natural history studies and clinical-decision making. Although early 
investigations suggested that peak Doppler gradient reliably estimated the peak-to-peak 
catheter gradient (Currie et al., 1985), it was later demonstrated that it consistently 
overerestimates it by 20-30%, with an exacerbation in presence of significant valvar 
regurgitation (Baumgartner et al., 1999; Levine et al., 1989; Villavicencio et al., 2003). This is 
explained by the fact that Doppler technique reflects the maximal instantaneous velocity 
while peak-to-peak catheter gradient refers to the maximal difference between pressures 
measured in the left ventricle and the aorta, and also due to the phenomenon of pressure 
recovery (Clark, 1976). Pressure recovery occurs when the pressure drop across a stenotic 
orifice is partially recovered distal to the obstruction from conversion of kinetic energy into 
potential energy. Continuous-wave Doppler measures the point of highest velocity and 
lowest pressure or vena contracta, so the measured gradients will overestimate the catheter 
gradient if significant pressure recovery occurs. As higher flow rates secondary to greater 
resting heart frequencies and small aortas  have been shown to exacerbate the phenomenon 
of pressure recovery (Baumgartner et al., 1999) and both features are often present in 
children with aortic stenosis. This phenomenon is considered to play an important role 
while interpreting data derived from ultrasonography studies in this clinical context. To 
note, pressure recovery has been found to be more significant in mild to moderate aortic 
valve stenosis (Levine et al., 1989). Moreover, the mean Doppler gradient is a better estimate 
of the catheter-derived gradients (Fyler, 1992; Levine et al., 1989), although not consistent 
with the known fluid mechanics principles of left ventricular ejection. 
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The echocardiogram usually allows to determine with great accuracy the anatomical 
features of the valve, as well as to identify other cardiovascular lesions which may be 
associated with this valvulopathy, a subaortic membrane or supravalvar stenosis, if present. 
A normal aortic valve is formed by three thin cusps which open fully in systole and close 
completely in diastole. In opposition, a stenotic aortic valve usually has one or two leaflets, 
usually thick in appearance, with incomplete opening in systole. The parasternal short-axis 
plane is the best view to identify the number, mobility and thickening of the aortic cusps. A 
normal aortic valve has a “Y” pattern in diastole and a complete leaflet excursion in systole. 
It is crucial to explore in detail the hole cardiac cycle, because a bicuspid valve may appear 
normal in diastole but its typical “fish-mouth” opening can be observed in systole. In 
addition, the model of systolic opening serves to distinguish a raphe from a commissure. On 
parasternal long-axis plane (bidimensional and M-mode), a bicuspid valve usually has an 
eccentric diastolic line of coaptation, whereas a centered line is observed in normal aortic 
valves. A dome-shaped image secondary to limited excursion of the leaflets is often 
identified in stenosed aortic valves. The M-mode allows precise measurement of left 
ventricular function, enlargement and hypertrophy. 
The valve area estimate is underused in the typical clinical practice in general. Jet velocity, 
defined as the antegrade systolic highest velocity across the narrowed aortic valve, is 
measured using continuous-wave Doppler ultrasound. Accurate data recording mandates 
multiple acoustic windows in order to determine the peak velocity. Apical and suprasternal 
or right parasternal most frequently yield the highest velocity. Subcostal or supraclavicular 
windows are rarely required. Careful patient positioning and adjustment of transducer 
position and angle are crucial as velocity measurement assumes a parallel intercept angle 
between the ultrasound beam and direction of blood flow (Baumgartner et al., 2009). Peak 
Doppler gradient (in mmHg) can be calculated by the modified Bernoulli´s equation: 4 x (jet 
velocity in m/s)2. Mean transaortic Doppler pressure gradient is defined as the average 
difference in pressure between the left ventricle and the aorta during the entire systole. The 
mean transaortic gradient is easily measured with current echocardiography systems and 
provides useful information for clinical decision-making. It is calculated by averaging the 
instantaneous gradients over the ejection period, a function included in most clinical 
instrument measurement packages using the traced velocity curve. The acoustic windows 
used to measure the mean Doppler gradient are the same as those used in determining the 
jet velocity (Baumgartner et al., 2009). Table 1 shows the current classification of the various 
degrees of aortic stenosis based on the echocardiography.  
 
 Mild stenosis Moderate stenosis Severe stenosis 
Mean gradient < 25 mmHg 25-40 mmHg > 40 mmHg 
Jet velocity < 3 m/s 3-4 m/s > 4 m/s 
Table 1. Aortic stenosis degrees based on echocardiographic parameters in patients without 
left ventricular dysfunction. Current guidelines of the American College of 
Cardiology/American Heart Association (ACC/AHA) (Bonow & ACC/AHA, 2008). 
A special remark has to be done in reference to ultrasonographic findings of critical aortic 
stenosis. A small, poorly contracting left ventricle is often observed with varying degrees of 
endocardial fibroelastosis (seen as areas of increased echogenicity). Hypoplasia of the aortic 
annulus and the ascending aorta are other commonly associated features. Pulmonary 
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hypertension may develop secondary to left ventricular failure, causing right ventricular 
dilatation and tricuspid regurgitation. Finally, the severity of aortic stenosis stratification is 
not reliable when cardiac function is significantly altered in cases with critical stenosis. 
Occasionally associated with aortic stenosis, valvar regurgitation plays a decisive role on 
clinical decision-making. Although echocardiographic criteria for aortic regurgitation have 
not been completely established for the pediatric population, some parameters (summarized 
in Table 2) have been proposed (Snider, 1997; Tribouilloy et al., 1991). 
 
 Mild regurgitation Moderate regurgitation Severe regurgitation 
Color jet ending 
Proximal to the tip of 
the anterior mitral 
valve leaflet 
Distal to the mitral 
valve 
Distal to the mitral 
valve 
Jet width < 30% > 30% > 30% 
Pressure half time > 600 ms < 600 ms < 600 ms 
End-diastolic 
retrograde flow in 
the descending aorta 
< 20 cm/s 20-40 cm/s > 40 cm/s 
Other   
Pandiastolic 
retrograde flow in 
the abdominal aorta, 
and dilated left 
ventricle. 
Moderately to 
severely dilated left 
ventricle. 
Table 2. Aortic regurgitation degrees according to echocardiographic parameters. Jet width 
refers to the regurgitant flow compared with the left ventricular outflow tract diameter. 
ACC/AHA guidelines include: “Doppler echocardiography is recommended yearly in the 
asymptomatic adolescent or young adult with aortic stenosis who has a Doppler mean 
gradient greater than 30 mmHg or a peak velocity greater than 3.5 m/sec (peak gradient 
greater than 50 mmHg) and every 2 years if the Doppler gradient is less than or equal to 30 
mmHg or the peak jet velocity is less than or equal to 3.5 m/sec (peak gradient less than or 
equal to 50 mmHg) (Class I; Level of Evidence C)” (Bonow & ACC/AHA, 2008). 
Recently, three-dimensional echocardiography became more readily available, permitting “en 
face” views of intracardiac structures and volumetric measurements (Acar, 2006). In selected 
patients with valvar aortic stenosis, this emerging imaging technique can be helpful in 
assessing the morphology and number of leaflets, as well as the degree of fusion between the 
raphes. It may be useful in the differential diagnosis of valvar and subvalvar obstructions, 
especially in cases where an infravalvar membrane is very close to the valve and that had not 
been clearly defined by bidimensional echocardiography (Rubio et al., 2008). 
Fetal echocardiography makes a detailed prenatal diagnosis of suspected or known congenital 
heart disease feasible allowing thus an improved counseling of families; guidance for timing 
and optimal location of delivery, identification of fetuses requiring specific early postnatal 
therapy (especially those with ductal dependent lesions such as critical left heart obstructive 
lesions), and prompt evaluation of genetic syndromes and analysis of the fetal karyotype. It 
can also serve to identify potential candidates for in utero cardiac interventions (Jone & 
Schowengerdt, 2009). Mild cases of aortic stenosis can be detected prenatally. It is suggested 
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that prenatal diagnosis of aortic valvar stenosis, and other congenital heart disease alike, is 
associated with improved postnatal outcome (Chang et al., 1991).  
5.4 Cardiac catheterization 
The indications of cardiac catheterization for pure diagnostic purposes are very limited 
nowadays. The catheterization performed at the hemodynamics laboratory with the patient 
sedated. Peak-to-peak transaortic gradient has been considered for several decades the gold-
standard for grading the severity of aortic stenosis. As the aortic systolic pressure is higher 
and delayed compared to the ventricular pressure (the so-called “standing wave effect”) 
(Lock, 1987), it is not recommended to compare pressures between left ventricle and a distal 
artery (such as a femoral artery) in order to avoid a gradient underestimation. Other 
parameters including degree of aortic regurgitation, cardiac output, left ventricular systolic 
function and aortic annulus diameter can be also determined during catheterization. 
Diagnostic cardiac catheterization is currently recommended for adolescents and young 
adults, equally valid for children, in the following situations (Bonow & ACC/AHA, 
2008): 
Cardiac catheterization for the evaluation of aortic stenosis is an effective diagnostic tool in 
the asymptomatic adolescent or young adult when results of Doppler echocardiography are 
equivocal regarding severity of aortic stenosis or when there is a discrepancy between 
clinical and noninvasive findings regarding severity of aortic stenosis (Class I; Level of 
Evidence C). 
Cardiac catheterization is indicated in the adolescent or young adult with aortic stenosis 
who has symptoms of angina, syncope, or dyspnea on exertion if the Doppler mean 
gradient is greater than 30 mmHg or the peak velocity is greater than 3.5 m/sec (peak 
gradient greater than 50 mmHg) (Class I; Level of Evidence C). 
Cardiac catheterization is indicated in the asymptomatic adolescent or young adult with 
aortic stenosis who develops T-wave inversion at rest over the left precordium if the 
Doppler mean gradient is greater than 30 mmHg or the peak velocity is greater than 3,5 
m/sec (peak gradient greater than 50 mmHg) (Class I; Level of Evidence C). 
Cardiac catheterization for the evaluation of aortic stenosis is a reasonable diagnostic tool in 
the asymptomatic adolescent or young adult who has a Doppler mean gradient greater than 
40 mmHg or a peak velocity greater than 4 m/sec (peak gradient greater than 64 mmHg) 
(Class IIa; Level of Evidence C). 
Cardiac catheterization for the evaluation of aortic stenosis is reasonable in the adolescent or 
young adult who has a Doppler mean gradient greater than 30 mmHg or a peak velocity 
greater than 3.5 m/sec (peak gradient greater than 50 mmHg) if the patient is interested in 
athletic participation or becoming pregnant, or if the clinical findings and the Doppler 
echocardiographic findings are disparate (Class IIa; Level of Evidence C). 
5.5 Exercise testing 
Exercise testing can be useful in borderline cases (e.g., in patients interested in engaging in 
vigorous physical activities), but should be avoided in symptomatic patients owing to a high 
risk of complications. Stress testing can identify a limited exercise capacity, abnormal blood 
pressure responses, exercise-induced symptoms or electrocardiographic changes (ST-
segment depression or T-wave inversion). A significant obstruction may be present when 
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any of these abnormalities is identified. ACC/AHA guidelines refer to exercise testing as 
follows: “Graded exercise testing is a reasonable diagnostic evaluation in the adolescent or 
young adult with aortic stenosis who has a Doppler mean gradient greater than 30 mmHg 
or a peak velocity greater than 3.5 m/sec (peak gradient greater than 50 mmHg) if the 
patient is interested in athletic participation, or if the clinical findings and Doppler findings 
are disparate (Class IIa; Level of Evidence C)” (Bonow & ACC/AHA, 2008). 
5.6 Holter monitor 
The prevalence of serious ventricular arrhythmias (multiform premature ventricular 
contractions, ventricular couplets and ventricular tachycardia) is increased in patients with 
aortic stenosis. When the invasive peak-to-peak gradient is over 50 mmHg there is a higher 
incidence of sudden death (Keane et al., 1993; Wolfe et al., 1993). Considering that a clear 
consensus is well stated for the clinical decision-making of mild and severe cases (medical 
follow-up and intervention, respectively), Holter monitoring may be a useful tool in those 
patients with a moderate degree of aortic stenosis, but evidence based data is unavailable. 
5.7 Magnetic resonance 
Cardiovascular magnetic resonance has emerged as an alternative noninvasive imaging 
without ionizing radiation, particularly useful in patients with poor acoustic windows. It 
provides precise images of valve anatomy and allows quantitative evaluation of stenosis 
and regurgitation (Cawley at al., 2009). Delayed myocardial enhancement magnetic 
resonance can serve to delineate the location and transmural extent of endocardial 
fibroelastosis in infants, thus providing an accurate roadmap for the surgical planning of 
fibroelastosis resection and for monitoring the results (Tworetzky et al., 2005). Magnetic 
resonance is also proposed to aid fetal ultrasonography in the prenatal assessment of 
congenital cardiac malformations (Manganaro et al., 2008). 
6. Natural course 
Critical aortic stenosis produces severe congestive heart failure and shock in fetuses, 
neonates and infants. It usually leads to death within hours or days if left untreated. Before 
the era of surgery, it was estimated that aortic valvar stenosis presenting within the first 
year of life carried a mortality rate of 23% (Campbell, 1968). In a necropsy series of 26 
children with aortic stenosis under 15 years old, 43% died within the first month of life and 
77% within the first year (Samánek et al., 1988). Beyond these ages, children with untreated 
severe aortic stenosis seldom live more than 5 years from the time of diagnosis, similar to 
life expectancy reported in adults (Kitchiner et al., 1993; Wagner et al., 1977). The survival of 
patients with mild obstruction is slightly lower than that of the general population, probably 
related to sporadic deceases secondary to infective endocarditis or to unexpected quick 
incremental severity (Keane et al., 1993; Kitchiner et al., 1993). In patients with moderate 
obstruction who receive no treatment, the reported survival rate is 72.2% at 5 years and 
45.6% at 20 years (Kitchiner et al., 1993). 
The report from the Natural History Study of Congenital Heart Defects which included 462 
patients with aortic stenosis (60% between 2-11 years and 24% between 11-21 years at initial 
evaluation), observed that the obstruction tends to increase over time, especially in cases 
with higher gradients on enrolment. Whereas only 20% of those patients with initial peak-
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
8 
that prenatal diagnosis of aortic valvar stenosis, and other congenital heart disease alike, is 
associated with improved postnatal outcome (Chang et al., 1991).  
5.4 Cardiac catheterization 
The indications of cardiac catheterization for pure diagnostic purposes are very limited 
nowadays. The catheterization performed at the hemodynamics laboratory with the patient 
sedated. Peak-to-peak transaortic gradient has been considered for several decades the gold-
standard for grading the severity of aortic stenosis. As the aortic systolic pressure is higher 
and delayed compared to the ventricular pressure (the so-called “standing wave effect”) 
(Lock, 1987), it is not recommended to compare pressures between left ventricle and a distal 
artery (such as a femoral artery) in order to avoid a gradient underestimation. Other 
parameters including degree of aortic regurgitation, cardiac output, left ventricular systolic 
function and aortic annulus diameter can be also determined during catheterization. 
Diagnostic cardiac catheterization is currently recommended for adolescents and young 
adults, equally valid for children, in the following situations (Bonow & ACC/AHA, 
2008): 
Cardiac catheterization for the evaluation of aortic stenosis is an effective diagnostic tool in 
the asymptomatic adolescent or young adult when results of Doppler echocardiography are 
equivocal regarding severity of aortic stenosis or when there is a discrepancy between 
clinical and noninvasive findings regarding severity of aortic stenosis (Class I; Level of 
Evidence C). 
Cardiac catheterization is indicated in the adolescent or young adult with aortic stenosis 
who has symptoms of angina, syncope, or dyspnea on exertion if the Doppler mean 
gradient is greater than 30 mmHg or the peak velocity is greater than 3.5 m/sec (peak 
gradient greater than 50 mmHg) (Class I; Level of Evidence C). 
Cardiac catheterization is indicated in the asymptomatic adolescent or young adult with 
aortic stenosis who develops T-wave inversion at rest over the left precordium if the 
Doppler mean gradient is greater than 30 mmHg or the peak velocity is greater than 3,5 
m/sec (peak gradient greater than 50 mmHg) (Class I; Level of Evidence C). 
Cardiac catheterization for the evaluation of aortic stenosis is a reasonable diagnostic tool in 
the asymptomatic adolescent or young adult who has a Doppler mean gradient greater than 
40 mmHg or a peak velocity greater than 4 m/sec (peak gradient greater than 64 mmHg) 
(Class IIa; Level of Evidence C). 
Cardiac catheterization for the evaluation of aortic stenosis is reasonable in the adolescent or 
young adult who has a Doppler mean gradient greater than 30 mmHg or a peak velocity 
greater than 3.5 m/sec (peak gradient greater than 50 mmHg) if the patient is interested in 
athletic participation or becoming pregnant, or if the clinical findings and the Doppler 
echocardiographic findings are disparate (Class IIa; Level of Evidence C). 
5.5 Exercise testing 
Exercise testing can be useful in borderline cases (e.g., in patients interested in engaging in 
vigorous physical activities), but should be avoided in symptomatic patients owing to a high 
risk of complications. Stress testing can identify a limited exercise capacity, abnormal blood 
pressure responses, exercise-induced symptoms or electrocardiographic changes (ST-
segment depression or T-wave inversion). A significant obstruction may be present when 
 
Congenital Aortic Stenosis in Childhood   
 
9 
any of these abnormalities is identified. ACC/AHA guidelines refer to exercise testing as 
follows: “Graded exercise testing is a reasonable diagnostic evaluation in the adolescent or 
young adult with aortic stenosis who has a Doppler mean gradient greater than 30 mmHg 
or a peak velocity greater than 3.5 m/sec (peak gradient greater than 50 mmHg) if the 
patient is interested in athletic participation, or if the clinical findings and Doppler findings 
are disparate (Class IIa; Level of Evidence C)” (Bonow & ACC/AHA, 2008). 
5.6 Holter monitor 
The prevalence of serious ventricular arrhythmias (multiform premature ventricular 
contractions, ventricular couplets and ventricular tachycardia) is increased in patients with 
aortic stenosis. When the invasive peak-to-peak gradient is over 50 mmHg there is a higher 
incidence of sudden death (Keane et al., 1993; Wolfe et al., 1993). Considering that a clear 
consensus is well stated for the clinical decision-making of mild and severe cases (medical 
follow-up and intervention, respectively), Holter monitoring may be a useful tool in those 
patients with a moderate degree of aortic stenosis, but evidence based data is unavailable. 
5.7 Magnetic resonance 
Cardiovascular magnetic resonance has emerged as an alternative noninvasive imaging 
without ionizing radiation, particularly useful in patients with poor acoustic windows. It 
provides precise images of valve anatomy and allows quantitative evaluation of stenosis 
and regurgitation (Cawley at al., 2009). Delayed myocardial enhancement magnetic 
resonance can serve to delineate the location and transmural extent of endocardial 
fibroelastosis in infants, thus providing an accurate roadmap for the surgical planning of 
fibroelastosis resection and for monitoring the results (Tworetzky et al., 2005). Magnetic 
resonance is also proposed to aid fetal ultrasonography in the prenatal assessment of 
congenital cardiac malformations (Manganaro et al., 2008). 
6. Natural course 
Critical aortic stenosis produces severe congestive heart failure and shock in fetuses, 
neonates and infants. It usually leads to death within hours or days if left untreated. Before 
the era of surgery, it was estimated that aortic valvar stenosis presenting within the first 
year of life carried a mortality rate of 23% (Campbell, 1968). In a necropsy series of 26 
children with aortic stenosis under 15 years old, 43% died within the first month of life and 
77% within the first year (Samánek et al., 1988). Beyond these ages, children with untreated 
severe aortic stenosis seldom live more than 5 years from the time of diagnosis, similar to 
life expectancy reported in adults (Kitchiner et al., 1993; Wagner et al., 1977). The survival of 
patients with mild obstruction is slightly lower than that of the general population, probably 
related to sporadic deceases secondary to infective endocarditis or to unexpected quick 
incremental severity (Keane et al., 1993; Kitchiner et al., 1993). In patients with moderate 
obstruction who receive no treatment, the reported survival rate is 72.2% at 5 years and 
45.6% at 20 years (Kitchiner et al., 1993). 
The report from the Natural History Study of Congenital Heart Defects which included 462 
patients with aortic stenosis (60% between 2-11 years and 24% between 11-21 years at initial 
evaluation), observed that the obstruction tends to increase over time, especially in cases 
with higher gradients on enrolment. Whereas only 20% of those patients with initial peak-
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to-peak transaortic gradient lower than 25 mmHg at initial catheterization required a 
cardiac intervention during 25 years of follow-up, children with baseline peak-to-peak 
transaortic gradient over 50 mmHg were at risk for serious cardiovascular events, including 
arrhythmias, endocarditis and sudden death, at a rate of 1.2% per year (Keane et al., 1993; 
Kitchiner et al., 1993). The rate of aortic stenosis progression is highly variable and appears 
to be age related. It is fast in infants, moderate in children and slow in adolescents; probably 
related to the inability of the valve orifice to increase in proportion to somatic growth (el-
Said et al., 1972). In line with this assumption, a study in which 129 children with aortic 
stenosis were followed periodically with serial echocardiograms, showed that 89% of 
children under 2 years old and 61% of children over 2 years old experimented progression 
of the obstruction (Kiraly et al., 2003). Although significant and progressive aortic 
regurgitation is commonly acquired after surgery or percutaneous balloon valvuloplasty, it 
can also occur in patients with untreated aortic stenosis (Keane et al., 1993). 
Sudden death, with an average incidence of 0.3% per year (Keane et al., 1993), occurs almost 
exclusively in patients with a peak Doppler gradient higher than 50 mmHg even in the 
absence of symptoms (Keane et al., 1993; Otto et al., 1997). About half of these fatal events 
occur during or immediately after exercise (Lambert et al., 1974). Bacterial endocarditis 
occurs in 1-4% of patients with untreated aortic stenosis (18-31 per 10000 patient-years) 
(Campbell, 1968; Gersony et al., 1993; Hossack et al., 1980). The risk is present in mild cases, 
with higher incidence in patients with more severe stenosis. Aortic regurgitation does not 
seem to increase the risk of developing bacterial endocarditis however (Gersony et al., 1993). 
Clinical presentation of patients with bicuspid aortic valve varies from severe valve disease 
in infancy to asymptomatic valve or thoracic aorta disease in the older child, but symptoms 
usually develop in adulthood (Siu & Silversides, 2010). Although aortic stenosis can be 
present in children secondarily to a small valve orifice, the valve usually has none or mild 
degree of obstruction in childhood and experience a progressive worsening over time 
because of sclerosis and calcification (Chui et al., 2001). High levels of serum cholesterol 
have been associated with an acceleration of the sclerosing process of the bicuspid valve 
(Chui et al., 2001). A study performed on adult patients with bicuspid aortic valves showed 
a median increase of 0.7 mmHg per year in peak Doppler gradient (Tzemos et al., 2008). 
Pure aortic incompetence due to a prolapsed leaflet may occur in childhood but is more 
likely to develop and progress later in time; nevertheless, this remains an infrequent cause 
of intervention requirement even in adults. Aortic root dilatation has been documented in 
childhood, suggesting that this process begins early in life (Beroukhim et al., 2006; Gurvitz 
et al., 2004). Its progression is more likely in children with a larger aorta at baseline, but it is 
extremely rare to necessitate intervention before adulthood (Holmes et al., 2007). 
7. Management 
Balloon aortic valvoplasty constitutes the therapeutic procedure of choice in most centers for 
the treatment of congenital aortic stenosis (Khalid et al., 2006). Other interventional options, 
including both surgical and hybrid techniques and also fetal intervention are also discussed. 
7.1 Balloon aortic valvoplasty 
Balloon aortic valvoplasty, first described in the early 1980s, is a widely used technique in 
the treatment of valvar aortic stenosis in children (Lababidi, 1983; Lababidi et al., 1984). The 
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technique is performed under deep sedation, with the exception of the neonates and the 
critically ill patients. Vascular access is usually obtained with a retrograde approach using 
the femoral artery. In neonates and small infants, other sites of access have been used in 
order to avoid the risk of femoral arterial compromise (Weber, 2006). These include: 
The umbilical artery route was initially advocated as a way to avoid femoral artery injury in 
view of the large diameter balloon dilatation catheters that were available at the time 
(Beekman et al., 1991). Although technically feasible, it may be difficult to traverse the 
tortuous umbilical-iliac artery system, may introduce bacteria from the umbilicus and may 
cause excessive loss of blood during wire and catheter exchanges. 
The right scapular artery was reported to be safe and effective in infants with critical aortic 
valve stenosis (Alekyan et al., 1995). It typically requires surgical exposure of the artery and 
is contraindicated in the presence of an aberrant right subclavian artery. 
The anterograde transvenous approach may be performed via the foramen ovale or by a 
transeptal puncture when the atrial septum is intact (Hausdorf et al., 1993). This procedure 
spares the femoral arteries for potential future use but may be technically challenging and 
may cause mitral valve damage. 
The right carotid artery was firstly used based on the extensive experience with carotid artery 
cannulation for extracorporeal membrane oxigenation in newborns (Fischer et al., 1990). it is 
reported to be effective and safe, and it allows performing the entire procedure at the bedside 
with the aid of continuous transesophageal echocardiographic guidance, thus avoiding the use 
of fluoroscopy (Weber et al., 2000). Its disadvantages include the risk of carotid artery injury 
with potential neurologic complications and the need of surgical exposure. 
Above all, the retrograde femoral arterial approach remains the most commonly used. The 
potential associated complications have been significantly reduced with the availability of low 
profile diameter balloons. Once the vascular access is assured, the aortic annulus diameter and 
the degree of aortic regurgitation are determined, a complete right and left cardiac 
catheterization is performed and the peak-to-peak transaortic gradient is determined from 
simultaneous or sequential measurements of left ventricular and ascending aorta pressures.  
Balloon aortic valvoplasty is contraindicated when an aortic regurgitation of moderate or 
higher degree is present, and it is not recommended if the valve is significantly calcified. It is 
performed in cases of critical aortic stenosis with variable institutional preferences. 
Recommendations for aortic balloon valvoplasty in adolescents and young adults, which 
may be applied to children, are the following (Bonow & ACC/AHA, 2008): 
Aortic balloon valvotomy is indicated in the adolescent or young adult patient with aortic 
stenosis who has symptoms of angina, syncope, or dyspnea on exertion and a 
catheterization peak LV–to–peak aortic gradient greater than or equal to 50 mmHg without 
a heavily calcified valve (Class I; Level of Evidence C). 
Aortic balloon valvotomy is indicated for the asymptomatic adolescent or young adult 
patient with aortic stenosis who has a catheterization peak LV–to–peak aortic gradient 
greater than 60 mmHg (Class I; Level of Evidence C). 
Aortic balloon valvotomy is indicated in the asymptomatic adolescent or young adult 
patient with aortic stenosis who develops ST or T-wave changes over the left precordium on 
ECG at rest or with exercise and who has a catheterization peak LV–to–aortic gradient 
greater than 50 mmHg (Class I; Level of Evidence C). 
Aortic balloon valvotomy is reasonable in the asymptomatic adolescent or young adult 
patient with aortic stenosis when catheterization peak LV–to–peak aortic gradient is greater 
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to-peak transaortic gradient lower than 25 mmHg at initial catheterization required a 
cardiac intervention during 25 years of follow-up, children with baseline peak-to-peak 
transaortic gradient over 50 mmHg were at risk for serious cardiovascular events, including 
arrhythmias, endocarditis and sudden death, at a rate of 1.2% per year (Keane et al., 1993; 
Kitchiner et al., 1993). The rate of aortic stenosis progression is highly variable and appears 
to be age related. It is fast in infants, moderate in children and slow in adolescents; probably 
related to the inability of the valve orifice to increase in proportion to somatic growth (el-
Said et al., 1972). In line with this assumption, a study in which 129 children with aortic 
stenosis were followed periodically with serial echocardiograms, showed that 89% of 
children under 2 years old and 61% of children over 2 years old experimented progression 
of the obstruction (Kiraly et al., 2003). Although significant and progressive aortic 
regurgitation is commonly acquired after surgery or percutaneous balloon valvuloplasty, it 
can also occur in patients with untreated aortic stenosis (Keane et al., 1993). 
Sudden death, with an average incidence of 0.3% per year (Keane et al., 1993), occurs almost 
exclusively in patients with a peak Doppler gradient higher than 50 mmHg even in the 
absence of symptoms (Keane et al., 1993; Otto et al., 1997). About half of these fatal events 
occur during or immediately after exercise (Lambert et al., 1974). Bacterial endocarditis 
occurs in 1-4% of patients with untreated aortic stenosis (18-31 per 10000 patient-years) 
(Campbell, 1968; Gersony et al., 1993; Hossack et al., 1980). The risk is present in mild cases, 
with higher incidence in patients with more severe stenosis. Aortic regurgitation does not 
seem to increase the risk of developing bacterial endocarditis however (Gersony et al., 1993). 
Clinical presentation of patients with bicuspid aortic valve varies from severe valve disease 
in infancy to asymptomatic valve or thoracic aorta disease in the older child, but symptoms 
usually develop in adulthood (Siu & Silversides, 2010). Although aortic stenosis can be 
present in children secondarily to a small valve orifice, the valve usually has none or mild 
degree of obstruction in childhood and experience a progressive worsening over time 
because of sclerosis and calcification (Chui et al., 2001). High levels of serum cholesterol 
have been associated with an acceleration of the sclerosing process of the bicuspid valve 
(Chui et al., 2001). A study performed on adult patients with bicuspid aortic valves showed 
a median increase of 0.7 mmHg per year in peak Doppler gradient (Tzemos et al., 2008). 
Pure aortic incompetence due to a prolapsed leaflet may occur in childhood but is more 
likely to develop and progress later in time; nevertheless, this remains an infrequent cause 
of intervention requirement even in adults. Aortic root dilatation has been documented in 
childhood, suggesting that this process begins early in life (Beroukhim et al., 2006; Gurvitz 
et al., 2004). Its progression is more likely in children with a larger aorta at baseline, but it is 
extremely rare to necessitate intervention before adulthood (Holmes et al., 2007). 
7. Management 
Balloon aortic valvoplasty constitutes the therapeutic procedure of choice in most centers for 
the treatment of congenital aortic stenosis (Khalid et al., 2006). Other interventional options, 
including both surgical and hybrid techniques and also fetal intervention are also discussed. 
7.1 Balloon aortic valvoplasty 
Balloon aortic valvoplasty, first described in the early 1980s, is a widely used technique in 
the treatment of valvar aortic stenosis in children (Lababidi, 1983; Lababidi et al., 1984). The 
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technique is performed under deep sedation, with the exception of the neonates and the 
critically ill patients. Vascular access is usually obtained with a retrograde approach using 
the femoral artery. In neonates and small infants, other sites of access have been used in 
order to avoid the risk of femoral arterial compromise (Weber, 2006). These include: 
The umbilical artery route was initially advocated as a way to avoid femoral artery injury in 
view of the large diameter balloon dilatation catheters that were available at the time 
(Beekman et al., 1991). Although technically feasible, it may be difficult to traverse the 
tortuous umbilical-iliac artery system, may introduce bacteria from the umbilicus and may 
cause excessive loss of blood during wire and catheter exchanges. 
The right scapular artery was reported to be safe and effective in infants with critical aortic 
valve stenosis (Alekyan et al., 1995). It typically requires surgical exposure of the artery and 
is contraindicated in the presence of an aberrant right subclavian artery. 
The anterograde transvenous approach may be performed via the foramen ovale or by a 
transeptal puncture when the atrial septum is intact (Hausdorf et al., 1993). This procedure 
spares the femoral arteries for potential future use but may be technically challenging and 
may cause mitral valve damage. 
The right carotid artery was firstly used based on the extensive experience with carotid artery 
cannulation for extracorporeal membrane oxigenation in newborns (Fischer et al., 1990). it is 
reported to be effective and safe, and it allows performing the entire procedure at the bedside 
with the aid of continuous transesophageal echocardiographic guidance, thus avoiding the use 
of fluoroscopy (Weber et al., 2000). Its disadvantages include the risk of carotid artery injury 
with potential neurologic complications and the need of surgical exposure. 
Above all, the retrograde femoral arterial approach remains the most commonly used. The 
potential associated complications have been significantly reduced with the availability of low 
profile diameter balloons. Once the vascular access is assured, the aortic annulus diameter and 
the degree of aortic regurgitation are determined, a complete right and left cardiac 
catheterization is performed and the peak-to-peak transaortic gradient is determined from 
simultaneous or sequential measurements of left ventricular and ascending aorta pressures.  
Balloon aortic valvoplasty is contraindicated when an aortic regurgitation of moderate or 
higher degree is present, and it is not recommended if the valve is significantly calcified. It is 
performed in cases of critical aortic stenosis with variable institutional preferences. 
Recommendations for aortic balloon valvoplasty in adolescents and young adults, which 
may be applied to children, are the following (Bonow & ACC/AHA, 2008): 
Aortic balloon valvotomy is indicated in the adolescent or young adult patient with aortic 
stenosis who has symptoms of angina, syncope, or dyspnea on exertion and a 
catheterization peak LV–to–peak aortic gradient greater than or equal to 50 mmHg without 
a heavily calcified valve (Class I; Level of Evidence C). 
Aortic balloon valvotomy is indicated for the asymptomatic adolescent or young adult 
patient with aortic stenosis who has a catheterization peak LV–to–peak aortic gradient 
greater than 60 mmHg (Class I; Level of Evidence C). 
Aortic balloon valvotomy is indicated in the asymptomatic adolescent or young adult 
patient with aortic stenosis who develops ST or T-wave changes over the left precordium on 
ECG at rest or with exercise and who has a catheterization peak LV–to–aortic gradient 
greater than 50 mmHg (Class I; Level of Evidence C). 
Aortic balloon valvotomy is reasonable in the asymptomatic adolescent or young adult 
patient with aortic stenosis when catheterization peak LV–to–peak aortic gradient is greater 
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than 50 mmHg and the patient wants to play competitive sports or desires to become 
pregnant (Class IIa; Level of Evidence C). 
In the adolescent or young adult patient with aortic stenosis, aortic balloon valvotomy is 
probably recommended over valve surgery when balloon valvotomy is possible. Patients 
should be referred to a center with expertise in balloon valvotomy (Class IIa; Level of Evidence C). 
Aortic balloon valvotomy should not be performed when the asymptomatic adolescent or 
young adult patient with aortic stenosis has a catheterization peak LV–to–peak aortic gradient 
less than 40 mmHg without symptoms or ECG changes (Class III; Level of Evidence C). 
The recommended size of the balloon for the valvoplasty is 80-90% of the measured aortic 
annulus; smaller ones may not be able to accurately relief the obstruction. If the reduction in 
gradient is below 50% or the residual gradient is higher than 50 mmHg and the degree of 
insufficiency remains less than moderate, sequential progressive dilatations using larger 
balloons may be performed, but the size of the balloon may not exceed 120% of the diameter of 
the valvar ring in order to avoid iatrogenic regurgitation (McCrindle et al., 1996; Phillips et al., 
1987; Sholler et al., 1988). The balloon is carefully positioned across the aortic valve and then 
inflated until the waist produced by the valve on the balloon disappears. This technique can be 
performed by using one balloon, or two for large diameter valves. In the double-balloon 
valvoplasty, two separate arterial catheters are used to cross the aortic valve. The typical 
flattening of the balloons against each other during inflation mandates a higher ratio of the 
sum of the balloons nominal diameters to valve annulus to around 130% (both with similar 
diameter and length); the two balloons are positioned across the valve and inflated 
simultaneously. The results in terms of gradient relief and degree of iatrogenic aortic 
regurgitation are similar when compared to the single-balloon procedure, with the additional 
advantages to reduce vessel trauma and to avoid the complete obstruction of the left 
ventricular outflow tract as would occur during inflation of a single large balloon (Beekman et 
al., 1988; Mullins et al., 1987). The rapid movements of the inflated balloon up and down at the 
left ventricular outflow tract during valvoplasty, is thought to favor aortic insufficiency 
(Daehnert et al., 2004). Hence, different maneuvers such as the use of more rigid wires, 
induced asystole with adenosine or ventricular fibrillation have been employed aiming to 
improve balloon stability (Kahn et al., 1998, 2000). Rapid ventricular pacing, is an alternative 
effective and safe way to stabilize the balloon. It consists on electrically stimulating the right 
ventricle rapidly to accelerate the ventricular frequency until a 50% systolic aortic pressure 
drop is achieved, and inflating the balloon at this point (David et al., 2007). An effective relief 
of the obstruction is usually achieved by the valvoplasty, with a 50-70% reduction of the 
pressure gradient in children with isolated aortic stenosis and in those with associated 
cardiovascular lesions (Crespo et al., 2009; Gatzoulis et al., 1995; Kusa et al., 2004; McCrindle et 
al., 1996; Rao et al., 1989). Independent risk factors for suboptimal gradient reduction are high 
pre-valvoplasty transaortic gradient, children aged less than a month or more than 14 years, 
high pre-procedural left ventricle end diastolic pressure, the use of a balloon to annulus ratio 
less than 0.9, and fused bicuspid valve as opposed to pure bicuspid valve (Crespo et al., 2009; 
Kusa et al., 2004; McCrindle et al., 1996). Repeated balloon dilatation, and valvoplasty for 
residual stenosis after surgical valvotomy seem to be efficient (Crespo et al., 2009; Meliones et 
al., 1989; Phillips et al., 1987; Shim et al., 1997; Sholler et al., 1988). Valvoplasty may cause 
aortic regurgitation as the result of commissural avulsion, cusp dehiscence and or tear 
perforation. This iatrogenic regurgitation, which was described to be associated with fused 
bicuspid valves (Reich et al., 2004), has been proven to be related to oversized balloons which 
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lead to improve practice and guidelines, therefore high degrees of immediate post procedural 
insufficiency became uncommon (McCrindle et al., 1996; Phillips et al., 1987; Sholler et al., 
1988). The rate of at least moderate aortic regurgitation shortly after the procedure is between 
7.3-22.6% and may progress afterwards (Crespo et al., 2009; Fratz et al., 2008; McCrindle et al., 
1996; McElhinney et al., 2005; Reich et al., 2004). Iatrogenic aortic insufficiency, severe 
hypotension, ventricular arrhythmias, vessel damage, complete atrioventricular block, cardiac 
tamponade and mitral valve injury are the main serious procedural related complications. In a 
large multi-institutional series of 630 balloon dilatations which did not exclude children with 
associated cardiovascular anomalies major complications occured in 7.1%, significantly more 
frequent in newborns (McCrindle et al., 1996). Mortality attributable to the valvoplasty varies 
between 0 and 2.1%, again with a clearly higher incidence during the neonatal period (Kusa et 
al., 2004; McCrindle et al., 1996; Crespo et al., 2009; Moore et al., 1996). Both progressive 
worsening of aortic regurgitation and an increase in residual transvalvar gradient seem to be 
inevitable. Aortic inssuficiency of at least moderate grade varies between 22.3% and 35% after 
5 to 5.3 years (McElhinney et al., 2005; Reich et al., 2004) and is about 50% at 7.5 years follow-
up interval (Pedra et al., 2003). The increase in residual transvalvar gradient, or restenosis, 
varies between 0% and 32.1% according to different definitions of residual gradients used by 
different investigators (Balmer et al., 2004; Rao et al., 1989; Reich et al., 2004). In a very recent 
series, including both neonates and older children, 10% of the patients needed reintervention 
in the long term due to restenosis (Fratz et al., 2008). The survival rate after valvoplasty at 6 
and 14.4 years varies between 93% and 100% in older children (Fratz et al., 2008; Galal et al., 
1997; Moore et al., 1996; Reich et al., 2004), whereas it varies between 71–74.6% (Fratz et al., 
2008; McElhinney et al., 2005) and 71% (Reich et al., 2004) at 10 and 14.4 years respectively 
when performed in the neonatal period. The freedom from reintervention at mid and long-
term follow up varies between 46 and 76% (Fratz et al., 2008; Galal et al., 1997; Moore et al., 
1996; Rao, 1999; Reich et al., 2004) after 8–14.4 years in older children, whereas it varies 
between 47–57.6% (Fratz et al., 2008; McElhinney et al., 2005; Villalba et al., 2002) and 26% 
(Reich et al., 2004) at 5–10 years and 14.4 years respectively when performed in the neonatal 
period. A significant decrease in dispersion of the ventricular repolarisation is reported 
following valvoplasty in patients with severe congenital aortic stenosis, which would 
theoretically diminish the electrical instability, preventing ventricular arrhythmias later on in 
life (Sarubbi et al., 2004). In conclusion, balloon valvoplasty is a safe an effective method for the 
treatment of congenital aortic valve stenosis, constituting the therapeutic procedure of choice 
in most centers. 
7.2 Fetal intervention 
Congenital heart disease constitutes the most frequent congenital anomaly and the main 
cause of death among infants in the United States, thus it is an attractive target for 
prenatal diagnosis and therapy (Turner et al., 2009). In the case of critical aortic stenosis, 
early in utero relief of the obstruction is thought to reverse the progression toward left 
ventricular hypoplasia (De Oliveira et al., 2004; Tweddell et al., 2002). As hypoplastic left 
heart syndrome is one of the most severe congenital heart defects that requires multi-
staged palliative surgery or even heart transplantation, severe aortic valve stenosis is the 
defect for which fetal intervention is most likely to be considered (Brown et al., 2003; 
McCrindle et al., 2001; McElhinney et al., 2005). The aim of fetal aortic valvuloplasty is to 
relief the left obstruction of the ventricle outlet to prevent progression to endocardial 
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than 50 mmHg and the patient wants to play competitive sports or desires to become 
pregnant (Class IIa; Level of Evidence C). 
In the adolescent or young adult patient with aortic stenosis, aortic balloon valvotomy is 
probably recommended over valve surgery when balloon valvotomy is possible. Patients 
should be referred to a center with expertise in balloon valvotomy (Class IIa; Level of Evidence C). 
Aortic balloon valvotomy should not be performed when the asymptomatic adolescent or 
young adult patient with aortic stenosis has a catheterization peak LV–to–peak aortic gradient 
less than 40 mmHg without symptoms or ECG changes (Class III; Level of Evidence C). 
The recommended size of the balloon for the valvoplasty is 80-90% of the measured aortic 
annulus; smaller ones may not be able to accurately relief the obstruction. If the reduction in 
gradient is below 50% or the residual gradient is higher than 50 mmHg and the degree of 
insufficiency remains less than moderate, sequential progressive dilatations using larger 
balloons may be performed, but the size of the balloon may not exceed 120% of the diameter of 
the valvar ring in order to avoid iatrogenic regurgitation (McCrindle et al., 1996; Phillips et al., 
1987; Sholler et al., 1988). The balloon is carefully positioned across the aortic valve and then 
inflated until the waist produced by the valve on the balloon disappears. This technique can be 
performed by using one balloon, or two for large diameter valves. In the double-balloon 
valvoplasty, two separate arterial catheters are used to cross the aortic valve. The typical 
flattening of the balloons against each other during inflation mandates a higher ratio of the 
sum of the balloons nominal diameters to valve annulus to around 130% (both with similar 
diameter and length); the two balloons are positioned across the valve and inflated 
simultaneously. The results in terms of gradient relief and degree of iatrogenic aortic 
regurgitation are similar when compared to the single-balloon procedure, with the additional 
advantages to reduce vessel trauma and to avoid the complete obstruction of the left 
ventricular outflow tract as would occur during inflation of a single large balloon (Beekman et 
al., 1988; Mullins et al., 1987). The rapid movements of the inflated balloon up and down at the 
left ventricular outflow tract during valvoplasty, is thought to favor aortic insufficiency 
(Daehnert et al., 2004). Hence, different maneuvers such as the use of more rigid wires, 
induced asystole with adenosine or ventricular fibrillation have been employed aiming to 
improve balloon stability (Kahn et al., 1998, 2000). Rapid ventricular pacing, is an alternative 
effective and safe way to stabilize the balloon. It consists on electrically stimulating the right 
ventricle rapidly to accelerate the ventricular frequency until a 50% systolic aortic pressure 
drop is achieved, and inflating the balloon at this point (David et al., 2007). An effective relief 
of the obstruction is usually achieved by the valvoplasty, with a 50-70% reduction of the 
pressure gradient in children with isolated aortic stenosis and in those with associated 
cardiovascular lesions (Crespo et al., 2009; Gatzoulis et al., 1995; Kusa et al., 2004; McCrindle et 
al., 1996; Rao et al., 1989). Independent risk factors for suboptimal gradient reduction are high 
pre-valvoplasty transaortic gradient, children aged less than a month or more than 14 years, 
high pre-procedural left ventricle end diastolic pressure, the use of a balloon to annulus ratio 
less than 0.9, and fused bicuspid valve as opposed to pure bicuspid valve (Crespo et al., 2009; 
Kusa et al., 2004; McCrindle et al., 1996). Repeated balloon dilatation, and valvoplasty for 
residual stenosis after surgical valvotomy seem to be efficient (Crespo et al., 2009; Meliones et 
al., 1989; Phillips et al., 1987; Shim et al., 1997; Sholler et al., 1988). Valvoplasty may cause 
aortic regurgitation as the result of commissural avulsion, cusp dehiscence and or tear 
perforation. This iatrogenic regurgitation, which was described to be associated with fused 
bicuspid valves (Reich et al., 2004), has been proven to be related to oversized balloons which 
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lead to improve practice and guidelines, therefore high degrees of immediate post procedural 
insufficiency became uncommon (McCrindle et al., 1996; Phillips et al., 1987; Sholler et al., 
1988). The rate of at least moderate aortic regurgitation shortly after the procedure is between 
7.3-22.6% and may progress afterwards (Crespo et al., 2009; Fratz et al., 2008; McCrindle et al., 
1996; McElhinney et al., 2005; Reich et al., 2004). Iatrogenic aortic insufficiency, severe 
hypotension, ventricular arrhythmias, vessel damage, complete atrioventricular block, cardiac 
tamponade and mitral valve injury are the main serious procedural related complications. In a 
large multi-institutional series of 630 balloon dilatations which did not exclude children with 
associated cardiovascular anomalies major complications occured in 7.1%, significantly more 
frequent in newborns (McCrindle et al., 1996). Mortality attributable to the valvoplasty varies 
between 0 and 2.1%, again with a clearly higher incidence during the neonatal period (Kusa et 
al., 2004; McCrindle et al., 1996; Crespo et al., 2009; Moore et al., 1996). Both progressive 
worsening of aortic regurgitation and an increase in residual transvalvar gradient seem to be 
inevitable. Aortic inssuficiency of at least moderate grade varies between 22.3% and 35% after 
5 to 5.3 years (McElhinney et al., 2005; Reich et al., 2004) and is about 50% at 7.5 years follow-
up interval (Pedra et al., 2003). The increase in residual transvalvar gradient, or restenosis, 
varies between 0% and 32.1% according to different definitions of residual gradients used by 
different investigators (Balmer et al., 2004; Rao et al., 1989; Reich et al., 2004). In a very recent 
series, including both neonates and older children, 10% of the patients needed reintervention 
in the long term due to restenosis (Fratz et al., 2008). The survival rate after valvoplasty at 6 
and 14.4 years varies between 93% and 100% in older children (Fratz et al., 2008; Galal et al., 
1997; Moore et al., 1996; Reich et al., 2004), whereas it varies between 71–74.6% (Fratz et al., 
2008; McElhinney et al., 2005) and 71% (Reich et al., 2004) at 10 and 14.4 years respectively 
when performed in the neonatal period. The freedom from reintervention at mid and long-
term follow up varies between 46 and 76% (Fratz et al., 2008; Galal et al., 1997; Moore et al., 
1996; Rao, 1999; Reich et al., 2004) after 8–14.4 years in older children, whereas it varies 
between 47–57.6% (Fratz et al., 2008; McElhinney et al., 2005; Villalba et al., 2002) and 26% 
(Reich et al., 2004) at 5–10 years and 14.4 years respectively when performed in the neonatal 
period. A significant decrease in dispersion of the ventricular repolarisation is reported 
following valvoplasty in patients with severe congenital aortic stenosis, which would 
theoretically diminish the electrical instability, preventing ventricular arrhythmias later on in 
life (Sarubbi et al., 2004). In conclusion, balloon valvoplasty is a safe an effective method for the 
treatment of congenital aortic valve stenosis, constituting the therapeutic procedure of choice 
in most centers. 
7.2 Fetal intervention 
Congenital heart disease constitutes the most frequent congenital anomaly and the main 
cause of death among infants in the United States, thus it is an attractive target for 
prenatal diagnosis and therapy (Turner et al., 2009). In the case of critical aortic stenosis, 
early in utero relief of the obstruction is thought to reverse the progression toward left 
ventricular hypoplasia (De Oliveira et al., 2004; Tweddell et al., 2002). As hypoplastic left 
heart syndrome is one of the most severe congenital heart defects that requires multi-
staged palliative surgery or even heart transplantation, severe aortic valve stenosis is the 
defect for which fetal intervention is most likely to be considered (Brown et al., 2003; 
McCrindle et al., 2001; McElhinney et al., 2005). The aim of fetal aortic valvuloplasty is to 
relief the left obstruction of the ventricle outlet to prevent progression to endocardial 
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fibroelastosis and ventricle hypoplasia. Some echocardiographic features found in 
midgestation fetuses with aortic stenosis and normal left ventricle length including 
retrograde flow in the transverse arch, left-to-right flow across the foramen ovale, 
monophasic mitral inflow and left ventricular dysfunction have been reported to predict 
progression to hypoplastic left heart syndrome (Makikallio et al., 2006). Fetal aortic 
valvuloplasty must be performed in the early second trimester. The procedure can be 
performed by laparotomy to expose the uterus or by uterine incision and fetal exposure. 
These invasive techniques offer better ultrasound imaging quality and shorter distance to 
the fetal heart, but they carry the risk of increased maternal morbidity and premature 
delivery. For these reasons less invasive techniques are preferred. Under bidimensional 
ultrasound guidance, a 19G cannula and stylet needle are advanced through the maternal 
abdomen, uterine wall and fetal chest wall, accessing the fetal heart by the left ventricle. 
The valvoplasty is performed with a small coronary artery balloon over a thin, floppy 
guide wire. The balloon is inflated and the procedure is considered successful if there is 
clear evidence of increased anterograde flow across the valve and/or new aortic 
regurgitation by color-Doppler (Marshall et al., 2005; McElhinney et al., 2009; Wilkins-
Haug et al., 2006). Complications of valvoplasty in the fetus include bradycardia (50% 
upon needle access to the ventricle), pericardial effusion, significant iatrogenic aortic 
regurgitation and fetal demise. Boston Children´s Hospital has the largest experience with 
the technique (McElhinney et al., 2009): 70 interventions were attempted in fetuses 
expected to progress to hypoplastic left heart syndrome without intervention; 52 
procedures were considered successful (74%); hemodynamic changes (bradycardia and 
ventricular dysfunction) treated with intramuscular and/or intracardiac medications 
and/or hemopericardium for which drainage was attempted occurred in 28 fetuses (40%) 
(Mizrahi-Arnaud et al., 2007); moderate or severe aortic regurgitation was noted in 20 
fetuses (38%), resolved or improved to mild regurgitation in all but 1 case. In the Boston 
series, 1 pregnancy was terminated and 8 others (13% total) ended in fetal death or 
preterm stillbirth. The rate of growth of the left cardiac structures was greater among 
fetuses that underwent successful intervention. Finally, 20 of the 70 patients (29%) 
achieved the ultimate goal of biventricular circulation. 
In conclusion, fetal aortic valvoplasty may be useful in fetuses with aortic stenosis. The 
potential benefits of the procedure must be weighted against the inherent serious risks. 
Based on the current knowledge, fetal aortic valvoplasty should not be performed in fetuses 
with aortic stenosis that will not otherwise progress to hypoplastic left heart syndrome. 
7.3 Surgery 
Two opposed clinical situations have to be considered when referring to surgical procedures 
in aortic stenosis. The single-ventricle end of the spectrum is characterized by a severe 
degree of underdevelopment of the left heart-aorta complex, resulting in obstruction to the 
systemic cardiac output and the inability of the left heart to support the systemic circulation. 
The two-ventricle end of the spectrum is characterized by a normal or moderately 
underdeveloped left heart-aorta complex, able to fully support the systemic circulation. 
7.3.1 Two-ventricle repair 
Surgical valvotomy is of historic interest and is rarely used as first attempt in children. 
When balloon aortic valvoplasty is ineffective or significant aortic regurgitation is present, 
valve repair or replacement may be necessary (Bonow & ACC/AHA, 2008). 
 




Open valvotomy with cardiopulmonary bypass, firstly described in 1958 (Spencer et al., 
1958), has remained the main therapeutic option for congenital aortic stenosis in neonates 
and infants until the advent of balloon valvoplasty in the early 1980s. It offers the advantage 
of a detailed examination of the valve and accurate valvotomy, in opposition to the blind 
dilatation of the balloon procedure. Its main disadvantages are the morbidity and mortality 
related to the surgery and the cardiopulmonary bypass, and an increase in the complexity of 
a future surgery due to redo sternotomy. The operation is performed on cardiopulmonary 
bypass with mild hypotermia, through median sternotomy (Hraska et al., 2007). The 
anterior part of the aortic root is dissected to identify the origin of the right coronary artery, 
and the aorta is incised 5-10 mm above the origin of the coronary artery. Holding sutures are 
placed on the edges of the aortotomy and the aortic valve is carefully examined. Finally, the 
fused commissures are carefully divided, ensuring that the leaflets are well supported and 
not liable to prolapse. Other techniques such as closed transventricular valvotomy have 
been also used for the initial management of critical neonatal aortic stenosis in some centers 
(Brown et al., 2006). Both the reduction of the transaortic gradient (53-67%) and the creation 
of significant aortic regurgitation (8-21%) after the surgical valvotomy are similar to those 
described for the valvoplasty technique (Alexiou et al., 2001; Brown et al., 2003; Miyamoto et 
al., 2006; Zafra et al., 1993). Early mortality after neonatal surgical aortic valvotomy was 
very high in the early experience but was significantly reduced in subsequent publications, 
with rates varying between 2.1% and 18% (Alexiou et al., 2001; Bhabra et al., 2003; Brown et 
al., 2003; Gildein et al., 1996; Hawkins et al., 1998; Miyamoto et al., 2006; Zain et al., 2006). 
Several risk factors for increased operative mortality include endocardial fibroelastosis, 
hypoplastic left ventricle, hypoplastic aortic annulus, associated cardiovascular anomalies, 
extremely small neonates, earlier era surgery, monocuspid aortic valve and impaired left 
ventricular function (Bhabra et al., 2003; Brown et al., 2006; Hawkins et al., 1998; Miyamoto 
et al., 2006). Similarly to what happens after balloon dilatation, progressive worsening of 
aortic insufficiency and re-stenosis occurs at long-term follow up after surgical valvotomy. 
The freedom from reintervention is 80-85% after 5-7 years (Brown et al., 2006; Cobanoglu & 
Dobbs, 1996; Miyamoto et al., 2006), 55-78% after 10 years (Alexiou et al., 2001; Brown et al., 
2006; Hawkins et al., 1998; Miyamoto et al., 2006) and 53-65% after 15-20 years (Brown et al., 
2006; Miyamoto et al., 2006). Long-term survival rate is 74-100% at 5-10 years (Alexiou et al., 
2001; Bhabra et al., 2003; Brown et al., 2003; Cowley et al., 2001; Gaynor et al., 1995; Hawkins 
et al., 1998) and 84-88% at 15-20 years (Brown et al., 2003; Gaynor et al., 1995). A 
retrospective review of infants undergoing primary surgical aortic valvotomy showed better 
long-term outcomes (in terms of survival and freedom from reintervention) when surgery 
resulted in trileaflet rather than bileaflet anatomy (Bhabra et al., 2003). 
7.3.1.2 Repair procedures 
When the aortic stenosis coexists with a severe degree of valvar incompetence both 
primarily or after a first approach by either balloon dilatation or surgical valvotomy, some 
authors have proposed reconstructive techniques such as reattachment of an avulsed cusp to 
the aortic annulus, relief of commissural fusion and debridement of thickened cusps instead 
of valvar replacement (Alsoufi et al. 2006; Bacha et al., 2001; Hawkins et al., 1996; Odim et 
al., 2005; Polimenakos et al., 2010; Schäfers et al.; 2008). Bicuspidisation procedure, whose 
principles are elevation of the comissure and augmentation of the cusps, has been advocated 
for unicuspid aortic valves (Schäfers et al.; 2008). This conversion into bicuspid anatomy has 
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fibroelastosis and ventricle hypoplasia. Some echocardiographic features found in 
midgestation fetuses with aortic stenosis and normal left ventricle length including 
retrograde flow in the transverse arch, left-to-right flow across the foramen ovale, 
monophasic mitral inflow and left ventricular dysfunction have been reported to predict 
progression to hypoplastic left heart syndrome (Makikallio et al., 2006). Fetal aortic 
valvuloplasty must be performed in the early second trimester. The procedure can be 
performed by laparotomy to expose the uterus or by uterine incision and fetal exposure. 
These invasive techniques offer better ultrasound imaging quality and shorter distance to 
the fetal heart, but they carry the risk of increased maternal morbidity and premature 
delivery. For these reasons less invasive techniques are preferred. Under bidimensional 
ultrasound guidance, a 19G cannula and stylet needle are advanced through the maternal 
abdomen, uterine wall and fetal chest wall, accessing the fetal heart by the left ventricle. 
The valvoplasty is performed with a small coronary artery balloon over a thin, floppy 
guide wire. The balloon is inflated and the procedure is considered successful if there is 
clear evidence of increased anterograde flow across the valve and/or new aortic 
regurgitation by color-Doppler (Marshall et al., 2005; McElhinney et al., 2009; Wilkins-
Haug et al., 2006). Complications of valvoplasty in the fetus include bradycardia (50% 
upon needle access to the ventricle), pericardial effusion, significant iatrogenic aortic 
regurgitation and fetal demise. Boston Children´s Hospital has the largest experience with 
the technique (McElhinney et al., 2009): 70 interventions were attempted in fetuses 
expected to progress to hypoplastic left heart syndrome without intervention; 52 
procedures were considered successful (74%); hemodynamic changes (bradycardia and 
ventricular dysfunction) treated with intramuscular and/or intracardiac medications 
and/or hemopericardium for which drainage was attempted occurred in 28 fetuses (40%) 
(Mizrahi-Arnaud et al., 2007); moderate or severe aortic regurgitation was noted in 20 
fetuses (38%), resolved or improved to mild regurgitation in all but 1 case. In the Boston 
series, 1 pregnancy was terminated and 8 others (13% total) ended in fetal death or 
preterm stillbirth. The rate of growth of the left cardiac structures was greater among 
fetuses that underwent successful intervention. Finally, 20 of the 70 patients (29%) 
achieved the ultimate goal of biventricular circulation. 
In conclusion, fetal aortic valvoplasty may be useful in fetuses with aortic stenosis. The 
potential benefits of the procedure must be weighted against the inherent serious risks. 
Based on the current knowledge, fetal aortic valvoplasty should not be performed in fetuses 
with aortic stenosis that will not otherwise progress to hypoplastic left heart syndrome. 
7.3 Surgery 
Two opposed clinical situations have to be considered when referring to surgical procedures 
in aortic stenosis. The single-ventricle end of the spectrum is characterized by a severe 
degree of underdevelopment of the left heart-aorta complex, resulting in obstruction to the 
systemic cardiac output and the inability of the left heart to support the systemic circulation. 
The two-ventricle end of the spectrum is characterized by a normal or moderately 
underdeveloped left heart-aorta complex, able to fully support the systemic circulation. 
7.3.1 Two-ventricle repair 
Surgical valvotomy is of historic interest and is rarely used as first attempt in children. 
When balloon aortic valvoplasty is ineffective or significant aortic regurgitation is present, 
valve repair or replacement may be necessary (Bonow & ACC/AHA, 2008). 
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1958), has remained the main therapeutic option for congenital aortic stenosis in neonates 
and infants until the advent of balloon valvoplasty in the early 1980s. It offers the advantage 
of a detailed examination of the valve and accurate valvotomy, in opposition to the blind 
dilatation of the balloon procedure. Its main disadvantages are the morbidity and mortality 
related to the surgery and the cardiopulmonary bypass, and an increase in the complexity of 
a future surgery due to redo sternotomy. The operation is performed on cardiopulmonary 
bypass with mild hypotermia, through median sternotomy (Hraska et al., 2007). The 
anterior part of the aortic root is dissected to identify the origin of the right coronary artery, 
and the aorta is incised 5-10 mm above the origin of the coronary artery. Holding sutures are 
placed on the edges of the aortotomy and the aortic valve is carefully examined. Finally, the 
fused commissures are carefully divided, ensuring that the leaflets are well supported and 
not liable to prolapse. Other techniques such as closed transventricular valvotomy have 
been also used for the initial management of critical neonatal aortic stenosis in some centers 
(Brown et al., 2006). Both the reduction of the transaortic gradient (53-67%) and the creation 
of significant aortic regurgitation (8-21%) after the surgical valvotomy are similar to those 
described for the valvoplasty technique (Alexiou et al., 2001; Brown et al., 2003; Miyamoto et 
al., 2006; Zafra et al., 1993). Early mortality after neonatal surgical aortic valvotomy was 
very high in the early experience but was significantly reduced in subsequent publications, 
with rates varying between 2.1% and 18% (Alexiou et al., 2001; Bhabra et al., 2003; Brown et 
al., 2003; Gildein et al., 1996; Hawkins et al., 1998; Miyamoto et al., 2006; Zain et al., 2006). 
Several risk factors for increased operative mortality include endocardial fibroelastosis, 
hypoplastic left ventricle, hypoplastic aortic annulus, associated cardiovascular anomalies, 
extremely small neonates, earlier era surgery, monocuspid aortic valve and impaired left 
ventricular function (Bhabra et al., 2003; Brown et al., 2006; Hawkins et al., 1998; Miyamoto 
et al., 2006). Similarly to what happens after balloon dilatation, progressive worsening of 
aortic insufficiency and re-stenosis occurs at long-term follow up after surgical valvotomy. 
The freedom from reintervention is 80-85% after 5-7 years (Brown et al., 2006; Cobanoglu & 
Dobbs, 1996; Miyamoto et al., 2006), 55-78% after 10 years (Alexiou et al., 2001; Brown et al., 
2006; Hawkins et al., 1998; Miyamoto et al., 2006) and 53-65% after 15-20 years (Brown et al., 
2006; Miyamoto et al., 2006). Long-term survival rate is 74-100% at 5-10 years (Alexiou et al., 
2001; Bhabra et al., 2003; Brown et al., 2003; Cowley et al., 2001; Gaynor et al., 1995; Hawkins 
et al., 1998) and 84-88% at 15-20 years (Brown et al., 2003; Gaynor et al., 1995). A 
retrospective review of infants undergoing primary surgical aortic valvotomy showed better 
long-term outcomes (in terms of survival and freedom from reintervention) when surgery 
resulted in trileaflet rather than bileaflet anatomy (Bhabra et al., 2003). 
7.3.1.2 Repair procedures 
When the aortic stenosis coexists with a severe degree of valvar incompetence both 
primarily or after a first approach by either balloon dilatation or surgical valvotomy, some 
authors have proposed reconstructive techniques such as reattachment of an avulsed cusp to 
the aortic annulus, relief of commissural fusion and debridement of thickened cusps instead 
of valvar replacement (Alsoufi et al. 2006; Bacha et al., 2001; Hawkins et al., 1996; Odim et 
al., 2005; Polimenakos et al., 2010; Schäfers et al.; 2008). Bicuspidisation procedure, whose 
principles are elevation of the comissure and augmentation of the cusps, has been advocated 
for unicuspid aortic valves (Schäfers et al.; 2008). This conversion into bicuspid anatomy has 
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been reported to have no mortality, good functional results and appropriate freedom from 
reintervention (67%) and from valve replacement (100%) at 4 years. Other non replacement 
strategy is aortic cusp extension valvuloplasty with selective use of tricuspidization 
(Polimenakos et al., 2010). Pericardial cusp extension counteracts the valve’s inherent 
sinuses of Valsalva shallowness, reestablishes normal depth of the sinuses, secures adequate 
and longer coaptation surface and restores the normal “crownlike” appearance of the valve; 
while tricuspidization ensures a larger central opening and minimizes turbulence. This 
technique has been proven to effectively reduce aortic insufficiency and regurgitation, and 
to improve left ventricular wall thickness and dimensions in infants and children. Its long-
term outcomes at 1, 5 and 10 years are 97, 71 and 51% free from moderate or greater aortic 
regurgitation; 97, 67 and 54% free from moderate or greater aortic stenosis; and 97, 71 and 
56% free from aortic valve replacement. 
7.3.1.3 Aortic valve replacement 
7.3.1.3.1 Ross operation 
The Ross operation was firstly described in 1967 (Ross, 1967). It was initially considered too 
complex by the surgical community and was relegated to single curiosity until 1988, when 
its long-term results were reported (Ross, 1988). The Ross procedure consists on aortic valve 
replacement with a pulmonary autograft. During the operation, the pulmonary native valve 
was substituted by a homograft in the first series, or alternatively by a valved conduit in 
subsequent practice constituted by a gluterhaldeheyde preserved bovine jugular vein. When 
the left ventricular outflow tract is enlarged during the procedure, then the surgery is 
denominated Ross-Konno (Reddy et al., 1996). The Ross operation appeared to be the 
panacea of aortic valve replacements for growing infants and children due to the excellent 
hemodynamic performance and growing capacity of the autograft, the long-term expected 
durability of the homograft and a very low thrombogenecity which makes anticoagulant 
therapy unnecessary (Elkins, 1999; Oury, 1996), but some patients did require reoperations 
because of autograft or homograft failure and progressive dilatation of the neo-aortic root. 
New improvements were applied to prevent neoaortic root dilatation and autograft 
regurgitation using graft inclusion techniques. A Ross operation may be considered 
whenever replacement of the aortic valve is indicated, especially in the youngest patients. 
Moreover, it is contraindicated in case of primary or iatrogenic lesions of the pulmonary 
valve for obvious reasons, in Marfan syndrome and in autoimmune tissue diseases (Corno 
et al., 2001). Early mortality is 1-2.5% (Brown et al., 2009; Kouchoukos et al., 2004; Oury et 
al., 1998) with a 10-15-year survival rate of 96-98% (Brown et al., 2009; Kouchoukos et al., 
2004), observing significantly better outcomes for children older than 1 year of age 
compared to children under 1 year (Brown et al., 2009). In a large series with infants, 
children and adults, overall freedom from reoperation was 91% at 15 years (Brown et al., 
2009). In a study on older children and young adults, event-free survival (freedom from 
death, reoperation, thromboembolism and endocarditis) was 93% at 5 years, 78% at 7 years, 
and 73% at 10 years postoperatively (Kouchoukos et al., 2004). A recent series of 27 infants 
less than 18 months of age who underwent the Ross procedure showed 3 early and no late 
deaths, and freedom for reintervention of 87% at 8 years (Williams et al., 2005).  
7.3.1.3.2 Mechanical valve replacement 
The selection of the most appropriate substitute in children with irreparable aortic valve lesion 
remains controversial. The first mechanical model was the caged-ball mechanical prosthesis, 
 
Congenital Aortic Stenosis in Childhood   
 
17 
used in the 1960s and early 1970s. The xenograft valve was introduced in the early to mid-
1970s and was initially considered better suited for children, but unfortunately these valves 
demonstrated early failure (Robbins et al., 1988). The new generation mechanical valves 
exhibit minimal structural degeneration, but continue to be prone to valve-related 
complications. Mechanical prosthetic valves carry the risks of thromboembolism, requiring 
anticoagulation. The use of these valves also faces the need of iterative replacement because of 
the valve outgrowth in the growing young patient. Nevertheless, its safety and reproducible 
implantation technique, good hemodynamic performance, low incidence of valve-related 
events, acceptable short and long-term outcomes and prolonged durability, convert it into a 
good alternative in cases where aortic valve replacement is mandatory (Alexiou et al., 2000). 
The longevity of mechanical prostheses is superior compared to bioprosthetic valves, but its 
implantation has been associated with very high early re-intervention rate and poor survival 
in neonates and small infants, limiting its use in these ages (Karamlou et al., 2005). Aortic valve 
replacement using mechanical prosthetic valves in children often requires annular 
enlargement to insert commercially available prostheses. This enlargement can be performed 
by different techniques: the Konno procedure involves incision of the ventricular septum, 
which might cause ventricular dysfunction, atrioventricular conduction block or arrhythmias; 
the Manouguian procedure with extension of the incision to the anterior mitral leaflet might 
cause mitral inssufficiency; and Yamaguchi procedure with an anterior incision in the aortic 
annulus is directed into the commissure between the right and left coronary cusps continued 
downward across the aortic ring to near full thickness of the right ventricular wall, is 
nowadays the technique of choice because it does not damage the ventricular septum or the 
mitral valve (Masuda et al., 2008). Operative death rate varies between 0-5% in several series 
(Alexiou et al., 2000; Karamlou et al., 2005; Masuda et al., 2008; Mazzitelli et al., 1998; Popov et 
al., 2009; Turrentine et al., 2001), mostly involving children with severe preoperative 
pulmonary hypertension or myocardial dysfunction. Although previous series showed worse 
outcomes, more recent studies report actuarial survival of 89-95% at 10 years (Alexiou et al., 
2000; Turrentine et al., 2001), 87-92% at 15 years (Masuda et al., 2008) and 85% at 20 years 
(Alexiou et al., 2000). Freedom from surgical re-intervention ranges between 80-92% at 10 
years (Alexiou et al., 2000; Champsaur et al., 1997; Mazzitelli et al., 1998; Turrentine et al., 
2001), 85-86% at 15 years (Alexiou et al., 2000; Turrentine et al., 2001) and 54-86% at 20 years 
(Alexiou et al., 2000; Mazzitelli et al., 1998). A very recent series from Japan of 45 children with 
a median follow-up of 9.2 years showed excellent outcomes, with an actuarial freedom from 
reoperation of 94% at 15 years (Masuda et al., 2008). This publication also noted that 40 of the 
42 (95%) survivors had a peak Doppler gradient less than 3 m/s at the latest evaluation. This 
finding endorses the previous report of 44 of the 50 (88%) survivors being in NYHA class I 
with a mean Doppler gradient across the aortic prosthesis of 17.9 mmHg at last follow-up 
(mean follow-up of 7.7 years) (Alexiou et al., 2000), thus highlighting the importance of the 
functional status and the hemodynamic performance. Some authors have observed a 
correlation among transprosthetic flow velocity and manufactured valve area, suggesting that 
implantation of mechanical valves of 19 mm or larger may not require further re-replacement 
(Masuda et al., 2008; Shanmugan et al., 2005). This is obviously a clear limitation for the low 
spectrum of the pediatric age group. 
7.3.2 Single-ventricle repair 
The single ventricle end of the spectrum is characterized by a severe degree of 
underdevelopment of the left heart-aorta complex, with a resulting inability of the left heart 
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been reported to have no mortality, good functional results and appropriate freedom from 
reintervention (67%) and from valve replacement (100%) at 4 years. Other non replacement 
strategy is aortic cusp extension valvuloplasty with selective use of tricuspidization 
(Polimenakos et al., 2010). Pericardial cusp extension counteracts the valve’s inherent 
sinuses of Valsalva shallowness, reestablishes normal depth of the sinuses, secures adequate 
and longer coaptation surface and restores the normal “crownlike” appearance of the valve; 
while tricuspidization ensures a larger central opening and minimizes turbulence. This 
technique has been proven to effectively reduce aortic insufficiency and regurgitation, and 
to improve left ventricular wall thickness and dimensions in infants and children. Its long-
term outcomes at 1, 5 and 10 years are 97, 71 and 51% free from moderate or greater aortic 
regurgitation; 97, 67 and 54% free from moderate or greater aortic stenosis; and 97, 71 and 
56% free from aortic valve replacement. 
7.3.1.3 Aortic valve replacement 
7.3.1.3.1 Ross operation 
The Ross operation was firstly described in 1967 (Ross, 1967). It was initially considered too 
complex by the surgical community and was relegated to single curiosity until 1988, when 
its long-term results were reported (Ross, 1988). The Ross procedure consists on aortic valve 
replacement with a pulmonary autograft. During the operation, the pulmonary native valve 
was substituted by a homograft in the first series, or alternatively by a valved conduit in 
subsequent practice constituted by a gluterhaldeheyde preserved bovine jugular vein. When 
the left ventricular outflow tract is enlarged during the procedure, then the surgery is 
denominated Ross-Konno (Reddy et al., 1996). The Ross operation appeared to be the 
panacea of aortic valve replacements for growing infants and children due to the excellent 
hemodynamic performance and growing capacity of the autograft, the long-term expected 
durability of the homograft and a very low thrombogenecity which makes anticoagulant 
therapy unnecessary (Elkins, 1999; Oury, 1996), but some patients did require reoperations 
because of autograft or homograft failure and progressive dilatation of the neo-aortic root. 
New improvements were applied to prevent neoaortic root dilatation and autograft 
regurgitation using graft inclusion techniques. A Ross operation may be considered 
whenever replacement of the aortic valve is indicated, especially in the youngest patients. 
Moreover, it is contraindicated in case of primary or iatrogenic lesions of the pulmonary 
valve for obvious reasons, in Marfan syndrome and in autoimmune tissue diseases (Corno 
et al., 2001). Early mortality is 1-2.5% (Brown et al., 2009; Kouchoukos et al., 2004; Oury et 
al., 1998) with a 10-15-year survival rate of 96-98% (Brown et al., 2009; Kouchoukos et al., 
2004), observing significantly better outcomes for children older than 1 year of age 
compared to children under 1 year (Brown et al., 2009). In a large series with infants, 
children and adults, overall freedom from reoperation was 91% at 15 years (Brown et al., 
2009). In a study on older children and young adults, event-free survival (freedom from 
death, reoperation, thromboembolism and endocarditis) was 93% at 5 years, 78% at 7 years, 
and 73% at 10 years postoperatively (Kouchoukos et al., 2004). A recent series of 27 infants 
less than 18 months of age who underwent the Ross procedure showed 3 early and no late 
deaths, and freedom for reintervention of 87% at 8 years (Williams et al., 2005).  
7.3.1.3.2 Mechanical valve replacement 
The selection of the most appropriate substitute in children with irreparable aortic valve lesion 
remains controversial. The first mechanical model was the caged-ball mechanical prosthesis, 
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used in the 1960s and early 1970s. The xenograft valve was introduced in the early to mid-
1970s and was initially considered better suited for children, but unfortunately these valves 
demonstrated early failure (Robbins et al., 1988). The new generation mechanical valves 
exhibit minimal structural degeneration, but continue to be prone to valve-related 
complications. Mechanical prosthetic valves carry the risks of thromboembolism, requiring 
anticoagulation. The use of these valves also faces the need of iterative replacement because of 
the valve outgrowth in the growing young patient. Nevertheless, its safety and reproducible 
implantation technique, good hemodynamic performance, low incidence of valve-related 
events, acceptable short and long-term outcomes and prolonged durability, convert it into a 
good alternative in cases where aortic valve replacement is mandatory (Alexiou et al., 2000). 
The longevity of mechanical prostheses is superior compared to bioprosthetic valves, but its 
implantation has been associated with very high early re-intervention rate and poor survival 
in neonates and small infants, limiting its use in these ages (Karamlou et al., 2005). Aortic valve 
replacement using mechanical prosthetic valves in children often requires annular 
enlargement to insert commercially available prostheses. This enlargement can be performed 
by different techniques: the Konno procedure involves incision of the ventricular septum, 
which might cause ventricular dysfunction, atrioventricular conduction block or arrhythmias; 
the Manouguian procedure with extension of the incision to the anterior mitral leaflet might 
cause mitral inssufficiency; and Yamaguchi procedure with an anterior incision in the aortic 
annulus is directed into the commissure between the right and left coronary cusps continued 
downward across the aortic ring to near full thickness of the right ventricular wall, is 
nowadays the technique of choice because it does not damage the ventricular septum or the 
mitral valve (Masuda et al., 2008). Operative death rate varies between 0-5% in several series 
(Alexiou et al., 2000; Karamlou et al., 2005; Masuda et al., 2008; Mazzitelli et al., 1998; Popov et 
al., 2009; Turrentine et al., 2001), mostly involving children with severe preoperative 
pulmonary hypertension or myocardial dysfunction. Although previous series showed worse 
outcomes, more recent studies report actuarial survival of 89-95% at 10 years (Alexiou et al., 
2000; Turrentine et al., 2001), 87-92% at 15 years (Masuda et al., 2008) and 85% at 20 years 
(Alexiou et al., 2000). Freedom from surgical re-intervention ranges between 80-92% at 10 
years (Alexiou et al., 2000; Champsaur et al., 1997; Mazzitelli et al., 1998; Turrentine et al., 
2001), 85-86% at 15 years (Alexiou et al., 2000; Turrentine et al., 2001) and 54-86% at 20 years 
(Alexiou et al., 2000; Mazzitelli et al., 1998). A very recent series from Japan of 45 children with 
a median follow-up of 9.2 years showed excellent outcomes, with an actuarial freedom from 
reoperation of 94% at 15 years (Masuda et al., 2008). This publication also noted that 40 of the 
42 (95%) survivors had a peak Doppler gradient less than 3 m/s at the latest evaluation. This 
finding endorses the previous report of 44 of the 50 (88%) survivors being in NYHA class I 
with a mean Doppler gradient across the aortic prosthesis of 17.9 mmHg at last follow-up 
(mean follow-up of 7.7 years) (Alexiou et al., 2000), thus highlighting the importance of the 
functional status and the hemodynamic performance. Some authors have observed a 
correlation among transprosthetic flow velocity and manufactured valve area, suggesting that 
implantation of mechanical valves of 19 mm or larger may not require further re-replacement 
(Masuda et al., 2008; Shanmugan et al., 2005). This is obviously a clear limitation for the low 
spectrum of the pediatric age group. 
7.3.2 Single-ventricle repair 
The single ventricle end of the spectrum is characterized by a severe degree of 
underdevelopment of the left heart-aorta complex, with a resulting inability of the left heart 
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to support the systemic circulation. The hypoplasia of the left cardiac structures makes a 
biventricular approach unfeasible, which lead to the complex medical surgical management 
with a single ventricle multistage palliation and heart transplantation in specific situations. 
7.3.2.1 Staged surgical palliation 
The goal of staged reconstruction is creating separate pulmonary and systemic circulations 
supported by a single (right) ventricle. The Norwood procedure is usually the initial 
palliative procedure in the newborn, followed by a hemi-Fontan or bidirectional Glenn 
anastomosis (bidirectional cavopulmonary shunt) at 4-6 months and by a modified Fontan 
procedure (total cavopulmonary connection) at 2-4 years of age (Ashburn et al., 2003; Barron 
et al., 2009; Bove et al., 2004). 
The Norwood procedure (Norwood et al., 1983) consists on atrial septectomy, reconstruction 
of the aortic arch to remove associated hypoplasia or coarctation, connection of the main 
pulmonary artery into this reconstructed arch and placement of a small shunt between the 
systemic and the pulmonary circulations achieved either by a Blalock-Taussig or by a Gore-
tex shunt (the classical Norwood operation) or by a right ventricular to pulmonary artery 
conduit (the Norwood procedure with the Sano modification) (Sano et al., 2004). The Sano 
modification typically eliminates the diastolic runoff into the pulmonary circulation with 
subsequent coronary steal and potential risk of sudden death, with the limiting factor of 
limited pulmonary artery growth requiring performing the bidirectional cavopulmonary 
shunt earlier than what is required following the classical Norwood procedure. Early 
mortality of the first stage of palliation was very high (30-35%) in the first series but has 
dramatically improved, with current early survival of 80-90% (McGuirk et al., 2006; Stasik et 
al., 2006; Tweddell et al., 2002). Several operative risk factors have been identified including 
late initial presentation, prematurity, low birthweight (less than 3 kg), associated genetic 
anomalies, an ascending aorta smaller than 2 mm, intact or restrictive atrial septum, 
moderate or severe tricuspid regurgitation and pre-existing ventricular dysfunction 
(Ashburn et al., 2003; Azakie et al., 2001; Stasik et al., 2006; Tweddell et al., 2002). Although 
the Norwood operation remains one of the highest risk procedures in pediatric cardiac 
surgery, the second and third stages are much less hazardous, with 1-6% of early mortality 
(Gentles et al., 1997; Hirsch et al., 2008). Considering both peri-procedural and interstage 
mortality, actuarial survival after a Norwood procedure is 58-66% at 1 year (Ashburn et al., 
2003; McGuirk et al., 2006; Tweddell et al., 2002), 40-61% at 5 years (Ashburn et al., 2003; 
Azakie et al., 2001; McGuirk et al., 2006; Tweddell et al., 2002) and 50% at 10 years (McGuirk 
et al., 2006). Long-term and functional outcome data following the staged univentricular 
palliation is being evaluated, with the expectation that these ventricles are likely to fail, on 
the basis of observations of other situations in which the right ventricle supports the 
systemic circulation, such as congenitally corrected transposition (Barron et al., 2009). 
7.3.2.2 Cardiac transplantation 
The concept of transplantation as a treatment for hypoplastic left heart syndrome developed 
together with the palliative approach of the Norwood procedure. Data from several centers 
show an 11-14% early mortality following the procedure (Chrisant et al., 2005; Razzouk et 
al., 1996), with a post-transplant actuarial survival of 84% (Razzouk et al., 1996), 72-76% 
(Chrisant et al., 2005; Razzouk et al., 1996) and 70% (Razzouk et al., 1996) at 1, 5 and 7 years, 
respectively. Innovations in peri-transplant management such as the development of new 
immunosuppressive strategies and the realization that ABO incompatibility is possible in 
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neonatal transplantation because the immune response is not mature, have contributed to 
significantly improve its outcomes. Unfortunately, 20-25% of the patients die while awaiting 
for suitable donors (Jenkins et al., 2000; Razzouk et al., 1996), decreasing the rate of actuarial 
survival to 54-55% at 5 years when also accounting for these deaths (Chrisant et al., 2005; 
Jenkins et al., 2000). Although the benefit of a biventricular physiology produces better 
quality of life in children who receive a successful transplant compared with age-matched 
palliative-staged patients, major disadvantages of cardiac transplantation include high 
mortality on the waiting list as well as the immunosuppressant side-effects and morbidities. 
Some authors have suggested that cardiac transplantation may be offered to those patients 
at higher risk in staged surgery (Jenkins et al., 2000). 
7.3.2.3 The hybrid procedure 
The hybrid procedure has recently emerged as an innovative alternative to the Norwood 
operation (Akintuerk et al., 2002). This technique offers the advantage of avoiding 
cardiopulmonary bypass, cardioplegic arrest and circulatory arrest in the neonatal period. 
As infants are thought to be less vulnerable to postoperative myocardial and neurologic 
injury than neonates, this strategy may be associated with improved neurodevelopmental 
and functional outcomes (Akintuerk et al., 2002; Bacha & Hijazi, 2005; Galantowicz & 
Cheatham, 2005). The hybrid procedure, which involves both surgeons and interventional 
cardiologists, consists on placing bilateral pulmonary bands to limit flow to the lungs, 
implanting a stent in the ductus arteriosus and performing a balloon atrial septostomy 
(occasionally placing a stent). It is performed through a standard sternotomy but does not 
require cardiopulmonary bypass. The second step of the staged palliation is carried out as 
usual at 4-6 months. It will include both cavopulmonary shunt and aortic arch 
reconstruction, typically without full circulatory arrest to the brain. It has been advocated 
that it may have an overall survival advantage due to the fact that an in-series circulation 
(hybrid procedure) is more stable than a balanced circulation (Norwood procedure), and 
it might also have a role in stabilizing patients awaiting suitable cardiac donors (Bacha et 
al., 2006). On the other hand, complications such as stent migration and stent occlusion 
may occur, and the second stage of the palliation may be more extensive and complex 
thus carrying increased operative mortality. Finally, no consensus exists on the future of 
the hybrid approach. The potential benefits it offers may be weighted against the risks it 
carries. 
7.4 Percutaneous aortic valve replacement 
Percutaneous valve replacement is being developed. Although semilunar valve replacement 
has been successfully performed in adults for the aortic position and also in children for the 
pulmonary valve position, an aortic replacement during childhood seems to be more 
challenging technically due to sheath size, coronary artery blockage and potential mitral 
valve injury (Schneider et al., 2004). Anyway, percutaneous valve implantation is currently 
in development and may have a role on selected pediatric patients in the future. 
7.5 Physical activity 
Physical activity is not restricted in asymptomatic patients with mild aortic stenosis; these 
patients can participate in competitive sports. Patients with severe aortic stenosis should be 
restricted from all competitive athletic sports, while those with moderate aortic stenosis 
should avoid competitive sports that involve high dynamic and static muscular demands. 
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to support the systemic circulation. The hypoplasia of the left cardiac structures makes a 
biventricular approach unfeasible, which lead to the complex medical surgical management 
with a single ventricle multistage palliation and heart transplantation in specific situations. 
7.3.2.1 Staged surgical palliation 
The goal of staged reconstruction is creating separate pulmonary and systemic circulations 
supported by a single (right) ventricle. The Norwood procedure is usually the initial 
palliative procedure in the newborn, followed by a hemi-Fontan or bidirectional Glenn 
anastomosis (bidirectional cavopulmonary shunt) at 4-6 months and by a modified Fontan 
procedure (total cavopulmonary connection) at 2-4 years of age (Ashburn et al., 2003; Barron 
et al., 2009; Bove et al., 2004). 
The Norwood procedure (Norwood et al., 1983) consists on atrial septectomy, reconstruction 
of the aortic arch to remove associated hypoplasia or coarctation, connection of the main 
pulmonary artery into this reconstructed arch and placement of a small shunt between the 
systemic and the pulmonary circulations achieved either by a Blalock-Taussig or by a Gore-
tex shunt (the classical Norwood operation) or by a right ventricular to pulmonary artery 
conduit (the Norwood procedure with the Sano modification) (Sano et al., 2004). The Sano 
modification typically eliminates the diastolic runoff into the pulmonary circulation with 
subsequent coronary steal and potential risk of sudden death, with the limiting factor of 
limited pulmonary artery growth requiring performing the bidirectional cavopulmonary 
shunt earlier than what is required following the classical Norwood procedure. Early 
mortality of the first stage of palliation was very high (30-35%) in the first series but has 
dramatically improved, with current early survival of 80-90% (McGuirk et al., 2006; Stasik et 
al., 2006; Tweddell et al., 2002). Several operative risk factors have been identified including 
late initial presentation, prematurity, low birthweight (less than 3 kg), associated genetic 
anomalies, an ascending aorta smaller than 2 mm, intact or restrictive atrial septum, 
moderate or severe tricuspid regurgitation and pre-existing ventricular dysfunction 
(Ashburn et al., 2003; Azakie et al., 2001; Stasik et al., 2006; Tweddell et al., 2002). Although 
the Norwood operation remains one of the highest risk procedures in pediatric cardiac 
surgery, the second and third stages are much less hazardous, with 1-6% of early mortality 
(Gentles et al., 1997; Hirsch et al., 2008). Considering both peri-procedural and interstage 
mortality, actuarial survival after a Norwood procedure is 58-66% at 1 year (Ashburn et al., 
2003; McGuirk et al., 2006; Tweddell et al., 2002), 40-61% at 5 years (Ashburn et al., 2003; 
Azakie et al., 2001; McGuirk et al., 2006; Tweddell et al., 2002) and 50% at 10 years (McGuirk 
et al., 2006). Long-term and functional outcome data following the staged univentricular 
palliation is being evaluated, with the expectation that these ventricles are likely to fail, on 
the basis of observations of other situations in which the right ventricle supports the 
systemic circulation, such as congenitally corrected transposition (Barron et al., 2009). 
7.3.2.2 Cardiac transplantation 
The concept of transplantation as a treatment for hypoplastic left heart syndrome developed 
together with the palliative approach of the Norwood procedure. Data from several centers 
show an 11-14% early mortality following the procedure (Chrisant et al., 2005; Razzouk et 
al., 1996), with a post-transplant actuarial survival of 84% (Razzouk et al., 1996), 72-76% 
(Chrisant et al., 2005; Razzouk et al., 1996) and 70% (Razzouk et al., 1996) at 1, 5 and 7 years, 
respectively. Innovations in peri-transplant management such as the development of new 
immunosuppressive strategies and the realization that ABO incompatibility is possible in 
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neonatal transplantation because the immune response is not mature, have contributed to 
significantly improve its outcomes. Unfortunately, 20-25% of the patients die while awaiting 
for suitable donors (Jenkins et al., 2000; Razzouk et al., 1996), decreasing the rate of actuarial 
survival to 54-55% at 5 years when also accounting for these deaths (Chrisant et al., 2005; 
Jenkins et al., 2000). Although the benefit of a biventricular physiology produces better 
quality of life in children who receive a successful transplant compared with age-matched 
palliative-staged patients, major disadvantages of cardiac transplantation include high 
mortality on the waiting list as well as the immunosuppressant side-effects and morbidities. 
Some authors have suggested that cardiac transplantation may be offered to those patients 
at higher risk in staged surgery (Jenkins et al., 2000). 
7.3.2.3 The hybrid procedure 
The hybrid procedure has recently emerged as an innovative alternative to the Norwood 
operation (Akintuerk et al., 2002). This technique offers the advantage of avoiding 
cardiopulmonary bypass, cardioplegic arrest and circulatory arrest in the neonatal period. 
As infants are thought to be less vulnerable to postoperative myocardial and neurologic 
injury than neonates, this strategy may be associated with improved neurodevelopmental 
and functional outcomes (Akintuerk et al., 2002; Bacha & Hijazi, 2005; Galantowicz & 
Cheatham, 2005). The hybrid procedure, which involves both surgeons and interventional 
cardiologists, consists on placing bilateral pulmonary bands to limit flow to the lungs, 
implanting a stent in the ductus arteriosus and performing a balloon atrial septostomy 
(occasionally placing a stent). It is performed through a standard sternotomy but does not 
require cardiopulmonary bypass. The second step of the staged palliation is carried out as 
usual at 4-6 months. It will include both cavopulmonary shunt and aortic arch 
reconstruction, typically without full circulatory arrest to the brain. It has been advocated 
that it may have an overall survival advantage due to the fact that an in-series circulation 
(hybrid procedure) is more stable than a balanced circulation (Norwood procedure), and 
it might also have a role in stabilizing patients awaiting suitable cardiac donors (Bacha et 
al., 2006). On the other hand, complications such as stent migration and stent occlusion 
may occur, and the second stage of the palliation may be more extensive and complex 
thus carrying increased operative mortality. Finally, no consensus exists on the future of 
the hybrid approach. The potential benefits it offers may be weighted against the risks it 
carries. 
7.4 Percutaneous aortic valve replacement 
Percutaneous valve replacement is being developed. Although semilunar valve replacement 
has been successfully performed in adults for the aortic position and also in children for the 
pulmonary valve position, an aortic replacement during childhood seems to be more 
challenging technically due to sheath size, coronary artery blockage and potential mitral 
valve injury (Schneider et al., 2004). Anyway, percutaneous valve implantation is currently 
in development and may have a role on selected pediatric patients in the future. 
7.5 Physical activity 
Physical activity is not restricted in asymptomatic patients with mild aortic stenosis; these 
patients can participate in competitive sports. Patients with severe aortic stenosis should be 
restricted from all competitive athletic sports, while those with moderate aortic stenosis 
should avoid competitive sports that involve high dynamic and static muscular demands. 
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Other forms of exercise can be performed safely, but it is advisable to evaluate such patients 
with an exercise test before they begin an exercise or athletic program. Patients with treated 
aortic stenosis are restricted from competitive sports on the basis of subsequent residual 
gradients after intervention by the same criteria (Bonow et al., 2005). 
7.6 Endocarditis prophylaxis 
Endocarditis prophylaxis for the prevention of infective endocarditis was recommended in 
the past for any degree of valvar aortic stenosis and even in patients with normal 
functioning bicuspid aortic valve. Antibiotic prophylaxis is no longer indicated in these 
patients. This new guideline emphasizes that maintenance of optimal oral health and 
hygiene may reduce the incidence of bacteremia from daily activities and is more important 
than prophylactic antibiotics for a dental procedure. ACC/AHA recommendations are 
outlined in table 3 (Nishimura & ACC/AHA, 2008). 
 
Prophylaxis against infective endocarditis is reasonable for the following patients at 
highest risk for adverse outcomes from infective endocarditis who undergo dental 
procedures that involve manipulation of either gingival tissue or the periapical region of 
teeth or perforation of the oral mucosa: 
1. Patients with prosthetic cardiac valves or prosthetic material used for cardiac valve 
repair (Class IIa; Level of Evidence B). 
2. Patients with previous infective endocarditis (Class IIa; Level of Evidence B). 
3. Patients with CHD (Class IIa; Level of Evidence B): 
 Unrepaired cyanotic CHD, including palliative shunts and conduits. 
 Completely repaired congenital heart defect repaired with prosthetic material or 
device, whether placed by surgery or by catheter intervention, during the first 6 
months after the procedure. 
 Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic 
patch or prosthetic device (both of which inhibit endothelialization). 
4. Cardiac transplant recipients with valve regurgitation due to a structurally abnormal 
valve (Class IIa; Level of Evidence C). 
Prophylaxis against infective endocarditis is not recommended for nondental procedures 
(such as transesophageal echocardiogram, esophagogastroduodenoscopy, or colonoscopy) 
in the absence of active infection (Class III; Level of Evidence B). 
Table 3. Current infective endocarditis prophylaxis recommendations of the ACC/AHA 
related to aortic valvar stenosis and bicuspid aortic valve (Nishimura & ACC/AHA, 2008). 
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outlined in table 3 (Nishimura & ACC/AHA, 2008). 
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patch or prosthetic device (both of which inhibit endothelialization). 
4. Cardiac transplant recipients with valve regurgitation due to a structurally abnormal 
valve (Class IIa; Level of Evidence C). 
Prophylaxis against infective endocarditis is not recommended for nondental procedures 
(such as transesophageal echocardiogram, esophagogastroduodenoscopy, or colonoscopy) 
in the absence of active infection (Class III; Level of Evidence B). 
Table 3. Current infective endocarditis prophylaxis recommendations of the ACC/AHA 
related to aortic valvar stenosis and bicuspid aortic valve (Nishimura & ACC/AHA, 2008). 
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1. Introduction 
There is a trend towards a worldwide aging in the last decades and diseases which are 
common in the elderly people would take important place in clinical practice. Aortic 
stenosis (AS) is a common and important condition among the elderly. 
2. Etiology and prevalence 
Currently, AS is the most frequent heart valve disease in industrialized countries and its 
prevalence sharply increases with age (Iung et al., 2003; Nkomo et al., 2006). Thus with 
the prolongation of life expectancy, the population of old patients with AS is expected to 
grow in the future. In elderly patients AS is most frequently caused by progressive 
calcification and degeneration of the tricuspid aortic cusps (Otto et al., 1997; Lindroos et 
al., 1994). The comissures are not fused as in rheumatic AS. Traditionally, AS has been 
thought of as a passive degenerative ”wear and tear” disease associated with aging. 
Certain clinical factors like coronary artery disease (CAD), hypertension, obesity, 
diabetes mellitus, smoking, hyperlipidemia and chronic kidney disease (CKD) are 
associated with AS. However, the studies of Otto CM et al. support that the 
histopathological property of calcific aortic valve disease represents an active process 
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common in the elderly people would take important place in clinical practice. Aortic 
stenosis (AS) is a common and important condition among the elderly. 
2. Etiology and prevalence 
Currently, AS is the most frequent heart valve disease in industrialized countries and its 
prevalence sharply increases with age (Iung et al., 2003; Nkomo et al., 2006). Thus with 
the prolongation of life expectancy, the population of old patients with AS is expected to 
grow in the future. In elderly patients AS is most frequently caused by progressive 
calcification and degeneration of the tricuspid aortic cusps (Otto et al., 1997; Lindroos et 
al., 1994). The comissures are not fused as in rheumatic AS. Traditionally, AS has been 
thought of as a passive degenerative ”wear and tear” disease associated with aging. 
Certain clinical factors like coronary artery disease (CAD), hypertension, obesity, 
diabetes mellitus, smoking, hyperlipidemia and chronic kidney disease (CKD) are 
associated with AS. However, the studies of Otto CM et al. support that the 
histopathological property of calcific aortic valve disease represents an active process 
with some similarities to atherosclerosis, including lipid deposition, macrophage and T 
cell infiltration, basement membrane disruption and microscopic calcification (Otto et al., 
1994). Both AS and atherosclerosis have many clinical risk factors in common such as 
diabetes mellitus, hypertension, dyslipidemia, CKD, and tobacco use. (Peltier et al., 
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respectively. This cohort study showed that the average time interval of aortic sclerosis to 
AS was 8 years. 
Other causes of AS in the elderly include rheumatic aortic valve disease (always occurs 
in conjunction with mitral valve involvement) and late degeneration of congenital 
bicuspid valves (Beppu et al., 1993; Pachulski et al., 1993). Congenital bicuspid valve 
anomaly accounts for about one fourth of AS in patients older 70 than years (Passik et al., 
1987). 
3. Pathopysiology 
Regardless of the etiology, AS results in obstruction of LVOT. Obstruction of the LVOT 
leads to concentric hypertrophy (increase in LV wall thickness and mass) which normalizes 
systolic wall stress and maintains normal LV ejection fraction (LVEF) and cardiac output 
(Kennedy et al., 1968; Hood et al., 1968). Although hypertrophy helps to preserve ejection 
performance, it leads to abnormal LV compliance, LV diastolic dysfunction with reduced LV 
diastolic filling, increased LV end diastolic pressure and is associated with increased 
mortality (Levy et al., 1990; Zile et al., 2002). As the left ventricle becomes less compliant, 
atrial systole becomes more important for maintaining cardiac output, and onset of atrial 
fibrillation (AF) may result in clinical worsening and ventricular decompensation. The 
increases in systolic blood pressure, ventricular mass and ejection time lead to increased 
consumption of oxygen by the myocardium. Increased oxygen demand by the hypertrophic 
myocardium and abnormal patterns of coronary flow lead to angina pectoris in AS (Gould 
et al., 1997; Julius et al., 1997; Villari et al., 1992). Coexisting coronary disease is common 
with significant coronary narrowing in about 50% of elderly patients with AS (Georeeson et 
al., 1990). The increase in oxygen consumption and its contribution to decreased myocardial 
ischemia cause further deterioration of LV function. The stroke volume and cardiac output 
decrease and the mean left atrial and pulmonary capillary pressures increase and 
pulmonary hypertension occurs. This stage usually coincides with the occurrence of severe 
stenosis and the onset of symptoms. Several mechanisms have been postulated to explain 
the third cardinal symptom of AS, syncope. Although ventricular arrhythmias, 
bradyarrythmias and left ventricular systolic dysfunction have been proposed, most of the 
data suggests that an acute drop in blood pressure caused by inappropriate LV baroreceptor 
response because of increased LV pressures (Johnson et al., 1971; Richards et al., 1984). 
4. Natural history 
The patient with AS is generally asymptomatic for a prolonged period despite the 
obstruction and increased pressure load on the heart. Adults with asymptomatic AS have an 
excellent clinical outcome, indistinguishable from age-matched controls without aortic valve 
disease. It was estimated that sudden cardiac death accounted for 3-5% of all deaths in 
patients with asymptomatic AS (Braunwald, 1990). Hemodynamic progression in patients 
with AS has an average rate of increase in aortic jet velocity of 0.3 m/s per year, with an 
increase in mean transaortic pressure gradient of 7 mmHg per year and decrease in aortic 
valve area (AVA) of 0.1 cm2 per year (Otto et al., 1989; Faggiano et al., 1996). However there 
is a wide range of hemodynamic progression among the patients with AS. Predictors of 
symptom onset in two studies included baseline jet velocity, the rate of change in jet velocity 
over time, the extent of valvular calcification, and functional status (Otto et al., 1997; 
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Rosenhek et al., 2000). The prognosis changes dramatically with the onset of symptoms of 
angina, syncope, or heart failure (HF) after a long latent period. The development of 
symptoms is a critical point in the natural history of AS. Older adults, who typically have 
decreased activity levels, experience delayed onset of clinical symptoms or they tend to 
relate their symptoms to other coexisting conditions. Ross and Braunwald found that the 
average survival after the onset of angina pectoris, syncope and HF was 3, 3 and 1.5-2 years 
respectively (Ross & Braunwald, 1968). In the study of Bouma et al., non-operated elderly 
patients with severe AS had a wide range of survival rates (Bouma et al., 1999). In this 
study, the three poor prognostic factors were a New York Heart Association (NYHA) 
functional class of III-IV, coexisting mitral regurgitation, and left ventricular systolic 
dysfunction. Survival was particularly poor (20% at 3 years) in the presence of NYHA III-IV 
symptoms and impaired left ventricle systolic function. The presence of AS in older adults 
increases their risk of having myocardial infarction and cardiovascular death (Aronow et al., 
1998). Additional comorbidities which also affect survival are frequent in elderly patients 
with AS. 
5. Symptoms 
The cardinal manifestations of acquired AS are angina pectoris, syncope, and ultimately HF. 
Aranow et al. observed that in elderly patients, HF, syncope, or angina pectoris was present in 
90%, 69% and 27% of patients with severe, moderate and mild AS respectively (Aranow et al., 
1998). In the elderly, a clear description of the symptoms and their onset may be difficult to 
obtain. Most common initial symptom in the elderly is impaired exercise tolerance, exertional 
dyspnea and dizziness. In elderly symptoms of chest pain, shortness of breath, exercise 
intolerance, and dizziness are common and have many other potential causes, so that AS is 
generally not considered in the differential diagnosis. Symptoms may be absent in inactive 
elderly patient or may not be elicited from a patient with memory impairment. Establishment 
of symptomatic status and the severity of valvular disease can be troublesome because of 
subjectivity of symptom assessment and ambiguity of individual functional capacity in elderly 
(Sciomer et al., 2004). Concordantly, significant AS is underdiagnosed in the elderly. 
Some patients may experience severe gastrointestinal bleeding secondary to angiodysplasia 
in association with AS (Heyde Syndrome, Bhutani et al., 1995). Infective endocarditis is less 
common in elderly patients with severe AS than in younger patients because endocardial 
surface is more calcific in the elderly. Endocarditic vegetations, AF and aortic atheromas 
represent important causes of systemic embolism including stroke in the elderly patients 
(Furberg et al., 1994; Tunick et al., 1994). Rarely, fragments of the calcific valve may 
embolize into the systemic circulation. Sudden death rarely occurs in asymptomatic 
patients. In the presurgical era, the incidence of sudden death in patients with symptomatic 
AS was estimated to be as high as 15-20% (Ross, 1968). Nowadays these rates decreased due 
to early surgical intervention in patients with symptomatic AS.  
6. Signs 
AS is often diagnosed after a systolic murmur elicited on physical examination necessitates 
an echocardiogaphic examination. Signs of AS include systolic ejection cresendo-
decrescendo murmur that radiates to the neck and is often accompanied by a thrill. 
However, the murmur may radiate to the apex instead of the carotidis in elderly patients 
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consumption of oxygen by the myocardium. Increased oxygen demand by the hypertrophic 
myocardium and abnormal patterns of coronary flow lead to angina pectoris in AS (Gould 
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al., 1990). The increase in oxygen consumption and its contribution to decreased myocardial 
ischemia cause further deterioration of LV function. The stroke volume and cardiac output 
decrease and the mean left atrial and pulmonary capillary pressures increase and 
pulmonary hypertension occurs. This stage usually coincides with the occurrence of severe 
stenosis and the onset of symptoms. Several mechanisms have been postulated to explain 
the third cardinal symptom of AS, syncope. Although ventricular arrhythmias, 
bradyarrythmias and left ventricular systolic dysfunction have been proposed, most of the 
data suggests that an acute drop in blood pressure caused by inappropriate LV baroreceptor 
response because of increased LV pressures (Johnson et al., 1971; Richards et al., 1984). 
4. Natural history 
The patient with AS is generally asymptomatic for a prolonged period despite the 
obstruction and increased pressure load on the heart. Adults with asymptomatic AS have an 
excellent clinical outcome, indistinguishable from age-matched controls without aortic valve 
disease. It was estimated that sudden cardiac death accounted for 3-5% of all deaths in 
patients with asymptomatic AS (Braunwald, 1990). Hemodynamic progression in patients 
with AS has an average rate of increase in aortic jet velocity of 0.3 m/s per year, with an 
increase in mean transaortic pressure gradient of 7 mmHg per year and decrease in aortic 
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respectively (Ross & Braunwald, 1968). In the study of Bouma et al., non-operated elderly 
patients with severe AS had a wide range of survival rates (Bouma et al., 1999). In this 
study, the three poor prognostic factors were a New York Heart Association (NYHA) 
functional class of III-IV, coexisting mitral regurgitation, and left ventricular systolic 
dysfunction. Survival was particularly poor (20% at 3 years) in the presence of NYHA III-IV 
symptoms and impaired left ventricle systolic function. The presence of AS in older adults 
increases their risk of having myocardial infarction and cardiovascular death (Aronow et al., 
1998). Additional comorbidities which also affect survival are frequent in elderly patients 
with AS. 
5. Symptoms 
The cardinal manifestations of acquired AS are angina pectoris, syncope, and ultimately HF. 
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1998). In the elderly, a clear description of the symptoms and their onset may be difficult to 
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intolerance, and dizziness are common and have many other potential causes, so that AS is 
generally not considered in the differential diagnosis. Symptoms may be absent in inactive 
elderly patient or may not be elicited from a patient with memory impairment. Establishment 
of symptomatic status and the severity of valvular disease can be troublesome because of 
subjectivity of symptom assessment and ambiguity of individual functional capacity in elderly 
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AS is often diagnosed after a systolic murmur elicited on physical examination necessitates 
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decrescendo murmur that radiates to the neck and is often accompanied by a thrill. 
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with AS (Gallavardin phenomenon). A prominent fourth heart sound (S4) follows atrial 
systole in patients with sinus rhythm and noncompliant left ventricle. In the elderly, S4 is 
less specific for AS, because hypertension, CAD, and other disorders which are common in 
older individuals can diminish left ventricular compliance (Lombard et al., 1987). In this 
setting, the physical examination findings of a soft murmur with an early peak, an upstroke 
of carotid impulse with normal timing, and a split second heart sound (S2) suggest that mild 
or moderate AS is present. In a prospective study, carotid upstroke delay and amplitude, 
systolic murmur grade and peak, and a single S2 predicted AS severity and clinical 
outcomes of death and symptom onset (Munt et al., 1999). On multivariate Cox regression 
analysis, the only physical examination finding which predicted the outcome was carotid 
upstroke amplitude. But most elderly patients with severe valve obstruction have only 
grade 2 or grade 3 murmur and some have an even softer murmur despite severe disease 
because of presence of concomitant HF or chronic lung disease (Lombard et al., 1987; Otto et 
al., 1997). The pulse pressure may be normal, or even wide, and the carotid upstroke may be 
rapid in the elderly with severe stenosis due to concomitant atherosclerosis of the arterial 
tree (Otto et al., 1997). So a slow rising, low amplitude carotid pulse has a relatively high 
specificity, but a low sensitivity, for the presence of severe AS in the elderly. No single 
physical examination finding or a combination of findings has both a high sensitivity and 
specificity for detection of severe AS. Older adults have an absent A2 component of the S2 
due to aortic valve leaflet calcification which predominates with increasing age. Elderly 
patients with severe AS and aortic regurgitation have an A2 component of the S2, and in this 
situation, a soft diastolic murmur of aortic regurgitation may be heard. 
7. Diagnostic tests 
7.1 Electrocardiography 
The ECG in patients with AS is not diagnostic. Findings of LVH are the most common 
findings on ECG in patients with severe AS. In the elderly patients, findings of LVH on ECG 
were seen in about two thirds of patients (Aronow et al., 1991). The voltage of the QRS 
complex may be markedly increased and ST-T wave changes which reflect chronic 
subendocardial ischemia are common. Other nonspecific signs include, left atrial 
enlargement, left axis deviation and left bundle branch block. AF can be seen at late stages 
and may otherwise suggest coexisting mitral valve disease or CAD. 
7.2 Chest radiography 
The chest radiography in AS is nonspecific. It is usually normal when AS is mild to 
moderate. Calcification the region of the aortic valve represents relevant chest radiography 
findings in the elderly, since calcific degeneration is the hallmark of AS in this age group. 
The radiographic features of compensated AS include concentric hypertrophy of the LV 
without cardiomegaly and poststenotic dilatation of the aorta. Of equal importance, the 
presence of cardiomegaly in a normotensive patient with isolated AS indicates 
decompensated AS.  
7.3 Echocardiography 
Doppler echocardiography is a cost–effective and accurate strategy to diagnose AS in the 
elderly (Otto et al., 1997). Echocardiography allows for the noninvasive assessment of the 
 
Geriatric Aspects of Aortic Stenosis     
 
39 
valvular structures and the real time evaluation of its hemodynamic consequences. It 
assesses left-ventricular functions, extent of hypertrophy, and amount of valve 
calcification. Standard evaluation of AS severity includes measurement of aortic velocity, 
mean transaortic pressure gradient, and continuity equation valve area (Figure 1). 
Anatomic images show the etiology of AS, level of obstruction, valve calcification, leaflet 
motion and aortic root anatomy. Echocardiography is also used to determine diastolic 
dysfunction by the presence of abnormal left ventricular relaxation. The velocity of blood 
flow increases as the stenotic orifice area decreases. Velocity measurements can be 
translated into pressure gradients across the aortic valve by using the Bernoulli equation. 
Aortic velocity allows classification of stenosis as mild (2.6-3 m/s), moderate (3 to 4 
m/s), or severe (>4m/s). In case of leaflet thickening and calcification, presence of 
adequate leaflet motion and a velocity of <2.5 m/s defines aortic sclerosis. A mean aortic 




Fig. 1. To obtain the mean gradient, "trace" is used to trace the envelope of the aortic 
outflow. A mean aortic valve gradient greater than 40 mm Hg on Doppler 
echocardiography is indicative of severe AS. 
The AVA can be estimated with the use of the continuity equation which depends on the 
principle of the law of continuity of flow (Carabello et al., 2003). Currently AS is graded as 
mild, moderate, and severe when the AVA is >1.5 cm2, 1-1.5 cm2, and <1 cm2 respectively 
(Table 1). The most frequent error in measuring the AVA is due to the inaccuracy of LVOT 
diameter measurement. This is especially difficult in older adults in whom accumulation of 
calcium is present on the annulus. In order to avoid these errors some authorities suggest 
the use of dimensionless ratio for the assessment of AS. This index is simply the ratio of the 
velocity across the LVOT to the velocity across the aortic valve and completely eliminates 
the area of the LVOT from the equation (Otto et al., 2006). A ratio of 0.9-1 is accepted normal 
and a ratio of <0.25 indicates a valve area 25% of expected, corresponding to severe stenosis. 
Transesophageal echocardiography provides excellent short-axis images of the aortic valve, 
thus allows for direct measurement of the AVA by planimetry in many patients (Naqvi et 
al., 1999). Real time three dimensional transthoracic echocardiography offers an increased 
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specificity for detection of severe AS. Older adults have an absent A2 component of the S2 
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patients with severe AS and aortic regurgitation have an A2 component of the S2, and in this 
situation, a soft diastolic murmur of aortic regurgitation may be heard. 
7. Diagnostic tests 
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were seen in about two thirds of patients (Aronow et al., 1991). The voltage of the QRS 
complex may be markedly increased and ST-T wave changes which reflect chronic 
subendocardial ischemia are common. Other nonspecific signs include, left atrial 
enlargement, left axis deviation and left bundle branch block. AF can be seen at late stages 
and may otherwise suggest coexisting mitral valve disease or CAD. 
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moderate. Calcification the region of the aortic valve represents relevant chest radiography 
findings in the elderly, since calcific degeneration is the hallmark of AS in this age group. 
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without cardiomegaly and poststenotic dilatation of the aorta. Of equal importance, the 
presence of cardiomegaly in a normotensive patient with isolated AS indicates 
decompensated AS.  
7.3 Echocardiography 
Doppler echocardiography is a cost–effective and accurate strategy to diagnose AS in the 
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valvular structures and the real time evaluation of its hemodynamic consequences. It 
assesses left-ventricular functions, extent of hypertrophy, and amount of valve 
calcification. Standard evaluation of AS severity includes measurement of aortic velocity, 
mean transaortic pressure gradient, and continuity equation valve area (Figure 1). 
Anatomic images show the etiology of AS, level of obstruction, valve calcification, leaflet 
motion and aortic root anatomy. Echocardiography is also used to determine diastolic 
dysfunction by the presence of abnormal left ventricular relaxation. The velocity of blood 
flow increases as the stenotic orifice area decreases. Velocity measurements can be 
translated into pressure gradients across the aortic valve by using the Bernoulli equation. 
Aortic velocity allows classification of stenosis as mild (2.6-3 m/s), moderate (3 to 4 
m/s), or severe (>4m/s). In case of leaflet thickening and calcification, presence of 
adequate leaflet motion and a velocity of <2.5 m/s defines aortic sclerosis. A mean aortic 




Fig. 1. To obtain the mean gradient, "trace" is used to trace the envelope of the aortic 
outflow. A mean aortic valve gradient greater than 40 mm Hg on Doppler 
echocardiography is indicative of severe AS. 
The AVA can be estimated with the use of the continuity equation which depends on the 
principle of the law of continuity of flow (Carabello et al., 2003). Currently AS is graded as 
mild, moderate, and severe when the AVA is >1.5 cm2, 1-1.5 cm2, and <1 cm2 respectively 
(Table 1). The most frequent error in measuring the AVA is due to the inaccuracy of LVOT 
diameter measurement. This is especially difficult in older adults in whom accumulation of 
calcium is present on the annulus. In order to avoid these errors some authorities suggest 
the use of dimensionless ratio for the assessment of AS. This index is simply the ratio of the 
velocity across the LVOT to the velocity across the aortic valve and completely eliminates 
the area of the LVOT from the equation (Otto et al., 2006). A ratio of 0.9-1 is accepted normal 
and a ratio of <0.25 indicates a valve area 25% of expected, corresponding to severe stenosis. 
Transesophageal echocardiography provides excellent short-axis images of the aortic valve, 
thus allows for direct measurement of the AVA by planimetry in many patients (Naqvi et 
al., 1999). Real time three dimensional transthoracic echocardiography offers an increased 
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confidence level in the direct measurement of AVA (Vengala et al., 2004). Dobutamine stress 
echocardiography is often useful to estimate AVA and gradient at a higher cardiac output. It 
is particularly useful in patients with moderate to severe AS with low gradient and 
depressed LVEF. Truly severe AS shows only small changes (an increase of <0.2 cm2) in 
AVA which remains <1 cm2 with increasing flow rate but significant increase in gradients 
(mean gradient > 40 mmHg), whereas pseudosevere AS shows a marked increase in AVA 
with a final value of > 1 cm2 but only minor changes in gradients. Dobutamine stress 
echocardiography also provides evidence of myocardial contractile reserve (increase of 
>20% of stroke volume during low dose dobutamine administration) (Vahanian et al., 2007; 
Bonow et al., 2006). Echocardiography is recommended to be performed yearly in patients 
with severe AS, every 2 years in patients with moderate AS, and every 5 years in patients 
with mild AS. 
 
 Mild Moderate Severe 
AoVmax (m/s) 2.5-3.0 3.0-4.0 >4.0 
Peak gradient 
(mmHg) <40 40-65 >65 
Mean gradient 
(mmHg) <20 20-40 (50)*
  >40 (50)* 
EOA (cont eq) (cm2) >1.5 1.0-1.5 <1.0 
EOAi (cm2/ m2) >0.85 0.60-0.85 <0.60 
Dimensionless index  >0.50 0.25-0.50 <0.25 
Table 1. Grading of aortic stenosis. *EAE guidelines only, otherwise both EAE and ASE. 
7.4 Exercise testing 
Severe AS is considered a contraindication for exercise testing (Ha, 2003). Nonetheless, in 
elderly patients with hemodynamically significant AS and ambiguous symptoms, exercise 
testing may be useful and safe if performed by an experienced physician. It is reasonable to 
perform the exercise testing it in patients over 70 years if they are still highly active. In 
asymptomatic patients, this test also may determine the recommended level of physical 
activity. 
7.5 Cardiac catheterization 
Its principle goal is to asses the extent of concomitant CAD (which is common in the elderly) 
by angiography rather than to determine the hemodynamic severity of AS. The valve should 
almost never be crossed, because the risk of death, stroke, or pulmonary edema is 7% if the 
valve is crossed and 3% for coronary angiography (Chambes, 2004). If the clinical findings 
are not consistent with the Doppler echocardiographic results, cardiac catheterization is 
recommended for further hemodynamic assessment. Cardiac catheterization should consist 
of the simultaneous measurement of the pressures in the left ventricle and in the aorta, 
enabling the calculation of the mean gradient. A ‘’pull-back’’ tracing from the left ventricle 
to the aorta may be used in patients with normal sinus rhythm but it is not accurate in 
patients with rhythms disturbances or low-output states. In elderly patients with tortuous 
vessels the pull back technique may be preferred to a second femoral puncture needed to 
obtain a proper LV and proximal aortic pressure recording. 
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7.6 Computer tomography (CT) 
Electron beam CT has the ability to detect and quantify calcification in AS (Pohle, 2004). It 
also allows detection of calcifications in coronary vessels and assessment of the ascending 
aorta (Pohle et al., 2004; Bouma et al., 1999). CT has shown high accuracy and 
reproducibility in quantifying aortic valve calcification and its progression. In patients 
with inadequate and inconclusive echocardiogram, CT may be as an alternative to obtain 
AVA. 
7.7 Magnetic Resonance Imaging (MRI) 
Cardiac MRI may be used to assess LV volume, function and mass. MR planimetry is 
reported to be highly reproducible and well tolerated and the results correlate very well 
with TEE results (Anna et al., 2003). Cardiac MRI is useful when acoustic windows in the 
echocardiogram are poor or when there is discordant imaging and catheterization 
results. It may also be an alternative to CT in patients with increased risk of contrast 
nephropathy because of older age and diminished baseline glomerular filtration rate 
(GFR). 
8. Medical treatment 
When symptoms of angina, syncope, or HF develop in patients with AS, the prognosis 
dramatically worsens. AVR represents the only proven treatment modality for 
symptomatic and hemodynamically significant AS. Other treatments such as medical 
therapy and TAVI are still controversial and researches are on way. There is no effective 
medical treatment for AS. Although medical therapy is unlikely to prolong survival, it 
may provide limited symptomatic relief. Hemodynamically significant AS is adversely 
affected by changes in preload and afterload. Potentially, all drugs used in symptomatic 
patients may cause worsening of the patients’ conditions. Therefore, in patients with 
severe AS, drugs that reduce preload or afterload should be used with caution. In 
addition, due to the fact that chronic renal failure, autonomic dysfunction, and rhythm 
and conduction disturbances are more frequently seen in the elderly, side effects of drugs 
may be more dangerous. 
8.1 Statins 
Lipids are known to have important role in development of fibrosis and calcification seen in 
AS. Therefore, the use of lipid lowering drugs, especially the statins are recommended. 
Various studies suggested that the use of statins may reduce or prevent the worsening of 
fibrosis and calcification in patients with AS especially when used in the early periods. 
However, the results of the studies are conflicting and the effects of statins on the course of 
disease are not clear. Findings of several retrospective studies and at least one prospective 
trial show that patients receiving statins have slower progression of stenosis severity than 
do individuals not receiving them.(Rajamannan & Otto, 2004; Novaro et al., 2001). However, 
in a randomized trial of patients with moderate AS, Cowell and colleagues failed to show a 
benefit of high dose statin use in terms of halting the progression of valvular stenosis or 
inducing its regression (Cowell et al., 2005). Although the use of statins in patients with 
valvular AS is controversial, statins should be used in patients with AS and atherosclerotic 
vascular disease (Rossebø et al., 2008). 
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confidence level in the direct measurement of AVA (Vengala et al., 2004). Dobutamine stress 
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>20% of stroke volume during low dose dobutamine administration) (Vahanian et al., 2007; 
Bonow et al., 2006). Echocardiography is recommended to be performed yearly in patients 
with severe AS, every 2 years in patients with moderate AS, and every 5 years in patients 
with mild AS. 
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of the simultaneous measurement of the pressures in the left ventricle and in the aorta, 
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dramatically worsens. AVR represents the only proven treatment modality for 
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therapy and TAVI are still controversial and researches are on way. There is no effective 
medical treatment for AS. Although medical therapy is unlikely to prolong survival, it 
may provide limited symptomatic relief. Hemodynamically significant AS is adversely 
affected by changes in preload and afterload. Potentially, all drugs used in symptomatic 
patients may cause worsening of the patients’ conditions. Therefore, in patients with 
severe AS, drugs that reduce preload or afterload should be used with caution. In 
addition, due to the fact that chronic renal failure, autonomic dysfunction, and rhythm 
and conduction disturbances are more frequently seen in the elderly, side effects of drugs 
may be more dangerous. 
8.1 Statins 
Lipids are known to have important role in development of fibrosis and calcification seen in 
AS. Therefore, the use of lipid lowering drugs, especially the statins are recommended. 
Various studies suggested that the use of statins may reduce or prevent the worsening of 
fibrosis and calcification in patients with AS especially when used in the early periods. 
However, the results of the studies are conflicting and the effects of statins on the course of 
disease are not clear. Findings of several retrospective studies and at least one prospective 
trial show that patients receiving statins have slower progression of stenosis severity than 
do individuals not receiving them.(Rajamannan & Otto, 2004; Novaro et al., 2001). However, 
in a randomized trial of patients with moderate AS, Cowell and colleagues failed to show a 
benefit of high dose statin use in terms of halting the progression of valvular stenosis or 
inducing its regression (Cowell et al., 2005). Although the use of statins in patients with 
valvular AS is controversial, statins should be used in patients with AS and atherosclerotic 
vascular disease (Rossebø et al., 2008). 
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8.2 Angiotensin converting enzyme inhibitors (ACEI) 
When patients with severe AS who can not tolerate AVR develop left HF symptoms, the use 
of ACEI may provide improvement in symptoms. Similar to statins, ACEI have been 
suggested to slow the progression of calcic valvular stenosis, but this suggestion has not 
been confirmed by findings of prospective studies (Rosenhek et al., 2004). On the other 
hand, the use of ACEI in patients with severe AS may increase the transvalvular gradient by 
reducing afterload or preload and may cause sudden deterioration of the patients’ status. 
ACEI treatment should be initiated at low doses and gradually increased, avoidance of 
hypotension is crucial especially in the elderly patients. 
8.3 Beta blockers 
Beta blockers are not recommended for routine use. Patients with symptoms and signs of 
HF are not good candidates for beta blocker treatment because beta blockers may aggravate 
the symptoms of HF. Beta blockers are recommended for patients who experience angina 
pectoris or have AF with rapid ventricular response. 
8.4 Diuretics 
Diuretics are recommended in patients with lung congestion, ascites and edema. Diuretics 
provide improvement in HF symptoms by reducing left ventricular end-diastolic pressure. 
Diuretics should be used with caution because a low preload may exacerbate symptoms due 
to low cardiac output. Elderly patients may not excrete free water as efficiently as younger 
people do, and they may be more prone to develop hyponatremia after diuretic treatment 
(Clark et al., 1994). Thiazide diuretics are more commonly associated with hyponatremia 
than loop diuretics (Hwang & Kim, 2010). Nocturia is frequently seen in elderly patients and 
disruption of normal circadian rhythm of antidiuretic hormone may be an important factor 
in this issue (Moon et al., 2004). Elderly patients are also more prone to diuretic induced 
hyponatremia, because concomitant use of other medications like selective serotonin 
reuptake inhibitors (SSRI), which may precipitate hyponatremia, is common. Diuretics also 
lead to orthostatic hypotension by inducing volume depletion. Because falls are more 
frequent and are associated with greater morbidity and mortality in the elderly patients, 
monitoring of blood pressure at home and avoidance of hypotension is crucial. Evening and 
night doses of diuretics are also associated with more frequent nocturia and may increase 
the risk of falls during night. Thus, administration of diuretics in earlier hours may be safer. 
8.5 Nitrates 
Nitrates may be used in patients with severe AS who experience angina pectoris. Because it 
may cause sudden hypotension, it should be initiated at low doses and gradually increased. 
Concomitant use of nitrates with phosphodiesterase inhibitors, which are commonly used in 
the elderly patients with erectile dysfunction, should be avoided to prevent substantial 
hypotension. 
8.6 Digoxin 
Digoxin has a narrow therapeutic index and elderly patients may be more prone to side 
effects associated with its use (Cheng & Nayar, 2009). Digoxin is eliminated by the kidneys 
and impairment of kidney functions with aging is an important issue in this context. The 
recent ACC/AHA guideline recommends an initial dose of 0.125 mg daily or every other 
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day if the patient is more than 70 years old, has impaired kidney function, or has a low lean 
body mass (Hunt et al., 2009). Using a target drug concentration of 0.5-1 ng/ml is 
recommended despite conventional therapeutic serum concentration is defined as 0.8-2 
ng/ml (Hunt et al., 2009). A digoxin concentration above 1 ng/ml may not be more effective 
in terms of symptomatic relief and may potentially be associated with increased morbidity 
and mortality (Cheng & Nayar, 2009; Hunt et al., 2009). When hypokalemia, 
hypomagnesemia or hypothyroidism coexists, digoxin toxicity may occur with lower 
digoxin concentrations (Hunt et al., 2009). Elderly patients may also be more prone to 
develop adverse effects of digoxin like anorexia, nausea, vomiting, confusion, visual 
problems, and rhythm and conduction disturbances (Cheng & Nayar, 2009). Concomitant 
use of drugs which may interact with digoxin may also be common in the elderly. In this 
context, clarithromycin, erythromycin, amiodarone, itraconazole, cyclosporine, verapamil, 
and quinidine can increase serum digoxin concentrations (Hunt et al., 2009). The use of 
digoxin is contraindicated in patients with severe AS and sinus rhythm. When AF with 
rapid ventricular response and hemodynamic deterioration is present, digoxin may be used 
to reduce the ventricular rate. Because beta blockers improve survival in patients with HF 
and may effectively control heart rate alone, digoxin which is associated with 
aforementioned potential harms, should be used with caution as an adjunctive agent for 
heart rate control. 
9. Perioperative evaluation and management 
9.1 Evaluation and management 
Decision to identify patients who are at high risk for cardiac surgery is cumbersome. This 
issue may be further complicated in the elderly. Some risk score algorithms like Ambler 
score, logistic EuroSCORE and Society of Thoracic Surgeons Predicted Risk of Mortality 
(STS-PROM) are widely used to identify patients at high risk for cardiac surgery. Ambler 
score was dedicated to predict in-hospital mortality after heart valve surgery (Ambler et al., 
2005). EuroSCORE integrates increased age, female gender, chronic pulmonary disease, 
extracardiac arteriopathy, neurological dysfunction, previous cardiac surgery, increased 
serum creatinine, active endocarditis, critical perioperative state, unstable angina, LV 
dysfunction, recent MI, and pulmonary hypertension as patient and cardiac related factors 
and some operation related factors like emergency, other than isolated CABG, surgery on 
thoracic aorta, and postinfarct septal rupture (Nashef et al., 1999). An online calculator is 
available in their official website (http://www.euroscore.org/). The STS-PROM risk scoring 
which is more complicated integrates age, gender, race, weight, creatinine level, various 
chronic cardiac and non-cardiac diseases, previous cardiovascular interventions, 
perioperative cardiac status, hemodynamic status, and operative risk factors. This scoring 
estimates the rates of postoperative morbidity, mortality, permanent stroke, prolonged 
ventilation, renal failure, and reoperation. It is updated regularly and calculation can be 
performed only via the online calculator (http://www.sts.org/). Recent data indicates that 
these scores may also predict hospital charges and resource use (Arnaoutakis et al., 2011). 
These risk score algorithms are widely used and validated, but they are not perfect and have 
many limitations (Rosenhek et al., 2011). Elderly patients above 75 years old constituted a 
small proportion of the cohorts used in these risk scores, thus extrapolation of these results 
to frail elderly patients who are generally above 75 years old may not give accurate results. 
In this context, a recent study which involved 1245 elderly patients (mean age 77.2 years) 
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to frail elderly patients who are generally above 75 years old may not give accurate results. 
In this context, a recent study which involved 1245 elderly patients (mean age 77.2 years) 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
44
who underwent AVR with or without additional bypass surgery, suggested that among 
these three risk scores, only STS-PROM was correlated with operative mortality (Frilling et 
al., 2010). The authors emphasized that risk scores aimed specifically at geriatric patients 
might be necessary to accurately identify patients with high surgical risk. These scores have 
mainly been validated in patients undergoing CABG surgery, compromising their accuracy 
in patients undergoing heart valve replacement surgery (Rosenhek et al., 2011). 
Comorbidities not included in these algorithms may increase the risk of surgery. Rosenhek 
et al suggest necessity of including additional variables like cognitive and functional 
capacity to the risk assessment tools (Rosenhek et al., 2011). Moreover, the weighting of the 
risk factors are variable between these algorithms. For example, EuroSCORE includes a 
cutoff point for creatinine (200 μmol/L), which means a creatinine level above this level 
increases the risk, whereas a lower level does not increase the risk. This suggestion has two 
limitations. First, a creatinine level above this threshold in a 65 year old male who weights 
90 kg may suggest a better renal function than a creatinine level below this level in an 85 
year old female who weights 50 kg. Furthermore, the creatinine level may not reflect 
glomerular filtration rate (GFR) accurately in a slim and sarcopenic elderly patient. 
Pulmonary arterial systolic pressure is also categorized in a binary fashion, thus decreasing 
the value of this important risk factor in this scoring system. STS-PROM does not use a 
cutoff for creatinine level and utilizes creatinine level as a continuous variable. However, the 
muscle mass is an important determinant of creatinine levels. A low muscle mass may 
actually represent a poor prognostic factor while it would be associated with a lower 
creatinine level, thus decreasing the STS-PROM risk score. Using more accurate estimations 
of GFR like Cockcroft-Gault formula may give more important prognostic information. 
Cystatin C which is not influenced by muscle mass may potentially reflect GFR more 
accurately and its level increase in earlier stages of kidney insufficiency compared to 
creatinine. However, there are limitations with measurement techniques of cystatin C and 
estimation of GFR by cystatin C levels is not standardized because there are many cystatin C 
based formulas to estimate GFR. The physiologic changes associated with aging should 
always be considered. A comprehensive geriatric assessment would also provide invaluable 
information in the preoperative evaluation and postoperative follow up of the elderly 
patients. 
Morbidity and mortality rates may also be influenced by other factors like experience of 
the surgeon and the center (Rosenhek et al., 2011). Thus it would be logical to compare 
local outcomes with those predicted by the risk scores. Nonetheless, the decision of an 
experienced physician or of a specialized team may be more accurate than the risk scores. 
A recent trial which utilized STS-PROM, presence of pulmonary hypertension, presence 
of porcelain aorta and the decision of the medical team that the patient is frail as the 
criteria to decide a patient is inoperable and to enroll them to TAVI procedures (Rodés-
Cabau el al., 2010). They suggested that frail patients even with a low STS-PROM score 
had increased risk. Although the decision of an experienced medical team that a patient is 
frail may be accurate, usage of widely used criteria to identify frailty may be more 
accurate and enable utilization of frailty as a risk factor in the preoperative evaluation in a 
standardized manner. 
Brain natriuretic peptide (BNP) is widely used for prognostic prediction in heart diseases. 
BNP is higher in symptomatic patients compared to asymptomatic patients (Carabello & 
Paulus, 2009). BNP may also predict onset of symptoms when elevated values are found in 
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an asymptomatic patient and facilitate advising surgery to an asymptomatic patient with AS 
(Carabello & Paulus, 2009). Recently Monin et al. followed up 107 asymptomatic patients 
with moderate to severe AS to predict death or need for AVR and to build a continuous risk 
score using the independent predictors of this outcome (Monin et al., 2009). One of the most 
powerful predictors of outcome was BNP in this study. BNP levels were shown to predict 
postoperative survival and complications (Bergler-Klein et al., 2004; Nozohoor el al., 2009; 
Pedrazzini et al., 2008). Limitations of utilizing BNP include absence of a standardized 
cutoff for prediction of outcome in AS, interference of the predictive value of BNP with 
presence of renal dysfunction, pulmonary hypertension and obesity (Carabello & Paulus, 
2009). Unlike BNP, amino terminal-proBNP levels may increase significantly when renal 
dysfunction exists, thus it seems more suitable to use BNP levels in patients with renal 
dysfunction (Tagore et al., 2008). Bernstein et al. suggest adjustment of proBNP levels with a 
formula utilizing estimated GFR level and age (Bernstein et al., 2009). 
Sündermann at al utilized a comprehensive assessment of frailty (CAF) score to predict 
outcomes after cardiac interventions (CABG, valve surgery, TAVI or combined procedures) 
in 400 patients aged ≥74 years (Sündermann at al., 2011). This score integrated weakness 
assessed with grip strength, self-reported exhaustion assessed with a questionnaire, 
slowness of gait speed measured with 4 meter usual gait speed test, activity level evaluated 
by instrumental activities of daily living, standing balance, body control, forced expiratory 
volume in 1 s, and levels of albumin, creatinine, and BNP. Although the variables were used 
in a binary fashion in this study CAF score was found to be correlated with EuroSCORE and 
STS-PROM scores and also predicted 30-day mortality. 
A recent study which investigated influence of preoperative LV diastolic functions on 
development of postoperative LV systolic dysfunction showed that besides advanced age 
and prolonged myocardial ischemic time, preoperative LV diastolic dysfunction was also an 
important determinant of LV systolic dysfunction after AVR operation (Licker et al., 2010). 
Another recent study assessed presence and degree of myocardial fibrosis on the outcomes 
after AVR (Weidemann et al., 2009). Intraoperative myocardial biopsy and preoperative and 
postoperative cardiac MRI were used to assess myocardial fibrosis in this study. They found 
a significant correlation of myocardial fibrosis with NHYA class and markers of 
longitudinal systolic function but not with global ejection fraction or aortic valve area. They 
found significant correlations between the presence and degree of myocardial fibrosis and 
clinical outcomes. Another recent study evaluated the influence of preoperative illness 
beliefs on postoperative disability, physical functioning, psychological well being and 
depressive symptoms (Juergens et al., 2010). Postoperative outcomes were correlated with 
patients’ preoperative beliefs but not with cardiac risk factors used in this study 
(EuroSCORE and LVEF). 
Spirometric pulmonary functions were assessed preoperatively in a recent trial and 
percentage of predictive forced vital capacity was found to be an independent predictor of 
in-hospital mortality, even when adjusted for the logistic EuroSCORE (Nissinen et al., 2009). 
They also suggested that this parameter was an independent predictor of postoperative 
stroke. 
Preoperative six minute walk test with a cutoff value of 300 meters was utilized in patients 
undergoing AVR in a recent trial (de Arenaza et al., 2010). It was indicated that six minute 
walk test added prognostic information to EuroSCORE and was an independent predictor 
of the composite outcome of death, myocardial infarction or stroke at 12 months. 
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who underwent AVR with or without additional bypass surgery, suggested that among 
these three risk scores, only STS-PROM was correlated with operative mortality (Frilling et 
al., 2010). The authors emphasized that risk scores aimed specifically at geriatric patients 
might be necessary to accurately identify patients with high surgical risk. These scores have 
mainly been validated in patients undergoing CABG surgery, compromising their accuracy 
in patients undergoing heart valve replacement surgery (Rosenhek et al., 2011). 
Comorbidities not included in these algorithms may increase the risk of surgery. Rosenhek 
et al suggest necessity of including additional variables like cognitive and functional 
capacity to the risk assessment tools (Rosenhek et al., 2011). Moreover, the weighting of the 
risk factors are variable between these algorithms. For example, EuroSCORE includes a 
cutoff point for creatinine (200 μmol/L), which means a creatinine level above this level 
increases the risk, whereas a lower level does not increase the risk. This suggestion has two 
limitations. First, a creatinine level above this threshold in a 65 year old male who weights 
90 kg may suggest a better renal function than a creatinine level below this level in an 85 
year old female who weights 50 kg. Furthermore, the creatinine level may not reflect 
glomerular filtration rate (GFR) accurately in a slim and sarcopenic elderly patient. 
Pulmonary arterial systolic pressure is also categorized in a binary fashion, thus decreasing 
the value of this important risk factor in this scoring system. STS-PROM does not use a 
cutoff for creatinine level and utilizes creatinine level as a continuous variable. However, the 
muscle mass is an important determinant of creatinine levels. A low muscle mass may 
actually represent a poor prognostic factor while it would be associated with a lower 
creatinine level, thus decreasing the STS-PROM risk score. Using more accurate estimations 
of GFR like Cockcroft-Gault formula may give more important prognostic information. 
Cystatin C which is not influenced by muscle mass may potentially reflect GFR more 
accurately and its level increase in earlier stages of kidney insufficiency compared to 
creatinine. However, there are limitations with measurement techniques of cystatin C and 
estimation of GFR by cystatin C levels is not standardized because there are many cystatin C 
based formulas to estimate GFR. The physiologic changes associated with aging should 
always be considered. A comprehensive geriatric assessment would also provide invaluable 
information in the preoperative evaluation and postoperative follow up of the elderly 
patients. 
Morbidity and mortality rates may also be influenced by other factors like experience of 
the surgeon and the center (Rosenhek et al., 2011). Thus it would be logical to compare 
local outcomes with those predicted by the risk scores. Nonetheless, the decision of an 
experienced physician or of a specialized team may be more accurate than the risk scores. 
A recent trial which utilized STS-PROM, presence of pulmonary hypertension, presence 
of porcelain aorta and the decision of the medical team that the patient is frail as the 
criteria to decide a patient is inoperable and to enroll them to TAVI procedures (Rodés-
Cabau el al., 2010). They suggested that frail patients even with a low STS-PROM score 
had increased risk. Although the decision of an experienced medical team that a patient is 
frail may be accurate, usage of widely used criteria to identify frailty may be more 
accurate and enable utilization of frailty as a risk factor in the preoperative evaluation in a 
standardized manner. 
Brain natriuretic peptide (BNP) is widely used for prognostic prediction in heart diseases. 
BNP is higher in symptomatic patients compared to asymptomatic patients (Carabello & 
Paulus, 2009). BNP may also predict onset of symptoms when elevated values are found in 
 
Geriatric Aspects of Aortic Stenosis     
 
45 
an asymptomatic patient and facilitate advising surgery to an asymptomatic patient with AS 
(Carabello & Paulus, 2009). Recently Monin et al. followed up 107 asymptomatic patients 
with moderate to severe AS to predict death or need for AVR and to build a continuous risk 
score using the independent predictors of this outcome (Monin et al., 2009). One of the most 
powerful predictors of outcome was BNP in this study. BNP levels were shown to predict 
postoperative survival and complications (Bergler-Klein et al., 2004; Nozohoor el al., 2009; 
Pedrazzini et al., 2008). Limitations of utilizing BNP include absence of a standardized 
cutoff for prediction of outcome in AS, interference of the predictive value of BNP with 
presence of renal dysfunction, pulmonary hypertension and obesity (Carabello & Paulus, 
2009). Unlike BNP, amino terminal-proBNP levels may increase significantly when renal 
dysfunction exists, thus it seems more suitable to use BNP levels in patients with renal 
dysfunction (Tagore et al., 2008). Bernstein et al. suggest adjustment of proBNP levels with a 
formula utilizing estimated GFR level and age (Bernstein et al., 2009). 
Sündermann at al utilized a comprehensive assessment of frailty (CAF) score to predict 
outcomes after cardiac interventions (CABG, valve surgery, TAVI or combined procedures) 
in 400 patients aged ≥74 years (Sündermann at al., 2011). This score integrated weakness 
assessed with grip strength, self-reported exhaustion assessed with a questionnaire, 
slowness of gait speed measured with 4 meter usual gait speed test, activity level evaluated 
by instrumental activities of daily living, standing balance, body control, forced expiratory 
volume in 1 s, and levels of albumin, creatinine, and BNP. Although the variables were used 
in a binary fashion in this study CAF score was found to be correlated with EuroSCORE and 
STS-PROM scores and also predicted 30-day mortality. 
A recent study which investigated influence of preoperative LV diastolic functions on 
development of postoperative LV systolic dysfunction showed that besides advanced age 
and prolonged myocardial ischemic time, preoperative LV diastolic dysfunction was also an 
important determinant of LV systolic dysfunction after AVR operation (Licker et al., 2010). 
Another recent study assessed presence and degree of myocardial fibrosis on the outcomes 
after AVR (Weidemann et al., 2009). Intraoperative myocardial biopsy and preoperative and 
postoperative cardiac MRI were used to assess myocardial fibrosis in this study. They found 
a significant correlation of myocardial fibrosis with NHYA class and markers of 
longitudinal systolic function but not with global ejection fraction or aortic valve area. They 
found significant correlations between the presence and degree of myocardial fibrosis and 
clinical outcomes. Another recent study evaluated the influence of preoperative illness 
beliefs on postoperative disability, physical functioning, psychological well being and 
depressive symptoms (Juergens et al., 2010). Postoperative outcomes were correlated with 
patients’ preoperative beliefs but not with cardiac risk factors used in this study 
(EuroSCORE and LVEF). 
Spirometric pulmonary functions were assessed preoperatively in a recent trial and 
percentage of predictive forced vital capacity was found to be an independent predictor of 
in-hospital mortality, even when adjusted for the logistic EuroSCORE (Nissinen et al., 2009). 
They also suggested that this parameter was an independent predictor of postoperative 
stroke. 
Preoperative six minute walk test with a cutoff value of 300 meters was utilized in patients 
undergoing AVR in a recent trial (de Arenaza et al., 2010). It was indicated that six minute 
walk test added prognostic information to EuroSCORE and was an independent predictor 
of the composite outcome of death, myocardial infarction or stroke at 12 months. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
46
Monin et al suggested that a good outcome after AVR may be seen when severe AS caused 
left-ventricular dysfunction, especially if inotropic reserve is present (Monin et al., 2003). 
They utilized dobutamine stress Doppler hemodynamics to show presence of LV contractile 
reserve in their study. 
Aside from a high risk score, there are some other factors like patient refusal and porcelain 
aorta which deem some of the patients inoperable. The opinion of the experienced physician 
is also important to define patients at higher risk for surgery and to provide required 
precautions for the patients. Furthermore there are more non-invasive procedures like TAVI 
which may be used in patients with a high surgical risk. 
Current ESC and ACC/AHA guidelines were published in 2007 and 2008 respectively. ESC 
guidelines emphasize that AS is increasingly observed in the elderly and AVR could 
prolong and improve the quality of life despite the increased risks of morbidity and 
mortality in this population (Vahanian et al., 2007). It is also noticed that a large percentage 
of suitable candidates for AVR are not referred for surgery. It is recommended that age, per 
se, should not be considered a contraindication for surgery and decisions should be made 
on an individual basis, provided that patients’ wishes and cardiac and non-cardiac factors 
are taken into account. It is also denoted that early intervention at an asymptomatic stage 
should be avoided. ACC/AHA guidelines state that no effective medical treatment exists 
and balloon valvotomy is not a suitable alternative to surgery (Bonow et al., 2008). Among 
denotations about valve surgery in elderly patients in these guidelines are: CAD and LV 
dysfunction are associated with worse outcomes; advanced diseases like cancer, stroke and 
dementia render surgery inappropriate; and deconditioned and debilitated patients often do 
not return to an active life after surgery. Other peculiar considerations stated for the elderly 
are: a narrow LVOT and a small aortic annulus could require enlargement of the annulus, 
heavy calcification may require debridement, and a composite valve-aortic graft may be 
needed. Importance of recognition of marked LV hypertrophy which could be a marker of 
perioperative morbidity and mortality is emphasized. Absence of a perfect method to weigh 
all of the relevant factors and to identify high- and low-risk elderly is also noted.  
Data about comparison of mechanical prostheses and bioprostheses for AVR in the elderly is 
scarce. One recent report suggests good outcomes of bioprostheses for AVR after more than 
10 years of follow up in the elderly (Suojaranta-Ylinen et al., 2009). In the Veterans Affairs 
randomized trial, patients who underwent single AVR or mitral valve replacement with 
mechanical valve versus bioprosthesis were enrolled in a randomized fashion 
(Hammermeister et al., 2000). They found a better survival with mechanical valves largely 
because primary valve failure was virtually absent in this the mechanical valve group while 
it was seen in an important proportion of the bioprosthesis group. However primary valve 
failure was not significantly different between these groups in the elderly population. While 
the rate of thromboembolism was similar between the groups, bleeding complications were 
more common in the mechanical valve group. It is of note that lifelong warfarin treatment is 
required in patients who undergo AVR with mechanical valves and bleeding complications 
with warfarin is more common in the elderly. Further trials are needed to compare the 
outcomes of AVR with mechanical valves and bioprostheses in the elderly. 
Patients with severe AS may have markedly reduced platelet functions and thus experience 
increased postoperative blood loss. One recent double-blind placebo controlled trial 
investigated effects of infusion of desmopressin (0.3 μg/kg) on platelet functions and 
postoperative blood loss (Steinlechner et al., 2011). They recommended assessing of platelet 
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functions and usage of desmopressin to avoid increased blood loss in patients with reduced 
platelet functions. 
Among perioperative cautions for the patient with AS, careful manipulation of 
hemodynamics is crucial (Frogel & Galusca, 2010). Main goals to decrease the perioperative 
cardiovascular risk are to maintain sinus rhythm, a relatively slow heart rate, and adequate 
preload and afterload (Frogel & Galusca, 2010). In this context, a slower heart rate decreases 
myocardial oxygen demand and increases coronary perfusion time. Routine antibiotic 
prophylaxis is not recommended unless the patient has a previous history of infective 
endocarditis (Frogel & Galusca, 2010). Regarding anesthetic premedication, anticholinergics 
may cause tachycardia in a dose dependent manner and careful titration of sedation is 
crucial because oversedation may cause hypotension and undersedation may increase the 
sympathetic tone (Frogel & Galusca, 2010). Because of the risk of serious arrhythmias, a 
defibrillator should be readily available and placed on the patient before sterile draping. 
Ideal heart rate is in the range of 60 to 70 beats per minute and bradicardia should be 
avoided especially in the elderly patients who may have predisposition to it (Frogel & 
Galusca, 2010). As atrial systole is necessary for maximal LV preload, maintenance of 
normal sinus rhythm is very important. Adequate hydration is very important as well, since 
patients with AS are preload dependent (Frogel & Galusca, 2010). Elderly patients and 
patients with central nervous system disorders affecting sensation of thirst have tendency to 
develop dehydration and need careful evaluation of hydration status. Regarding type of 
anesthesia, an epidural technique may be preferred to neuroaxial anesthesia with 
sympathectomy because it allows incremental dosing and does not cause sudden changes in 
systemic vascular resistance (Frogel & Galusca, 2010). Opioids, midazolam, etomidate and 
cisatracurium may be good options for general anesthesia because they offer relatively 
stable hemodynamic effects (Frogel & Galusca, 2010). Careful monitoring of the blood 
pressure is pivotal and hypotension should be avoided and once hypotension develops it 
should be controlled with pure α agonists since they do not cause tachycardia (Frogel & 
Galusca, 2010). Invasive arterial blood pressure and central venous pressure monitoring are 
also recommended. 
Elderly patients are at increased risk for experiencing adverse events like delirium and 
electrolyte disorders in the postoperative period. There are many metabolic, infectious and 
psychological factors which predispose the frail elderly to develop delirium. It is of note that 
delirium is very common after cardiac surgery and is associated with increased risk of short 
and long term morbidity and mortality (Maldonado et al., 2009). Psychotic symptoms of 
delirium like hallucinations and delusions are easily recognized, but many patients do not 
have these symptoms and routine assessment of attention and orientation is crucial. Of note, 
symptoms of delirium wax and wane and make identification of it difficult. Despite its high 
prevalence and adverse outcomes, many physicians do not recognize delirium (Maldonado 
et al., 2009). Giltay et al., focused on the psychotic symptoms of delirium after cardiac 
surgery and suggested that they are independently associated with adverse outcomes 
(Giltay et al., 2006). They found higher age, renal failure, dyspnea, HF, and left ventricle 
hypertrophy as independent preoperative predisposing factors and hypothermia (<33,8°C), 
hypoxemia, low hematocrit, renal failure, increased sodium, infection and stroke as 
independent precipitating factors. Careful monitorization of volume status, follow up of 
renal functions and electrolyte levels, adequate pain control and rational medication 
selection are of great importance. Many drugs like anticholinergics, antihistaminics, 
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Monin et al suggested that a good outcome after AVR may be seen when severe AS caused 
left-ventricular dysfunction, especially if inotropic reserve is present (Monin et al., 2003). 
They utilized dobutamine stress Doppler hemodynamics to show presence of LV contractile 
reserve in their study. 
Aside from a high risk score, there are some other factors like patient refusal and porcelain 
aorta which deem some of the patients inoperable. The opinion of the experienced physician 
is also important to define patients at higher risk for surgery and to provide required 
precautions for the patients. Furthermore there are more non-invasive procedures like TAVI 
which may be used in patients with a high surgical risk. 
Current ESC and ACC/AHA guidelines were published in 2007 and 2008 respectively. ESC 
guidelines emphasize that AS is increasingly observed in the elderly and AVR could 
prolong and improve the quality of life despite the increased risks of morbidity and 
mortality in this population (Vahanian et al., 2007). It is also noticed that a large percentage 
of suitable candidates for AVR are not referred for surgery. It is recommended that age, per 
se, should not be considered a contraindication for surgery and decisions should be made 
on an individual basis, provided that patients’ wishes and cardiac and non-cardiac factors 
are taken into account. It is also denoted that early intervention at an asymptomatic stage 
should be avoided. ACC/AHA guidelines state that no effective medical treatment exists 
and balloon valvotomy is not a suitable alternative to surgery (Bonow et al., 2008). Among 
denotations about valve surgery in elderly patients in these guidelines are: CAD and LV 
dysfunction are associated with worse outcomes; advanced diseases like cancer, stroke and 
dementia render surgery inappropriate; and deconditioned and debilitated patients often do 
not return to an active life after surgery. Other peculiar considerations stated for the elderly 
are: a narrow LVOT and a small aortic annulus could require enlargement of the annulus, 
heavy calcification may require debridement, and a composite valve-aortic graft may be 
needed. Importance of recognition of marked LV hypertrophy which could be a marker of 
perioperative morbidity and mortality is emphasized. Absence of a perfect method to weigh 
all of the relevant factors and to identify high- and low-risk elderly is also noted.  
Data about comparison of mechanical prostheses and bioprostheses for AVR in the elderly is 
scarce. One recent report suggests good outcomes of bioprostheses for AVR after more than 
10 years of follow up in the elderly (Suojaranta-Ylinen et al., 2009). In the Veterans Affairs 
randomized trial, patients who underwent single AVR or mitral valve replacement with 
mechanical valve versus bioprosthesis were enrolled in a randomized fashion 
(Hammermeister et al., 2000). They found a better survival with mechanical valves largely 
because primary valve failure was virtually absent in this the mechanical valve group while 
it was seen in an important proportion of the bioprosthesis group. However primary valve 
failure was not significantly different between these groups in the elderly population. While 
the rate of thromboembolism was similar between the groups, bleeding complications were 
more common in the mechanical valve group. It is of note that lifelong warfarin treatment is 
required in patients who undergo AVR with mechanical valves and bleeding complications 
with warfarin is more common in the elderly. Further trials are needed to compare the 
outcomes of AVR with mechanical valves and bioprostheses in the elderly. 
Patients with severe AS may have markedly reduced platelet functions and thus experience 
increased postoperative blood loss. One recent double-blind placebo controlled trial 
investigated effects of infusion of desmopressin (0.3 μg/kg) on platelet functions and 
postoperative blood loss (Steinlechner et al., 2011). They recommended assessing of platelet 
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functions and usage of desmopressin to avoid increased blood loss in patients with reduced 
platelet functions. 
Among perioperative cautions for the patient with AS, careful manipulation of 
hemodynamics is crucial (Frogel & Galusca, 2010). Main goals to decrease the perioperative 
cardiovascular risk are to maintain sinus rhythm, a relatively slow heart rate, and adequate 
preload and afterload (Frogel & Galusca, 2010). In this context, a slower heart rate decreases 
myocardial oxygen demand and increases coronary perfusion time. Routine antibiotic 
prophylaxis is not recommended unless the patient has a previous history of infective 
endocarditis (Frogel & Galusca, 2010). Regarding anesthetic premedication, anticholinergics 
may cause tachycardia in a dose dependent manner and careful titration of sedation is 
crucial because oversedation may cause hypotension and undersedation may increase the 
sympathetic tone (Frogel & Galusca, 2010). Because of the risk of serious arrhythmias, a 
defibrillator should be readily available and placed on the patient before sterile draping. 
Ideal heart rate is in the range of 60 to 70 beats per minute and bradicardia should be 
avoided especially in the elderly patients who may have predisposition to it (Frogel & 
Galusca, 2010). As atrial systole is necessary for maximal LV preload, maintenance of 
normal sinus rhythm is very important. Adequate hydration is very important as well, since 
patients with AS are preload dependent (Frogel & Galusca, 2010). Elderly patients and 
patients with central nervous system disorders affecting sensation of thirst have tendency to 
develop dehydration and need careful evaluation of hydration status. Regarding type of 
anesthesia, an epidural technique may be preferred to neuroaxial anesthesia with 
sympathectomy because it allows incremental dosing and does not cause sudden changes in 
systemic vascular resistance (Frogel & Galusca, 2010). Opioids, midazolam, etomidate and 
cisatracurium may be good options for general anesthesia because they offer relatively 
stable hemodynamic effects (Frogel & Galusca, 2010). Careful monitoring of the blood 
pressure is pivotal and hypotension should be avoided and once hypotension develops it 
should be controlled with pure α agonists since they do not cause tachycardia (Frogel & 
Galusca, 2010). Invasive arterial blood pressure and central venous pressure monitoring are 
also recommended. 
Elderly patients are at increased risk for experiencing adverse events like delirium and 
electrolyte disorders in the postoperative period. There are many metabolic, infectious and 
psychological factors which predispose the frail elderly to develop delirium. It is of note that 
delirium is very common after cardiac surgery and is associated with increased risk of short 
and long term morbidity and mortality (Maldonado et al., 2009). Psychotic symptoms of 
delirium like hallucinations and delusions are easily recognized, but many patients do not 
have these symptoms and routine assessment of attention and orientation is crucial. Of note, 
symptoms of delirium wax and wane and make identification of it difficult. Despite its high 
prevalence and adverse outcomes, many physicians do not recognize delirium (Maldonado 
et al., 2009). Giltay et al., focused on the psychotic symptoms of delirium after cardiac 
surgery and suggested that they are independently associated with adverse outcomes 
(Giltay et al., 2006). They found higher age, renal failure, dyspnea, HF, and left ventricle 
hypertrophy as independent preoperative predisposing factors and hypothermia (<33,8°C), 
hypoxemia, low hematocrit, renal failure, increased sodium, infection and stroke as 
independent precipitating factors. Careful monitorization of volume status, follow up of 
renal functions and electrolyte levels, adequate pain control and rational medication 
selection are of great importance. Many drugs like anticholinergics, antihistaminics, 
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narcotics and central acting drugs like benzodiazepines may precipitate delirium in an 
elderly patient with predisposing factors. When a precipitating factor for delirium is 
identified in a delirious patient, search of other potential causes of it should continue, 
because especially patients without dementia do not easily develop delirium. Maldonado et 
al. investigated the effects of postoperative sedation on the development of delirium in 
patients undergoing cardiac valve surgery (Maldonado et al., 2009). They compared 
dexmedetomidine, which is not a GABAergic agent, has no anticholinergic effects, promotes 
a more physiological sleep pattern without significant respiratory depression, and may be 
associated with a decreased need for opioid use, with current postoperative sedation 
practices (propofol or midazolam) in a prospective, randomized and open label trial. They 
showed a significantly decreased rate of delirium with dexmedetomidine compared to 
propofol and midazolam (rates of delirium 3%, 50% and 50% respectively). 
Because fluid and electrolyte disturbances are common in the elderly, especially in the 
postoperative period, avoidance of hypotonic fluid administration and monitorization of 
volume status and electrolytes are crucial. 
9.2 Perioperative management for noncardiac surgery in patients with aortic stenosis 
Regarding noncardiac operations, postponing elective surgery is recommended for patients 
with symptomatic severe AS or asymptomatic severe AS in whom evaluation of the valve 
has not been done within the last year (Fleisher et al., 2009). If AVR is not feasible because of 
comorbidities or patient refusal, mortality risk of noncardiac surgery is approximately 10% 
in patients with severe AS (Fleisher et al., 2009). Stratification of cardiac risk for noncardiac 
surgery reported in the current ACC/AHA guidelines is summarized in Table 2 (Fleisher et 
al., 2009). In patients with mild or moderate AS, no clear recommendation is present (Bonow 
et al., 2008). In the asymptomatic patient with severe AS, AVR is indicated if concurrent 
CABG operation is required; if EF is below 50%; or if likelihood of rapid progression is high 
(Bonow et al., 2008). If symptoms are equivocal, an exercise test can be performed and AVR 
may be planned if symptoms or hypotension occur during the test. Beta blocker treatment 
should be continued if class I indications for it exist. If the patient is not using beta blockers 
and has CAD or more than one cardiac risk factor, titration of beta blockers to heart rate and 
blood pressure is recommended if the patient will undergo high- or intermediate-risk 
surgery (Fleisher et al., 2009). These cardiac risk factors are listed in Table 3. Starting beta 
blocker treatment in low doses and careful titration is important in elderly patients who are 
at increased risk for bradycardia and hypotension and thus adverse events like falls. 
Furthermore, data about the role of beta blockers in intermediate- and low-risk patients and 
optimal type, dose, timing, duration, and titration of beta blockers are lacking (Fleisher et 
al., 2009). Withdrawal of beta blockers in the preoperative period is associated with adverse 
outcomes and should not be done unless necessary. Cessation of metformin and renin 
angiotensin system blockers, which increase the risk of postoperative lactic acidosis and 
renal insufficiency respectively, before the surgical procedure is essential. In a recent study 
by Calleja et al., elderly patients with asymptomatic severe AS had low morbidity rates that 
were similar to that seen in well-matched patients with mild-to-moderate AS following 
intermediate-to-low-risk noncardiac surgery (Calleja et al., 2010). No postoperative death or 
HF was observed until dismissal. However, intraoperative hypotension requiring 
vasopressor use was more common in patients with asymptomatic severe AS. BNP may also 
be used to predict postoperative poor outcomes in patients with heart disease undergoing 
noncardiac surgery, however data about BNP used for this purpose is scarce. Leibowitz et 
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al. suggest that it may be beneficial to measure BNP levels in the preoperative period for this 
purpose (Leibowitz et al., 2008). 
 
Risk Stratification Procedure Examples 
Vascular (reported CR often 
more than 5%) 
Aortic and other major vascular surgery 
Peripheral vascular surgery 
Intermediate (reported CR 
generally 1% to 5%) 
Intraperitoneal and intrathoracic surgery 
Carotid endarterectomy 
Head and neck surgery 
Orthopedic surgery 
Prostate surgery 
Low (reported CR generally 






* Combined incidence of cardiac death and nonfatal myocardial infarction. CR: cardiac risk. 
Table 2. Cardiac Risk* Stratification for Noncardiac Surgical Procedures 
 
History of ischemic heart disease 
History of compensated or prior heart failure 
History of cerebrovascular disease 
Diabetes Mellitus 
Renal insufficiency (defined as a preoperative serum creatinine of greater than 2 mg/dL). 
Table 3. Clinical risk factors for perioperative cardiovascular complications 
10. Surgery 
Approximately 2% to 5% of elderly individuals aged 75 years present with signs of severe 
AS and they are scheduled for elective AVR. AVR is the treatment of choice for patients with 
severe degenerative AS, offering both symptomatic relief and a potential for improved long-
term survival (Heinze et al., 2010). The results of the conventional surgery for octogenarians 
are satisfactory and 5% to 10% of mortality is noted for isolated AVR (Heinze et al., 2010). 
On the other hand, elderly patients stay longer in the hospitals and intensive care units 
during the postoperative period (Avery et al., 2001). 
In 1912, Theodore Tuffier was the first to attempt opening AS using his finger. Russel Brock 
and then Bailey used dilatators for stenotic aortic valves. Today more than 1000 patients 
have aortic valve surgery per year and surgery for AS is more common than it is for aortic 
insufficiency. (Barbour J.R. & Ikonmidis J.S., 2007). It’s obvious that AVR is indicated in all 
symptomatic patients and asymptomatic patients with severe AS undergoing open heart 
surgery. The surgery should immediately be programmed if the patient becomes 
symptomatic. United Kingdom heart valve registry observed 1100 elderly patients (56% 
women) who underwent AVR and the 30-day mortality was 6.6% (Asimakopoulos, 1997, as 
cited in Aronow, 2007). The actuarial survival was 89% at 1 year, 79% at 3 years, 69% at 5 
years, and 46% at 8 years. The mortality is rising up to 10% per year for the patient who 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
48
narcotics and central acting drugs like benzodiazepines may precipitate delirium in an 
elderly patient with predisposing factors. When a precipitating factor for delirium is 
identified in a delirious patient, search of other potential causes of it should continue, 
because especially patients without dementia do not easily develop delirium. Maldonado et 
al. investigated the effects of postoperative sedation on the development of delirium in 
patients undergoing cardiac valve surgery (Maldonado et al., 2009). They compared 
dexmedetomidine, which is not a GABAergic agent, has no anticholinergic effects, promotes 
a more physiological sleep pattern without significant respiratory depression, and may be 
associated with a decreased need for opioid use, with current postoperative sedation 
practices (propofol or midazolam) in a prospective, randomized and open label trial. They 
showed a significantly decreased rate of delirium with dexmedetomidine compared to 
propofol and midazolam (rates of delirium 3%, 50% and 50% respectively). 
Because fluid and electrolyte disturbances are common in the elderly, especially in the 
postoperative period, avoidance of hypotonic fluid administration and monitorization of 
volume status and electrolytes are crucial. 
9.2 Perioperative management for noncardiac surgery in patients with aortic stenosis 
Regarding noncardiac operations, postponing elective surgery is recommended for patients 
with symptomatic severe AS or asymptomatic severe AS in whom evaluation of the valve 
has not been done within the last year (Fleisher et al., 2009). If AVR is not feasible because of 
comorbidities or patient refusal, mortality risk of noncardiac surgery is approximately 10% 
in patients with severe AS (Fleisher et al., 2009). Stratification of cardiac risk for noncardiac 
surgery reported in the current ACC/AHA guidelines is summarized in Table 2 (Fleisher et 
al., 2009). In patients with mild or moderate AS, no clear recommendation is present (Bonow 
et al., 2008). In the asymptomatic patient with severe AS, AVR is indicated if concurrent 
CABG operation is required; if EF is below 50%; or if likelihood of rapid progression is high 
(Bonow et al., 2008). If symptoms are equivocal, an exercise test can be performed and AVR 
may be planned if symptoms or hypotension occur during the test. Beta blocker treatment 
should be continued if class I indications for it exist. If the patient is not using beta blockers 
and has CAD or more than one cardiac risk factor, titration of beta blockers to heart rate and 
blood pressure is recommended if the patient will undergo high- or intermediate-risk 
surgery (Fleisher et al., 2009). These cardiac risk factors are listed in Table 3. Starting beta 
blocker treatment in low doses and careful titration is important in elderly patients who are 
at increased risk for bradycardia and hypotension and thus adverse events like falls. 
Furthermore, data about the role of beta blockers in intermediate- and low-risk patients and 
optimal type, dose, timing, duration, and titration of beta blockers are lacking (Fleisher et 
al., 2009). Withdrawal of beta blockers in the preoperative period is associated with adverse 
outcomes and should not be done unless necessary. Cessation of metformin and renin 
angiotensin system blockers, which increase the risk of postoperative lactic acidosis and 
renal insufficiency respectively, before the surgical procedure is essential. In a recent study 
by Calleja et al., elderly patients with asymptomatic severe AS had low morbidity rates that 
were similar to that seen in well-matched patients with mild-to-moderate AS following 
intermediate-to-low-risk noncardiac surgery (Calleja et al., 2010). No postoperative death or 
HF was observed until dismissal. However, intraoperative hypotension requiring 
vasopressor use was more common in patients with asymptomatic severe AS. BNP may also 
be used to predict postoperative poor outcomes in patients with heart disease undergoing 
noncardiac surgery, however data about BNP used for this purpose is scarce. Leibowitz et 
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Approximately 2% to 5% of elderly individuals aged 75 years present with signs of severe 
AS and they are scheduled for elective AVR. AVR is the treatment of choice for patients with 
severe degenerative AS, offering both symptomatic relief and a potential for improved long-
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during the postoperative period (Avery et al., 2001). 
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becomes symptomatic. The indications for AVR in patients with AS according to the current 
ACC/AHA guidelines are listed in Table 4 (Bonow et al., 2006). 
 
Class I  
AVR is indicated for symptomatic patients with severe AS.* (Level of Evidence: B)  
AVR is indicated for patients with severe AS* undergoing coronary artery bypass graft 
surgery (CABG). (Level of Evidence: C)  
AVR is indicated for patients with severe AS* undergoing surgery on the aorta or other 
heart valves. (Level of Evidence: C)  
AVR is recommended for patients with severe AS* and LV systolic dysfunction (ejection 
fraction less than 0.50). (Level of Evidence: C)  
Class IIa  
AVR is reasonable for patients with moderate AS* undergoing CABG or surgery on the 
aorta or other heart valves (see Section 3.7 on combined multiple valve disease and 
Section 10.4 on AVR in patients undergoing CABG). (Level of Evidence: B)  
Class IIb  
AVR may be considered for asymptomatic patients with severe AS* and abnormal 
response to exercise (e.g., development of symptoms or asymptomatic hypotension). 
(Level of Evidence: C)  
AVR may be considered for adults with severe asymptomatic AS* if there is a high 
likelihood of rapid progression (age, calcification, and CAD) or if surgery might be 
delayed at the time of symptom onset. (Level of Evidence: C)  
AVR may be considered in patients undergoing CABG who have mild AS* when there is 
evidence, such as moderate to severe valve calcification, that progression may be rapid. 
(Level of Evidence: C)  
AVR may be considered for asymptomatic patients with extremely severe AS (aortic valve 
area less than 0.6 cm2, mean gradient greater than 60 mm Hg, and jet velocity greater than 
5.0 m per second) when the patient’s expected operative mortality is 1.0% or less. (Level of 
Evidence: C)  
Class III  
AVR is not useful for the prevention of sudden death in asymptomatic patients with AS 
who have none of the findings listed under the class IIa/IIb recommendations. (Level of 
Evidence: B)  
Table 4. Indications for Aortic Valve Replacement.  
Although the surgery for the asymptomatic patients is preferred due to risk of sudden death, 
surgery for asymptomatic octogenarians is controversial. The complex cardiac procedures 
have high risks for elderly patients. The mortality rate of valve surgery and risk of sudden 
death without surgery have to be carefully considered. Postoperatively symptoms diminish 
and quality of life is improved in the majority of patients ≥75 years who had undergone aortic 
valve surgery, but long term survival was not affected (Petersen & Poulsen, 2010). 
AVR usually performed under general anesthesia using conventional techniques of open-
heart surgery with median sternotomy. Minimally invasive procedures are associated with 
acceptable mortality and morbidity rates even in high risk patients. Minimally invasive 
aortic valve surgery can be performed through three different approaches. These are upper 
mini sternotomy, transverse sternotomy and right parasternal mini thoracotomy, sometimes 
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using port-access technique. This procedure has advantages such as less surgical trauma, 
decreased pain and faster recovery. Small incisions may also be associated with low 
infection rates (Olin et al., 1999). It reduces blood transfusions and shortens the length of 
hospital and ICU stay (Korach et al., 2010). It is a safe operation and is associated with lower 
incidence of atelectasis in the cardiac ICU (Foghsgaard et al., 2009). Port access aortic 
surgery also allows patients to be extubated earlier (Wheatley et al., 2004). Avoidance of full 
sternotomy for osteoporotic elderly patients prompts a comfortable postoperative period.  
Although the number of the aortic valve procedures increase worldwide, the ideal valve 
choice is still a debate. There are several options for valves. These are mechanical valve 
prostheses, stented and stentless bioprosthetic valves, aortic homografts and pulmonary 
autografts. The use of these valves differs from patient to patient due to comorbidities and 
anticoagulant needs. The bioprosthetic valves are good alternatives for elderly patients 
because long term anticoagulation use is not required. 
The other situation for the elderly patients undergoing AVR is the injurious effects of 
cardiopulmonarybypass to the organs. This results as a systemic inflammatory response and 
this may influence the post-operative course of the elderly patients adversely. 
Paroxysmal or chronic AF and a LVEF <35% is a risk factor for mortality in patients with 
severe AS  undergoing AVR. Of 83 elderly patients with severe AS and an LVEF <35%, 29 
(35%) had paroxysmal or chronic AF (Levy, 2006, as cited in Aronow, 2007). The 
perioperative mortality was 24% in the group with AF versus 5,5% in the group without 
AF. 
11. Transcatheter aortic valve implantation 
Surgical AVR is currently the gold-standard treatment for patients with severe symptomatic 
AS. Without surgery, the prognosis is extremely poor, with a 3-year survival rate of <30%. 
However, in the huge Euro Heart multinational registry in Europe, 33% of symptomatic 
patients over the age of 65 years were not referred for surgery. (Iung et al., 2003). The 
reasons for not planning surgery were not always the co morbidities. David Bach’s series 
showed the same issue and 33% of symptomatic patients were not referred for surgery, 
some of whom had a low Euro Score risk. (Bach et al., 2007). Balloon aortic valvuloplasty, 
which was described in the 1980s, was the first alternative to surgical therapy (Cribier et al., 
1986). Despite high rates of initial procedural success, restenosis is frequently encountered 
in the long term. The procedure has generally been abandoned in adult patients except as a 
palliative procedure often prior to surgical AVR (Eltchaninoff et al., 1995). Trans-catheter 
aortic valve implantation (TAVI) was first described by Andersen et al in 1992 (Andersen et 
al., 1992). They implanted an expandable aortic valve by a catheter technique in a closed 
chest pig model. The first attempt to use TAVI in man was in 2002 by Cribier et al. (Cribier 
et al., 2002). A percutaneous bioprosthesis was successfully implanted within the diseased 
native aortic valve through an antegrade transseptal approach. Percutaneous transcatheter 
implantation of the aortic valve has been utilized as an alternative to open heart surgery in 
high risk patients with symptomatic severe AS who are not suitable for open surgery. 
Patients might be considered candidates for TAVI if they fulfill the following criteria: 
symptomatic severe AS, a life expectancy of >1year, contraindications for surgery, high risk 
for surgery (clinical judgment plus Euro Score (logistic) >20%; STS Score>10%), and/or 
porcelain aorta, history of thoracic irradiation, severe thoracic deformity, patent coronary by 
pass, cachexia, recurrent pulmonary emboli, right ventricular insufficiency and cirrhosis. 
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Stented valves placed either transapically or percutaneously are garnering much attention 
(Lichtenstein et al., 2006; Criber et al., 2006). Within these procedures, firstly balloon aortic 
valvotomy is undertaken and a stented bioprosthesis is then deployed over a balloon into 
the aortic annulus. Inflation of the balloon anchors the valve in place in the annulus, 
effectively achieving AVR. Transapical approach necessitates a thoracotomy but the valve is 
deployed into the beating heart and extracorporeal circulation is not performed. In the 
percutaneous approach, the valve is deployed either antegradely via the transseptal route, 
or retrogradely across the native aortic valve. Contraindications for TAVI are as follows: an 
aortic annulus of <18 mm or >27 mm, bicuspid valves, heavy calcification in front of LM, 
presence of LV thrombus and need for CABG (relative). Some specific contraindications for 
transfemoral approach are; narrow peripheral arteries (diameter < 8-9 mm), severe 
tortuousity or calcification, history of aorto-femoral by pass, aneurysm of abdominal aorta 
with thrombosis, and severe atheroma of the arch. TAVI has revolutionized the 
management of patients with severe AS, with more than 10,000 implants performed to date. 
Two studies corroborated the results of previous reports in a real world population of 
consecutive patients within their respective countries (Eltchaninoff et al., 2010; Zahn et al., 
2011). They demonstrated a technical success rate of 98-99%, similar 30 day mortality rates 
(12%), and an incidence of stroke of 3-4%. A recently published study (Partner Trial) 
successfully met both primary and co-primary endpoints with a significant reduction in 1- 
year mortality (30.7% for TAVI versus 50.7% for standard therapy, p<0.001, Leon et al., 
2010). It also demonstrated there was a significant reduction in the composite endpoint of 
death from any cause or repeat hospitalization (42.5% for TAVI versus 71.6% for standard 
therapy, p<0.0001). However, TAVI as compared with standard therapy, was associated 
with a higher incidence of major strokes (5.0% versus 1.1 %, p=0.06) and major vascular 
complications (16.2% versus 1.1%, p <0.001 Leon et al., 2010). Despite continual technical 
advancement of TAVI devices and procedures, the combined mortality and morbidity is still 
high in the range of 5-10%, especially when we are facing a group of high surgical risk 
patients. In the future when it is a safer and more reliable procedure and further refinement 
of the device (i.e. smaller size delivery systems and multiple valve size options) is done, 
utilization of the procedure in patients with lower surgical risk may be possible. 
12. Geriatric aspects 
12.1 Activities of daily living 
Bemmel et al investigated the impact of valvular heart disease on the activities of daily 
living (ADL, assessed with Groningen Activity Restriction Scale) in eighty one 90-year old 
individuals (Bemmel et al., 2010). The study population consisted of individuals 78% of 
whom lived independently and only 35% had history of cardiovascular disease. Most 
common valve diseases were mitral regurgitation (73%) and aortic regurgitation (47%). AS 
was present in 17% (14 in 81) of the study population (9 mild, 4 moderate and 1 severe). No 
correlation between the presence of valve diseases and dependence in ADL was found in 
this population. It is not feasible to extend these results to the general population because 
the study population consisted of healthier and cognitively more intact individuals expected 
for this age. Because significant AS may cause deterioration in ADL via several mechanisms 
like limitation of functional capacity, depression and cognitive decline due to concomitant 
atherosclerosis in the central nervous system, studies assessing ADL in individuals with 
significant AS are needed. 
 




Frailty is a geriatric syndrome which is associated with weakness, instability, limitation, 
increased vulnerability to stressors, and adverse health outcomes like falls, hospitalization, 
institutionalization and mortality (Evans et al., 2010). Although there are various definitions 
to identify individuals with frailty, the most frequently and widely used one was described 
by Fried and colleagues (Fried et al., 2001; Evans et al., 2010). The following five criteria are 
used in this definition: poor grip strength, self-reported exhaustion, unexplained weight 
loss, slow walking speed, and reduced physical activity. An individual having at least three 
of these criteria is defined as being frail. Patients with significant AS might be prone to 
become frail. Self-reported exhaustion, slow walking speed and reduced physical activity 
would be seen in a high percentage of patients with limited physical activity due to 
exertional dyspnea or angina pectoris associated with significant AS. They may also have 
weight loss and poor grip strength associated with cardiac cachexia. Assessment of patients 
with AS about presence of frailty would also be beneficial in perioperative risk assessment 
as stated in section 9.1. Further studies about the impact of frailty on presence, severity and 
perioperative risk of AS are needed. 
12.3 Malnutrition 
Malnutrition is an important health issue in the elderly. Being underweight is associated 
with more frequent all-cause mortality than being overweight in the elderly (Berrington de 
Gonzalez et al., 2010). Undernutrition is also associated with tendency to adverse health 
problems like pressure sores, infections and sarcopenia. 
Data assessing the relationship between heart valve problems and malnutrition are very 
limited. Ikee et al investigated impact of malnutrition-inflammation complex on heart valve 
calcification in 105 patients on hemodialysis (Ikee et al., 2008). In this study mean age was 67 
and aortic (77.4%) and mitral (51.3%) valve calcification rates were very high. They found 
some association between malnutrition and valve calcification. However, as a marker of 
malnutrition they used only albumin level which is not specific for malnutrition. Wang et al 
investigated the association of malnutrition and fetuin-A, which has recently been identified 
as an important circulating inhibitor of calcification, in 238 patients on peritoneal dialysis 
treatment (Wang et al., 2005). Nutritional assessment was done with serum albumin levels 
and subjective global assessment tool in this study. Cardiac valve calcification was present 
in 26% of the patients. They showed a significant correlation between fetuin-A levels and 
presence and degree of malnutrition. Otto et al reported increased long-term mortality 
independently associated with cachexia in 674 elderly patients who underwent balloon 
aortic valvuloplasty for AS (Otto el al., 1994). 
Undernutrition may also influence outcomes after cardiac valve surgery. Tepsuwan et al. 
assessed the incidence and impact of cardiac cachexia retrospectively in 353 patients who 
underwent cardiac valve surgery (Tepsuwan et al., 2009). The study population was 
relatively young and most of them had mitral stenosis or mitral regurgitation. They used the 
finding of a body weight less than 80% of ideal body weight as cachexia which was present 
in 13% of the study population. They found significant association between presence of 
cachexia and worse New York Heart Association functional class, higher incidence of 
infective endocarditis and tricuspid regurgitation, longer postoperative hospitalization and 
more frequent postoperative complications and tendency to a higher mortality rate. 
Thourani et al investigated the impact of body mass index (BMI) on morbidity and mortality 
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after cardiac valve surgery in 4247 patients (Thourani et al., 2011). Most of their study 
population underwent isolated AVR (47.2%) or isolated mitral valve procedure (26%). They 
showed increased in-hospital and all-cause long-term mortality in patients with a BMI of 
less than 25 compared to patients with a BMI of 25-35 or higher than 35. However they had 
no laboratory or clinical data about nutritional status. Engelman et al retrospectively 
assessed impact of BMI and albumin levels on morbidity and mortality after cardiac surgery 
in 5168 patients undergoing coronary artery bypass or valve operations (Engelman et al., 
1999). In their study there was no correlation between albumin levels and BMI. Preoperative 
low albumin (<2.5 g/dl) and low BMI (<20 kg/m2) were independently associated with 
increased postoperative mortality. No nutritional assessment tool was utilized in this study. 
Potentially, significant AS may cause malnutrition via different mechanisms. Dietary 
restriction due to reduced physical capacity and depressive mood may enhance 
malnutrition. Abdominal angina may also cause avoidance from eating when concomitant 
systemic atherosclerosis is present in the mesenteric vessels. Further studies specifically 
investigating the association between malnutrition and AS are needed. 
12.4 Depression 
Depression is the most common psychiatric disorder in the elderly and later-life depression 
(LLD) is associated with disability and increased morbidity and mortality (Maixner et al., 
2011). Because atypical presentations like somatic symptoms are common and LLD is 
generally associated with medical comorbidities, recognition is difficult. Study of Bisschop 
et al., suggested that cardiac disease and arthritis are the most common predisposing factors 
for medical illness related depression (Bischop et al., 2004). Overall medical illness burden 
and degree of functional disability may be more important than specific medical illnesses 
alone (Maixner et al., 2011). Underlying medical illness may affect the prognosis of 
depression and depression may delay recovery from medical illnesses by decreasing 
motivation and compliance (Maixner et al., 2011). The importance of screening for 
depression in patients with heart disease is well established, but identifying patients with 
depression may be difficult because organic somatic symptoms possibly unrelated to mood 
may increase the score on depression ratings and many patients with depression deny a 
depressed mood (Maixner et al., 2011). Nonetheless, many symptoms like insomnia, fatigue, 
shortness of breath, weight loss, palpitations, and exercise intolerance overlap in heart 
disease and depression. Even when patients with depression deny sadness, they endorse 
anhedonia and most other depressive symptoms if further questioning is done (Maixner et 
al., 2011). 
Vascular depression is characterized with late onset or change in course after early onset, 
persistent symptoms, and association of depression with vascular disease or vascular risk 
factors and diffuse or multifocal cerebrovascular lesions (Maixner et al., 2011). Although no 
specific data exist about the association of vascular depression and AS in the elderly, 
atherosclerosis has pivotal role in the pathogenesis of both conditions. 
Among medications possibly precipitating depression are beta blockers, which is being used 
commonly in patients with heart disease. Although there is conflicting data about the 
association of beta blockers and depression, and individual susceptibility to depression may 
be important, patients with risk factors for depression like personal or family history of 
depression should be followed up in terms of development of depression (Verbeek et al., 
2011). Lipophilic beta blockers like propranolol, timolol, pindolol, metoprolol, carvedilol 
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and nebivolol are more strongly associated with depression than hydrophilic beta blockers 
like atenolol, nadolol, practolol and sotalol (Verbeek et al., 2011). It is also important not to 
be reluctant to begin beta blocker treatment when strong indications like CAD exist. 
SSRI are widely used in the treatment of depression. There is some data that indicate use of 
SSRI in patients with CAD and depression may improve cardiovascular outcomes (Kimmel 
et al., 2011). Because both treatment with SSRI and severe AS may reduce platelet functions, 
bleeding complications of surgical procedures may be increased in patients with severe AS 
using SSRI. Because treatment with SSRI may precipitate hyponatremia, monitorization of 
sodium levels is important in patients using SSRI, especially if older age and concomitant 
diuretic use is present. 
13. Conclusion 
Diagnosis and management of AS in the elderly have many differences compared to 
younger patients. Thus, involvement of experienced staff and utilization of comprehensive 
assessment in the management of these patients is crucial. 
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1. Introduction 
Valvular heart disease has significant effect on the outcome of practically any kind of 
surgical procedure involving general or regional anaesthesia. The most frequently 
encountered cardiac valve lesions produce pressure overload (mitral stenosis, aortic 
stenosis) or volume load (mitral regurgitation, aortic regurgitation) on the left atrium or left 
ventricle. Anaesthetic management during the perioperative period is based on the likely 
effects of drug induced changes in cardiac rhythm, heart rate, preload, afterload, myocardial 
contractility, systemic blood pressure, systemic vascular resistance and pulmonary vascular 
resistance relative to the pathophysiology of the heart disease.[1] 
1.1 Clinical essentials of aortic valve disease 
Timely diagnosis and treatment of diseases of the aortic valve is essential to avoid 
fatalities such as intra or post-operative heart failure, severe infection, in extreme cases 
sepsis, or even sudden death. Some patients present with severe symptoms, whereas 
others have few or hardly any symptoms at all. The diagnosis may be made on a routine 
physical examination performed at the ward or a pre-operative assessment. Regular 
medical follow-up, treatment to prevent infection of the valve (infective endocarditis), and 
optimal timing of surgery are necessary to avoid the severe consequences of improper 
functioning of the aortic valve. [2] 
As described earlier the ability of the left ventricle to generate the stroke volume (SV) 
depends on adequate filling or “preload,” the contractile state of the muscle, and the 
impedance to ejection (“afterload”). Valvular lesions impose additional requirements for 
compensation. Thus, stenotic lesions require the heart to force an adequate volume through 
a small orifice; regurgitant lesions on the other hand require the heart to eject a large volume 
because part of the ejected volume returns backwards. Compensation involves both the 
myocardium and the peripheral vasculature. Preoperative assessment in all patients with 
valve disease should include a recent (i.e. at least within 6 months) evaluation such as 
echocardiography, and a detailed assessment of symptom progression [3]. 
It is very important to Assess, Plan and Administer. 
Asses the degree of the valvular lesion preoperatively 
Plan with a multidisciplinary team based on the assessment 
Administer the proposed drug therapy particularly antibiotics. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
66
Weidemann, F.; Herrmann, S.; Störk, S.; Niemann, M.; Frantz, S.; Lange, V.; Beer, M.; 
Gattenlöhner, S.; Voelker, W.; Ertl, G. & Strotmann, J.M. (2009) Impact of 
myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation, 
Vol.120, No.7, (August 2009), pp.577-84. 
Wheatley, G.H; Prince, S.L; Herbert, M.A & Ryan, W.H. (2004). Port-access aortic valve 
surgery: a technique in evolution. Heart Surg Forum, Vol.7, No.6, (January, 2004), 
pp.628-31.  
Zahn, R; Gerckens, U; Grube, E; Linke, A; Sievert, H; Eggebrecht, H; Hambrecht, R; Sack, S; 
Hauptmann, K.E; Richardt G; Figulla, H.R; Senges, J. (2011). Transcatheter aortic 
valve implantation: rst results from a multi-centre real-world registry. Eur Heart J, 
Vol.32, No.2, (January 2011), pp.198–204. 
Zile, M.R; Brutsaert, D.L. (2002). New concepts in diastolic dysfunction and diastolic heart 
failure: part II—causal mechanisms and treatment. Circulation, Vol .105, No.12, 
(Mach 2002), pp.1503–08. 
3 
Anaesthetic Considerations for Patients  
with Severe Aortic Stenosis 
Subhamay Ghosh, Lajos Bogar and Ahmed Sabry 
Department of Anaesthesiology and Intensive Care, University of Pecs, Pecs,  
Hungary 
1. Introduction 
Valvular heart disease has significant effect on the outcome of practically any kind of 
surgical procedure involving general or regional anaesthesia. The most frequently 
encountered cardiac valve lesions produce pressure overload (mitral stenosis, aortic 
stenosis) or volume load (mitral regurgitation, aortic regurgitation) on the left atrium or left 
ventricle. Anaesthetic management during the perioperative period is based on the likely 
effects of drug induced changes in cardiac rhythm, heart rate, preload, afterload, myocardial 
contractility, systemic blood pressure, systemic vascular resistance and pulmonary vascular 
resistance relative to the pathophysiology of the heart disease.[1] 
1.1 Clinical essentials of aortic valve disease 
Timely diagnosis and treatment of diseases of the aortic valve is essential to avoid 
fatalities such as intra or post-operative heart failure, severe infection, in extreme cases 
sepsis, or even sudden death. Some patients present with severe symptoms, whereas 
others have few or hardly any symptoms at all. The diagnosis may be made on a routine 
physical examination performed at the ward or a pre-operative assessment. Regular 
medical follow-up, treatment to prevent infection of the valve (infective endocarditis), and 
optimal timing of surgery are necessary to avoid the severe consequences of improper 
functioning of the aortic valve. [2] 
As described earlier the ability of the left ventricle to generate the stroke volume (SV) 
depends on adequate filling or “preload,” the contractile state of the muscle, and the 
impedance to ejection (“afterload”). Valvular lesions impose additional requirements for 
compensation. Thus, stenotic lesions require the heart to force an adequate volume through 
a small orifice; regurgitant lesions on the other hand require the heart to eject a large volume 
because part of the ejected volume returns backwards. Compensation involves both the 
myocardium and the peripheral vasculature. Preoperative assessment in all patients with 
valve disease should include a recent (i.e. at least within 6 months) evaluation such as 
echocardiography, and a detailed assessment of symptom progression [3]. 
It is very important to Assess, Plan and Administer. 
Asses the degree of the valvular lesion preoperatively 
Plan with a multidisciplinary team based on the assessment 
Administer the proposed drug therapy particularly antibiotics. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
68
The severity and extent of aortic stenosis is of great value for risk assessment and for the 
design of a therapeutic plan. The plan which involves a detailed preoperative assessment 
and preparation, intra-operative caution and strict monitoring and post operative care can 
be further complicated with the association of other anomalies like genetic disorders, auto 
immune disorders or severe obesity. 
2. How valvular disease affects anaesthetic procedures 
Aortic stenosis is the commonest of the major valve lesions. While rheumatic disease was 
historically the most important cause, this has been displaced by degeneration of congenital 
bicuspid disease. This latter abnormality occurs in 1-2% of the population. Elderly patients 
may also have significant “senile” degeneration of a normal (tricuspid) aortic valve. Both 
rheumatic disease and congenital bicuspid disease become hemodynamically significant 
over a period of decades, with patients presenting with symptoms and the need for valve 
replacement usually during or after the 5th decade.[3] The gradual process of narrowing of 
the aortic orifice leads to concentric left ventricular hypertrophy and a reduction in left 
ventricular compliance – the myocardium becomes thick, the end-diastolic pressure rises, 
but there is no dilatation. Typically this occurs as the valve area decreases over years from 
the normal 2.5 – 3.5 cm2 to about 1 cm2. The left ventricle generates very high systolic 
pressures to overcome the stenosis, but aortic pressures are normal. Because of the 
decreased compliance, LV filling during diastole depends on adequate preload as well as 
atrial contraction. While the latter contributes less than 20% of filling in the normal heart, it 
may contribute twice this amount in AS. This phase of AS is termed “mild” stenosis with 
physiologic compensation. As the aortic valve area diminishes below 1 cm2 down to 0.5 cm2, 
the stenosis is termed “moderate.” Patients begin to develop symptoms as the heart 
struggles to maintain flow through the narrowing lesion. The increased work of the heart in 
association with decreased compliance and increased LVEDP results in angina in the 
majority of patients. This occurs in the absence of coronary artery disease (CAD), although 
up to 50% of patients may have significant CAD.[4] The left ventricle begins to dilate, the 
atrium may develop fibrillation, and the patient begins to experience symptoms of 
pulmonary congestion or even syncope with any type of excitement or exertion. “Critical” 
stenosis is present if the valve area is less than 0.5 cm2. The onset of angina is associated 
with an average survival of 5 years; heart failure or syncope are associated with less than 3 
years survival.[5] Valve replacement is recommended when the valve area is less than 0.8 
cm2 or if there is ventricular dysfunction, ventricular ectopy or an inadequate blood 
pressure response to exercise. Percutaneous balloon valvuloplasty is possible in selected 
patients. 
2.1 The detailed assessment 
2.1.1 Preoperative assessment 
The main aim of such an assessment is to determine the risks of the patient suffering from 
peri and/or postoperative deterioration of health and plan its prevention. Severe valvular 
disease in patients presenting for noncardiac surgery is a major predictor of increased peri-
operative cardiovascular risk, mandating intensive management that may result in delay or 
cancellation of, or pre-operative intervention before, surgery except in the case of emergency 
surgery[4]. Symptomatic stenotic lesions (aortic and mitral valve stenosis) are associated 
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with a higher risk of peri-operative cardiac complications than symptomatic regurgitation 
(aortic or mitral valve insufficiency),  which is usually better tolerated in the peri-operative 
setting or may even be stabilized pre-operatively with medical pretreatment[4]. The 
valvular disease with the highest risk for the non-cardiac surgical patient is severe aortic 
stenosis. 
2.1.1.1 Meeting the patient 
A review of the patient’s history and medical records to be sure the degree of stenosis, both 
clinically and objectively is appreciated. This review may result in a referral for valve 
replacement or valvuloplasty. Questions designed to define exercise tolerance are necessary 
to evaluate cardiac reserve to provide a functional classification according to the criteria 
established by the New York Heart Association (NYHA). When myocardial contractility is 
impaired patients complain of dyspnoea, orthopnea, and easy fatigability, a compensatory 
increase in the sympathetic nervous system activity may manifest as anxiety, diaphoresis, 
and resting tachycardia. Congestive heart failure (CHF) is a frequent complication of chronic 
valvular heart disease and its presence is noted by basilar chest rales, jugular venous 
distension and a third heart sound on physical examination. Cardiac dysrhythmias are 
common with valvular heart disease; angina pectoris may occur in patients with valvular 
heart disease even in the absence of coronary disease due to increased myocardial oxygen 
consumption and demand for the hypertrophied myocardium. Valvular heart disease and 
ischemic heart disease (IHD) frequently co-exist. 50% of patients with aortic stenosis who 
are older than 50 year of age have associated IHD. The presence of CAD with mitral or 




II Symptoms with ordinary activity but comfortably at rest 
III Symptoms with minimal activity but comfortable at rest 
IV symptoms at rest 
Table 1. NYHA functional classification of patients with heart disease [1] 
2.1.1.2 Charting out the assessment form 
Filling out the assessment form is the very backbone of the procedure to follow. Apart from 
the neurological, cardiac, respiratory, nephrology, gastrointestinal history, it is very 
important to discuss the use of the patient’s own medication prior to the surgical procedure. 
Allergies and complications during previous procedures should not be neglected. Detailed 
information should be availed regarding the discontinuation of anticoagulants like 
clopidogrel and its substitution by low molecular weight heparin 10 days before and 
immediately after the procedure.   
2.1.1.3 Discussing anaesthesia with the patient 
The patient should be informed about the procedure preferably in the presence of the 
surgeon. This way any question regarding the surgical details of the procedure can be 
answered appropriately. The patient has to be informed clearly regarding the steps of the 
anaesthetic procedure starting from leaving the ward through the events in the operating 
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theatre until reaching the intensive care unit. He/she needs to be reassured about optimal 
analgesia during the procedures involved. Proper information regarding the risks of the 
anaesthetic procedure and their possible solutions should be clarified. 
2.1.1.4 Discussing the procedure with the relative, parent in case of child 
In many cases patients prefer the preoperative assessment in the presence of their spouse or 
a relative. In case of children informed consent from the parent is essential. Any major 
surgical procedure and particularly cardiac surgery may spark fear of death during the 
procedure amongst patients and their relatives. Questions like ‘Will I wake up after the 
procedure?’ should be answered correctly, reassuring the patient and their relatives about 
the safety of the anaesthetic equipment, skill and care. Informed consent is essential prior to 
emergency procedures as well.  
2.1.1.5 Discussing the anaesthetic plan with the surgical/interdisciplinary team 
Details regarding the anaesthetic procedure and postoperative care need to be discussed 
well with the surgical side for each patient in order for allowing swift coordination and 
reduction of the possibility of error. In many cases not just the surgeon and the 
anaesthesiologist is involved but suggestions, investigations, examinations and consultation 
is required form cardiologists, obstetricians, psychiatrists, neurologists or other specialists. It 
is therefore essential to form a multidisciplinary team to ensure safe practice. The use of 
multidisciplinary protocols and drills are advised for emergency procedures.  
2.1.1.6 Preparing the patient for surgery 
The preparations start from the point the patient has been assessed pre-operatively but prior 
to the procedure it is essential that the anaesthetist personally visits the patient and 
preferably accompanies her or him to the operation theatre. Anxiety can cause serious 
problems before surgery. Anxiolysis might decrease the patient’s anxiety and hence 
decrease the sympathetic output which increases the heart rate, an undesirable parameter in 
patients with aortic stenosis, digitalis, ß blockers can be used for heart rate control which is 
essential for ventricular filling. Therefore pre-medication and anxiolytics hold an important 
place in preparing the patient for surgery. Introduction to the staff in theatre and friendly 
behaviour creates a stress free environment are useful to avoid unnecessary cardiovascular 
complications. 
Pre-operative management depends on the urgency of surgery and includes the following 
options: 
- open surgical repair before the non-cardiac surgical procedure; 
- balloon valvuloplasty before the non-cardiac surgical procedure; 
- clearance for surgery without further pre-operative intervention; 
- cancellation. 
In recently published guidelines[6], it is recommended that, if the aortic stenosis is severe 
and symptomatic, elective non-cardiac surgery should be postponed and aortic valve 
replacement performed before elective surgery. If the patient is not a candidate for valve 
replacement or surgery is semi-elective, balloon valvuloplasty may be performed. 
In patients without left ventricular failure, the mortality following aortic valve replacement 
ranges from 2% to 9% in most centres and may be as low as 1% in patients under the age of 
70 years. Concomitant coronary artery disease and poor left ventricular (LV) function are 
the most important variables affecting overall survival rate [7, 8]. 
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If the patients are not candidates for aortic valve replacement or balloon valvuloplasty, non-
cardiac surgery may be performed without pre-operative intervention in a selected group of 
patients at an acceptably low risk, probably because peri-operative anaesthesiological and 
surgical management has improved substantially over the past decade[9, 10]. In two recent 
studies, peri-operative mortality ranged from 1.9% to 7.1%. Peri-operative morbidity 
included pulmonary oedema in 17.3% of cases, which was effectively treated, and 
myocardial infarction in 1.9%[9, 10]. 
2.1.1.6.1 Premedication 
Anxiolysis might decease the patient’s anxiety and hence decrease the sympathetic output 
which increases the heart rate, an undesirable parameter in patients with aortic stenosis, 
digitalis, ß blockers can be used for heart rate control which is essential for ventricular 
filling.[1] 
Introduction to the staff in theatre and friendly behaviour creates a stress free environment 
are useful to avoid unnecessary cardiovascular complications. 
2.1.1.6.2 Endocarditis prophylaxis 
Prophylaxis against infective endocarditis is reasonable for the following patients at highest 
risk for adverse outcomes from infective endocarditis who undergo dental procedures that 
involve manipulation of either gingival tissue or the periapical region of teeth or perforation 
of the oral mucosa[11]: 
 Patients with prosthetic cardiac valve or prosthetic material used for cardiac valve 
repair.  
 Patients with previous infective endocarditis. 
 Patients with CHD. 
 Unrepaired cyanotic CHD, including palliative shunts and conduits. 
 Completely repaired congenital heart defect repaired with prosthetic material or device, 
whether placed by surgery or by catheter intervention, during the first 6 months after 
the procedure. 
 Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic 
patch or prosthetic device (both of which inhibit endothelialization). 
 Cardiac transplant recipients with valve regurgitation due to a structurally abnormal 
valve. 
Prophylaxis against infective endocarditis is not recommended for nondental procedures 
(such as transoesophageal echocardiogram, esophagogastroduodenoscopy, or colonoscopy) 
in the absence of active infection. [11] 
2.2 Monitoring during anaesthesia 
2.2.1 Non-invasive monitoring 
2.2.1.1 ECG 
Although even a single post-operative ECG demonstrating ischemia in the recovery room is 
predictive of a major cardiac complication later during the hospital stay, ECG monitoring 
alone is not adequate to detect ischemia in real time in the intensive care unit (ICU) and 
intraoperative settings [12-14]. Specifically, conventional visual ECG monitoring for the 
detection of transient ST segment changes is inaccurate[14]. Although lead V5 has been 
known as the best choice for the detection of intraoperative ischemia for many years [15, 16] 
one study found that lead V4 was more sensitive and appropriate than lead V5 for detecting 
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theatre until reaching the intensive care unit. He/she needs to be reassured about optimal 
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to the procedure it is essential that the anaesthetist personally visits the patient and 
preferably accompanies her or him to the operation theatre. Anxiety can cause serious 
problems before surgery. Anxiolysis might decrease the patient’s anxiety and hence 
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Pre-operative management depends on the urgency of surgery and includes the following 
options: 
- open surgical repair before the non-cardiac surgical procedure; 
- balloon valvuloplasty before the non-cardiac surgical procedure; 
- clearance for surgery without further pre-operative intervention; 
- cancellation. 
In recently published guidelines[6], it is recommended that, if the aortic stenosis is severe 
and symptomatic, elective non-cardiac surgery should be postponed and aortic valve 
replacement performed before elective surgery. If the patient is not a candidate for valve 
replacement or surgery is semi-elective, balloon valvuloplasty may be performed. 
In patients without left ventricular failure, the mortality following aortic valve replacement 
ranges from 2% to 9% in most centres and may be as low as 1% in patients under the age of 
70 years. Concomitant coronary artery disease and poor left ventricular (LV) function are 
the most important variables affecting overall survival rate [7, 8]. 
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Prophylaxis against infective endocarditis is reasonable for the following patients at highest 
risk for adverse outcomes from infective endocarditis who undergo dental procedures that 
involve manipulation of either gingival tissue or the periapical region of teeth or perforation 
of the oral mucosa[11]: 
 Patients with prosthetic cardiac valve or prosthetic material used for cardiac valve 
repair.  
 Patients with previous infective endocarditis. 
 Patients with CHD. 
 Unrepaired cyanotic CHD, including palliative shunts and conduits. 
 Completely repaired congenital heart defect repaired with prosthetic material or device, 
whether placed by surgery or by catheter intervention, during the first 6 months after 
the procedure. 
 Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic 
patch or prosthetic device (both of which inhibit endothelialization). 
 Cardiac transplant recipients with valve regurgitation due to a structurally abnormal 
valve. 
Prophylaxis against infective endocarditis is not recommended for nondental procedures 
(such as transoesophageal echocardiogram, esophagogastroduodenoscopy, or colonoscopy) 
in the absence of active infection. [11] 
2.2 Monitoring during anaesthesia 
2.2.1 Non-invasive monitoring 
2.2.1.1 ECG 
Although even a single post-operative ECG demonstrating ischemia in the recovery room is 
predictive of a major cardiac complication later during the hospital stay, ECG monitoring 
alone is not adequate to detect ischemia in real time in the intensive care unit (ICU) and 
intraoperative settings [12-14]. Specifically, conventional visual ECG monitoring for the 
detection of transient ST segment changes is inaccurate[14]. Although lead V5 has been 
known as the best choice for the detection of intraoperative ischemia for many years [15, 16] 
one study found that lead V4 was more sensitive and appropriate than lead V5 for detecting 
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prolonged post-operative ischemia and infarction [17]. Leads are not specific for ischemic 
events, and, furthermore, ischemic events are dynamic and may not always appear in the 
same lead. If a single lead is used for monitoring, there is an increased risk of missing 
ischemic events. With the use of selected lead combinations, more ischemic events can be 
precisely diagnosed in the intraoperative setting. In one study, although the best sensitivity 
was obtained with lead V5 (75%), followed by lead V4 (61%), combining leads V4 and V5 
increased the sensitivity to 90%.198 In the same study, when three leads (II, V4, and V5) 
were used simultaneously, the sensitivity increased to 96%.198 Similarly, in another study in 
which two or more precordial leads were used, the sensitivity of ECG monitoring was >95% 
for detection of perioperative ischemia and infarction [17]. It was also shown that ECG 
monitoring with fewer leads (as few as three leads) had lower sensitivity than monitoring 
with 12 leads, and there was a statistically significant association, independent of 
perioperative troponin values, between perioperative ischemia on a 12-lead ECG and long-
term mortality [18-20]. Thus, 12-lead ECG monitoring is recommended especially with high-
risk patients. 
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2.2.1.1.1 Other routine non-invasive monitoring  
Standard non-invasive procedures also apply including pulse oximetry, end tidal carbon 
dioxide monitoring with capnograph, and temperature measurement. 
2.2.2 Invasive haemodynamic monitoring 
2.2.2.1 Transoesophageal echocardiography 
TOE is recommended if acute and severe haemodynamic instability or life-threatening 
abnormalities develop during or after surgery[21].The main advantage of TOE over 
pulmonary artery catheterization is the more comprehensive evaluation of cardiac structure 
and function. Information is quickly available on regional or global, right and/or LV 
dysfunction, the presence of tamponade or cardiac thrombi, and preload estimation through 
the measurement of end-diastolic volume. Numerous indices of ventricular and atrial 
function have been proposed. However, most parameters are load dependent. The role of 
TOE for haemodynamic monitoring in patients at risk is more controversial. Automated 
analysis systems exist but are not yet sufficiently validated. There is no evidence that 
haemodynamic monitoring by TOE accurately stratifies risk or predicts outcome. TOE can 
be useful in the operating room in patients with severe valvular lesions. The loading 
conditions during general anaesthesia differ from those present in the preoperative 
evaluation. Functional and ischemic mitral regurgitation are usually reduced during general 
anaesthesia. Organic mitral regurgitation can, conversely, increase. In the setting of severe 
mitral regurgitation, the LV ejection fraction overestimates LV function, and other 
parameters may be more accurate, such as myocardial velocities or deformation obtained by 
tissue Doppler imaging or 2D speckle tracking, an angle independent method. These are 
promising techniques, but more validation is needed before they can be used routinely in 
this setting. In patients with severe aortic stenosis, appropriate preload is important during 
surgery. Monitoring of LV end-diastolic volume may be more accurate than that of 
pulmonary capillary pressure. An appropriate heart rate is crucial in patients with mitral 
stenosis and aortic regurgitation: a long diastolic period in the former and shorter duration 
of diastole in the latter. When inappropriate control of heart rate occurs, the consequences 
should be assessed: changes in transmitral mean gradient and pulmonary arterial pressures 
in mitral stenosis and changes in LV volumes and indices of LV function in aortic 
regurgitation. 
 
Recommendations on intraoperative and/or perioperative 
TOE in patients with or at risk of haemodynamic instability 
Classa Levelb 
TOE is recommended when acute sustained severe 
haemodynamic disturbances develop during surgery or in the 
perioperative period 
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TOE monitoring may be considered in patients at increased risk 
of significant haemodynamic disturbances during and after 
major non-cardiac surgery 
IIb C 
TOE monitoring may be considered in patients who present 
severe valvular lesions during major non-cardiac surgical 
procedures accompanied by significant haemodynamic stresses 
IIb C 
TOE, transoesophageal echocardiography. a Class of recommendation. b Level of evidence. 
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2.2.2.2 Invasive arterial blood pressure monitoring 
Invasive arterial blood pressure (IABP) measurement by means of an intra-arterial cannula 
is a key monitoring technique in high-risk patients both intra-operatively and on the 
intensive care or high-dependency unit. In addition to giving beat-to-beat blood pressure, 
the IABP system is increasingly being utilized as the basis of a variety of real-time 
haemodynamic monitoring systems based on pulse pressure1 or contour.[22] 
Its use in Aortic stenosis setting will allow real time beat to beat visualization and hence 
being proactive rather than reactive to any changes in blood pressure a parameter whose 
narrow fluctuations might decompromise the haemodynamics in tight valve lesions. 
2.2.2.3 The pulmonary artery catheter 
Aortic stenosis subjects the left ventricle to excessive afterload, resulting in hypertrophy and 
a loss of compliance. Unlike the afterload imposed by hypertension, the systemic circulation 
and especially the coronary circulation are subjected to reduced rather than elevated 
pressures. Coronary blood flow is impaired by systemic afterload reduction, increased 
ventricular diastolic pressure and tachycardia which reduces diastolic perfusion time, all 
may result in angina. Preload must be maintained for the left ventricle to generate an 
adequate cardiac output across the stenotic valve. Given a  noncompliant ventricle, small 
changes in fluid loading result in large changes in filling pressures. 
Critical aortic stenosis creates a narrow window of appropriate fluid loading. Small decrease 
in preload due to haemorrhage or regional anaesthesia may result in decreased cardiac 
output and clinical hypotension. Small increases in vascular volume may cause dramatic 
increases  in filling pressures, resulting in pulmonary oedema. 
The goal of haemodynamic management should be to maintain filling pressures within the 
narrow therapeutic window and to avoid tachycardia.[23]   
2.2.2.4 Glucose monitoring 
Diabetes mellitus is an important risk factor for perioperative cardiac complications and 
death. This condition promotes atherosclerosis, endothelial dysfunction, and activation of 
platelets and proinflammatory cytokines. Surgical stress is associated with haemodynamic 
stress and vasospasm and further enhances the prothrombotic state, while inhibiting 
fibrinolysis. Hyperglycaemia in the absence of established diabetes plays an important role, 
emphasizing the need for pre-operative management of hyperglycaemia where possible.  
Importantly, impaired glucose tolerance is often identified only after glucose loading. Data 
from the International Diabetes Foundation reveal a high and increasing prevalence of 
diabetes in Europe, rising from 7.8% in 2003 to 8.4% in 2007, with an estimated prevalence of 
at least 9.1% by 2025. [24]  
More than 30% of the cases were previously undiagnosed, pointing to underestimation of 
the problem. With ~48 million people affected, diabetes has become one of the main causes 
of morbidity and mortality in Europe. According to the World Health Organization, ~50% of 
these patients die of CVDs cardiovascular diseases. It has been well established that surgery 
in patients with diabetes is associated with longer hospital stay, higher healthcare resource 
utilization, and greater perioperative mortality. More recently, the emphasis has shifted 
from diabetes to hyperglycaemia on its own. New-onset hyperglycaemia, as compared with 
hyperglycaemia in known diabetics, may hold a much higher risk of adverse outcome[25].  
Evidence for strict blood glucose control for patients without known diabetes undergoing 
non-cardiac surgery is largely derived from studies in critically ill patients.[26] the Leuven 
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prospective randomized controlled study demonstrated major clinical benefits for surgical 
ICU patients whose blood glucose levels were maintained normal (5.0–5.6mmol/L; 90–100 
mg/dL) with intensive insulin therapy, compared with patients who received conventional 
glucose management and developed hyperglycaemia (8.3–8.9 mmol/L; 150– 160 
mg/dL)[27]. These benefits included lower ICU and in-hospital mortality and prevention of 
several critical illness-associated complications (critical illness polyneuropathy, severe 
infections, acute renal failure, and prolonged dependency on mechanical ventilation and 
intensive care). Also, long-term outcome improved, as shown for the cardiac surgery 
subgroup. Five years later the Leuven group reported findings from the medical ICU, 
showing prevention of morbidity, but no mortality benefit from intensive glucose control, 
except in a subgroup requiring critical care for 3 days [28]. 
Several risk factors for cardiac events after non-cardiac surgery are attenuated with strict 
blood glucose control in the ICU, including endothelial injury/dysfunction, CRP, and 
asymmetric dimethylarginine, apart from effects on mitochondrial damage, serum lipid 
profile, and the cortisol response. No effects, or only marginal ones, were seen on cytokines, 
coagulation, and fibrinolysis.  
 
Recommendations Classa Levelb 
Postoperative prevention of hyperglycaemia (targeting 
levels at least below 10 mmol/L with intensive insulin 
therapy is recommended in adults after high risk or 
complicated major surgery requiring admission to ICU 
I B 
Intraoperative prevention of hyperglycaemia with insulin 
may be considered IIb C 
Postoperative prevention of hyperglycaemia with insulin 
after uncomplicated elective surgery may be considered IIb C 
ICU, Intensive care unit. a Class of recommendation. b Level of evidence 
Table 4. Recommendations on blood glucose control 
3. Anaesthetic considerations 
The objectives of anaesthesia in patients with aortic stenosis include the prevention of 
hypotension and any haemodynamic change that will increase the cardiac output. 
Normal sinus rhythm must be maintained because the left ventricle is dependant on a 
properly timed atrial contraction to produce an optimal left ventricular end-diastolic 
volume. Loss of atrial contraction loosing the atrial kick, as during junctional rhythm or 
atrial fibrillation may produce a dramatic decrease in stroke volume and blood pressure. 
The heart rate is important because it determines the time available for ventricular filling, 
for ejection of the stroke volume, and for coronary perfusion. A sustained increase in heart 
rate decreases the time for left ventricular filling and ejection and reduces cardiac output. 
Hypotension reduces coronary blood flow and results in myocardial ischemia and further 
deterioration in left ventricular function and cardiac output. Aggressive treatment of 
hypotension is mandatory to prevent cardiogenic shock and/or cardiac arrest. 
Cardiopulmonary resuscitation is unlikely to be effective in patients with aortic stenosis 
because it is difficult, if not impossible, to create an adequate stroke volume across a stenotic 
aortic valve with cardiac compression[1]. 
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may result in angina. Preload must be maintained for the left ventricle to generate an 
adequate cardiac output across the stenotic valve. Given a  noncompliant ventricle, small 
changes in fluid loading result in large changes in filling pressures. 
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output and clinical hypotension. Small increases in vascular volume may cause dramatic 
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prospective randomized controlled study demonstrated major clinical benefits for surgical 
ICU patients whose blood glucose levels were maintained normal (5.0–5.6mmol/L; 90–100 
mg/dL) with intensive insulin therapy, compared with patients who received conventional 
glucose management and developed hyperglycaemia (8.3–8.9 mmol/L; 150– 160 
mg/dL)[27]. These benefits included lower ICU and in-hospital mortality and prevention of 
several critical illness-associated complications (critical illness polyneuropathy, severe 
infections, acute renal failure, and prolonged dependency on mechanical ventilation and 
intensive care). Also, long-term outcome improved, as shown for the cardiac surgery 
subgroup. Five years later the Leuven group reported findings from the medical ICU, 
showing prevention of morbidity, but no mortality benefit from intensive glucose control, 
except in a subgroup requiring critical care for 3 days [28]. 
Several risk factors for cardiac events after non-cardiac surgery are attenuated with strict 
blood glucose control in the ICU, including endothelial injury/dysfunction, CRP, and 
asymmetric dimethylarginine, apart from effects on mitochondrial damage, serum lipid 
profile, and the cortisol response. No effects, or only marginal ones, were seen on cytokines, 
coagulation, and fibrinolysis.  
 
Recommendations Classa Levelb 
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levels at least below 10 mmol/L with intensive insulin 
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complicated major surgery requiring admission to ICU 
I B 
Intraoperative prevention of hyperglycaemia with insulin 
may be considered IIb C 
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after uncomplicated elective surgery may be considered IIb C 
ICU, Intensive care unit. a Class of recommendation. b Level of evidence 
Table 4. Recommendations on blood glucose control 
3. Anaesthetic considerations 
The objectives of anaesthesia in patients with aortic stenosis include the prevention of 
hypotension and any haemodynamic change that will increase the cardiac output. 
Normal sinus rhythm must be maintained because the left ventricle is dependant on a 
properly timed atrial contraction to produce an optimal left ventricular end-diastolic 
volume. Loss of atrial contraction loosing the atrial kick, as during junctional rhythm or 
atrial fibrillation may produce a dramatic decrease in stroke volume and blood pressure. 
The heart rate is important because it determines the time available for ventricular filling, 
for ejection of the stroke volume, and for coronary perfusion. A sustained increase in heart 
rate decreases the time for left ventricular filling and ejection and reduces cardiac output. 
Hypotension reduces coronary blood flow and results in myocardial ischemia and further 
deterioration in left ventricular function and cardiac output. Aggressive treatment of 
hypotension is mandatory to prevent cardiogenic shock and/or cardiac arrest. 
Cardiopulmonary resuscitation is unlikely to be effective in patients with aortic stenosis 
because it is difficult, if not impossible, to create an adequate stroke volume across a stenotic 
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3.1 General anaesthesia 
General anaesthesia is often selected in preference to epidural or spinal anaesthesia because 
the sympathetic blockade produced by regional anaesthesia can lead to significant 
hypotension. [1]Nevertheless controversies do exist as for the careful titration of regional 
anaesthetic technique that might provide a favourable heamodynamic profile (see below). 
Induction of anaesthesia can be with an intravenous induction drug that does not decrease 
the systemic vascular resistance. An opioid  may be useful if left ventricular function is 
compromised.  
Maintenance of anaesthesia with a combination of nitrous oxide and volatile anaesthetic and 
opioid or by opioid alone. Advisable to avoid drugs depressing the sinus node to preserve  
atrial contraction which has an important role in the ventricular filling. Drugs that depress 
sinus node automaticity can produce junctional rhythm and loss of the properly timed atrial 
contraction. If left ventricular function is impaired, it is prudent to avoid any drugs that can 
cause additional depression of myocardial contractility. A decrease in systemic vascular 
resistance is very devastating. Maintenance of anaesthesia with nitrous oxide plus opioid or 
with opioids alone in high doses is recommended for patients with marked left ventricular 
dysfunction. Neuromuscular blocking drugs with minimal haemodynamic effects are best 
used. Intravascular volume should be maintained at normal levels. The onset of junctional 
rhythm  or bradycardia during anaesthesia and surgery requires treatment with 
glycopyrolate, atropine, or ephedrine. Persistant tachycardia can be treated with ß blockers 
such as esmolol. Supraventricular tachycardia should be promptly terminated with 
electrical cardioversion. Lidocaine and defibrillator should be kept available as these 
patients have a propensity to develop ventricular dysrhythmias[1]. 
3.2 Epidural block 
There is a lack of evidence based guidelines as for the best choice of regional technique to 
be used in patients with aortic stenosis to provide anaesthesia and analgesia. Patients with 
hip fractures for instance and cardiac co-morbidities benefit more from epidural analgesia 
than from opioid analgesia technique in terms of pain and reduced postoperative cardiac 
events [29]. In major knee surgery it has been demonstrated that earlier rehabilitation can 
be achieved by using epidural blockade in contrast to i.v. patient controlled morphine 
[30].  
So what is the rule?, When anaesthetizing a patient with aortic stenosis, the haemodynamic 
goals include avoiding sudden and profound decreases in systemic vascular resistance, 
maintaining contractility and sinus rhythm and avoiding hypovolaemia and tachycardia ( as 
mentioned earlier in the general anaesthesia section). Epidural blockade facilitate a gradual 
onset of anaesthesia and sympathetic block, and therefore a sudden and profound decrease 
in systemic vascular resistance is avoided. With incremental doses of local anaesthetics, an 
even higher degree of control is attained. Epidural anaesthesia does not affect myocardial 
contractility and with proper fluid loading, good control of the circulation can be 
accomplished. 
There are some studies e.g. Ho et al. suggested the use of hypotensive epidural anaesthesia 
in patients with aortic stenosis undergoing total hip replacement and rendered satisfactory 
results provided that the stenosis is asymptomatic and non-critical. Nevertheless the choice 
of anaesthesia in such cases should be made on individual basis and in the presence of 
skilled anaesthetist [31]. 
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3.3 Spinal anaesthesia 
Although general anaesthesia is historically considered the anaesthetic of choice for patients 
with aortic stenosis, Continuous spinal anaesthesia is an attractive alternative for the 
management of surgery on the lower extremities when used with appropriate invasive 
monitoring. 
Central neuroaxial blockade has been contraindicated in patients with severe aortic stenosis 
[32-35], because sympathetic blockade produced can rapidly cause a marked decrease in 
systemic vascular resistance with decreased venous return to the heart and coronary 
perfusion pressure. Large decreases in systemic vascular resistance, therefore, should be 
avoided to prevent the catastrophic cycle of hypotension-induced ischemia, subsequent 
ventricular dysfunction, and worsening hypotension. Indeed, hypotension-induced 
ischemia with resultant ventricular dysfunction has been described in patients with left 
ventricular outflow tract obstruction receiving spinal anaesthesia[36]. Recently, several 
authors have reported greater hemodynamic control achieved with continuous spinal 
anaesthesia over epidural or single-dose spinal anaesthesia in healthy patients [37, 38]. 
When regional anaesthesia is selected, epidural rather than spinal anaesthesia is often 
recommended, but continuous spinal anaesthesia offers many of the advantages of epidural 
anaesthesia. With the appropriate invasive monitoring, the onset of peripheral sympathetic 
block develops in a gradual and controlled fashion using continuous spinal anaesthesia. An 
additional advantage over epidural anaesthesia in that catheter placement is technically 
easier and aspiration of CSF provides confirmation of correct catheter placement, also the 
catheter can be left in place like an epidural catheter offering postoperative pain 
management, minimizing the need for systemic opiates and their attendant risks. However, 
the potential higher incidence of respiratory depression with spinal versus epidural opiate 
administration should not be overlooked [39]. 
Continuous spinal anaesthesia avoids many of the disadvantages of general anaesthesia. In 
contrast to general anaesthesia, use of a continuous spinal catheter allows patient 
communication of subjective feelings of distress throughout the operation. In addition, the 
hemodynamic perturbations of direct laryngoscopy and intubation are avoided with 
continuous spinal anaesthesia. Moreover, the use of volatile anaesthetics in patients with 
aortic stenosis may lead to myocardial depression, peripheral vasodilation, and loss of 
normal atrial systole. Likewise, continuous spinal anaesthesia obviates the need for 
neuromuscular blockade, which may lead to undesirable fluctuations though newer agents 
have fewer effects on heart rate.  
However, continuous spinal anaesthesia has potential complications: 
It should be used with caution in patients in whom a difficult endotracheal intubation is 
anticipated. Peripheral sympathetic nervous system block produced by continuous spinal 
anaesthesia may be deleterious in situations of profound blood loss. This is especially true in 
the setting of aortic stenosis where precipitous decreases in systemic vascular resistance can 
lead to the catastrophic cycle of hypotension-induced ischemia, subsequent ventricular 
dysfunction, and worsening hypotension. Aortic stenosis is often complicated by global 
ventricular hypokinesis and atrial fibrillation. These patients are often anticoagulated and 
Continuous spinal anaesthesia would be contraindicated. Finally, many of the complications 
associated with single-dose spinal anaesthesia including postdural puncture headache, 
persistent paresthesia, low back pain, and risk of infection also apply to continuous spinal 
anaesthesia. 
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management, minimizing the need for systemic opiates and their attendant risks. However, 
the potential higher incidence of respiratory depression with spinal versus epidural opiate 
administration should not be overlooked [39]. 
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contrast to general anaesthesia, use of a continuous spinal catheter allows patient 
communication of subjective feelings of distress throughout the operation. In addition, the 
hemodynamic perturbations of direct laryngoscopy and intubation are avoided with 
continuous spinal anaesthesia. Moreover, the use of volatile anaesthetics in patients with 
aortic stenosis may lead to myocardial depression, peripheral vasodilation, and loss of 
normal atrial systole. Likewise, continuous spinal anaesthesia obviates the need for 
neuromuscular blockade, which may lead to undesirable fluctuations though newer agents 
have fewer effects on heart rate.  
However, continuous spinal anaesthesia has potential complications: 
It should be used with caution in patients in whom a difficult endotracheal intubation is 
anticipated. Peripheral sympathetic nervous system block produced by continuous spinal 
anaesthesia may be deleterious in situations of profound blood loss. This is especially true in 
the setting of aortic stenosis where precipitous decreases in systemic vascular resistance can 
lead to the catastrophic cycle of hypotension-induced ischemia, subsequent ventricular 
dysfunction, and worsening hypotension. Aortic stenosis is often complicated by global 
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associated with single-dose spinal anaesthesia including postdural puncture headache, 
persistent paresthesia, low back pain, and risk of infection also apply to continuous spinal 
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3.3.1 Pulmonary artery catheter management under continuous spinal anaesthesia 
a. Low CVP and PCWP: warrants the administration of  e.g. crystalloids or colloids  to 
regain PCWP to the preoperative value, if this measure fails , it is advisable to add a 
vasoconstrictor to increase the systemic vascular resistance and cardiac filling 
pressures. 
b. In case of crystalloids usage and sudden increase in the PCWP of 3-4 mmHg upon 
administering 15ml/kg , so the infusion should be stopped immediately. 
c. Pulmonary artery catheter carries the advantage of detecting pulmonary hypertension, 
and left ventricular failure as a result of decreased left ventricular filling and decrease 
compliance[40] 
d. Inotropes should be considered in those with hypotension and high PCWP. 
Ephedrine should be used cautiously in the patient with aortic stenosis, as the resultant 
tachycardia may precipitate myocardial ischemia. With the aide of invasive hemodynamic 
monitoring, there is a successful induction and maintenance of Continuous spinal 
anaesthesia in a controlled fashion while maintaining control of the cardiac filling 
pressures. 
3.4 Post-operative pain management 
Post-operative pain is a major concern, reported in 5–10% of the patients. It may increase 
sympathetic drive and delay recovery [41, 42]. The evidence that pain causes organ 
complications after surgery is less clear. Neuraxial analgesia with local anaesthetics/opioids 
and/or α2-agonists, i.v. opioids alone or in combination with non-steroidal anti-
inflammatory drugs seems to be the most effective. The benefit of invasive analgesic 
techniques should be weighed against potential dangers. This is of special importance when 
considering the use of neuraxial blockade in patients under chronic antithrombotic therapy 
due to increased potential of a neuraxial haematoma. Patient-controlled analgesia is an 
alternative for postoperative pain relief. Recent meta-analyses of controlled randomized 
trials show that patient-controlled analgesia has some advantage with regard to patient 
satisfaction over nurse-controlled or on-demand analgesia[43]. No difference with regard to 
morbidity or final outcome was demonstrated. Patient-controlled analgesia is an adequate 
alternative in patients and situations not suited for regional anaesthesia. Routines for follow-
up and documentation of effects should be in place[42, 44-46] Non-steroidal anti-
inflammatory drugs and the cyclooxygenase- 2 (COX-2) inhibitors have the potential for 
promoting heart and renal failure as well as thromboembolic events and should be avoided 
in patients with myocardial ischemia. The COX-2 inhibitors cause less gastrointestinal 
ulceration and bronchospasm. The final role for these drugs in the treatment of post-
operative pain in cardiac patients undergoing non-cardiac surgery has not been defined. The 
drugs should be avoided in patients with renal and heart failure, elderly patients, patients 
on diuretics, as well as patients with unstable haemodynamics [47]. 
4. Obstetric considerations 
Management of pregnancy complicated by aortic stenosis requires an accurate assessment of 
the severity of the disease. Unlike mitral stenosis, clinical symptoms appear very late in the 
course of the disease. Once patients complain of angina, shortness of breath, or syncope, 
their risk of sudden death may be out of proportion to the severity of their clinical 
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symptoms. In the past accurate assessment of the severity of stenosis required cardiac 
catheterization and significant radiation exposure [48, 49].  
Intracardiac pressure gradients cab be accurately measured noninvasively by Doppler 
echocardiography [50, 51], pressure gradients are calculated by ΔP= 4V2 , where ΔP is the 
change in pressure and V is the velocity of blood flow determined by Doppler evaluation. 
Use of the technique has been described in pregnancy, . because pressure gradients are flow-
dependant, gradients alone may provide misleading information about the severity of valve 
narrowing during pregnancy, when cardiac output is increased. In this setting, calculation 
of aortic valve area provides an index of the stenosis that is independent  of changes in 
transaortic volume flow. Valve area can be determined noninvasively using the Doppler 
continuity equation [52]. 
Five principal changes in the cardiovascular system during pregnancy that present unique 
problems to the parturient with underlying heart disease have been well delineated: 
1. 50% increase in intravascular volume that generally peaks by the early to- middle third 
trimester. 
2. Progressive decrease in systemic vascular resistance (SVR) throughout pregnancy, 
thanks to this mean arterial blood pressure is preserved at normal values, despite a 
30%– 40% increase in cardiac output. 
3. Marked fluctuations in cardiac output during labour. Pain and apprehension may 
precipitate an increase in cardiac output to as much as 40%–50% over those levels seen 
in the late second stage of labour. 
4. Each uterine contraction serves as an auto transfusion to the central blood volume, an 
increase in cardiac output of 10%–25% is seen 
5. Hypercoagulability associated with pregnancy and the possible need for appropriate 
anticoagulation, especially in those patients at increased risk for arterial thrombosis and 
embolization (prosthetic heart valve). 
4.1 General anaesthesia versus other modalities 
Improvement of medical and surgical care lead to the decrease in the incidence of 
rheumatic heart disease and the relative increase in the congenital heat disease in women 
in the child bearing period. Congenital aortic stenosis is a congenital bicuspid valve 
leading to valve thickening, subvalvular or tunnel stenosis. In aortic stenosis the coronary 
blood vessels are distal to the obstruction and are supplied with blood mainly during 
diastole; in the pregnant state it becomes more difficult to maintain adequate blood flow 
to the left ventricle because of increasing systolic and end diastolic ventricular pressures. 
The work of the ventricle is increased and thus it requires a greater coronary artery blood 
flow; as this cannot be achieved the patient may experience angina and suffer 
subendocardial ischemia. Regional anaesthesia has been associated with ECG changes of 
ischemia of multifactorial origin in healthy parturients [53]. The detection of transient 
ischemia requires capture of ECG data from leads II and V5 and an analysis of changes 
from control. In spite of the spinal microcatheter technique, colloid infusion and 
vasopressors intravenously, the patient’s systolic blood pressure might decrease. 
However, it is the diastolic blood pressure which determines myocardial blood flow. The 
patient with aortic stenosis has a fixed stroke volume and to maintain cardiac output must 
elevate her heart rate, but this compromises left ventricular filling. The pregnant woman 
with aortic stenosis is extremely intolerant of change in left ventricular preload. A 
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change in pressure and V is the velocity of blood flow determined by Doppler evaluation. 
Use of the technique has been described in pregnancy, . because pressure gradients are flow-
dependant, gradients alone may provide misleading information about the severity of valve 
narrowing during pregnancy, when cardiac output is increased. In this setting, calculation 
of aortic valve area provides an index of the stenosis that is independent  of changes in 
transaortic volume flow. Valve area can be determined noninvasively using the Doppler 
continuity equation [52]. 
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increase in cardiac output of 10%–25% is seen 
5. Hypercoagulability associated with pregnancy and the possible need for appropriate 
anticoagulation, especially in those patients at increased risk for arterial thrombosis and 
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Improvement of medical and surgical care lead to the decrease in the incidence of 
rheumatic heart disease and the relative increase in the congenital heat disease in women 
in the child bearing period. Congenital aortic stenosis is a congenital bicuspid valve 
leading to valve thickening, subvalvular or tunnel stenosis. In aortic stenosis the coronary 
blood vessels are distal to the obstruction and are supplied with blood mainly during 
diastole; in the pregnant state it becomes more difficult to maintain adequate blood flow 
to the left ventricle because of increasing systolic and end diastolic ventricular pressures. 
The work of the ventricle is increased and thus it requires a greater coronary artery blood 
flow; as this cannot be achieved the patient may experience angina and suffer 
subendocardial ischemia. Regional anaesthesia has been associated with ECG changes of 
ischemia of multifactorial origin in healthy parturients [53]. The detection of transient 
ischemia requires capture of ECG data from leads II and V5 and an analysis of changes 
from control. In spite of the spinal microcatheter technique, colloid infusion and 
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However, it is the diastolic blood pressure which determines myocardial blood flow. The 
patient with aortic stenosis has a fixed stroke volume and to maintain cardiac output must 
elevate her heart rate, but this compromises left ventricular filling. The pregnant woman 
with aortic stenosis is extremely intolerant of change in left ventricular preload. A 
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decrease in preload caused by haemorrhage or associated with regional anaesthesia can 
produce cardiogenic shock. An increase in preload can precipitate pulmonary oedema. 
These are acute changes, but they may complicate a more chronic left ventricular 
hypertrophy which ultimately progresses to congestive cardiac failure. Control over left 
ventricular preload is less precise with regional techniques because ventilation cannot be 
manipulated as would be possible with IPPV and filling pressures are less predictable 
because they depend on fluid load and altered sympathetic nervous system responses. A 
segmental nerve block from the lowest sacral segment to T4 is necessary by any route to 
ensure adequate pain relief during Caesarean section and this invariably produces 
extensive sympathetic block [54]. Moreover, the risk of hypotension cannot be eliminated. 
Obstetric anaesthetists are agreed that in severe aortic stenosis tachycardia must be 
prevented, adverse therapeutic events must also be anticipated. If ephedrine is chosen as 
the vasoconstrictor, it has α and ß effects with a resultant tachycardia which is 
undesirable in a patient with aortic stenosis. Phenylephrine might be a better choice 
although it is a pure α agonist [55]. A multidisciplinary approach may be very beneficial 
in mothers with severe aortic stenosis. The cardiac surgery team in such cases is present 
during the caesarean section and may take over in case of an emergency [56]. 
Regardless of the anaesthetic used, blood loss reduces blood volume and to counteract this 
the uterus contracts and releases additional blood into the circulation. This process is 
augmented by the use of oxytocin after delivery to ensure uterine contraction and prevent 
postpartum haemorrhage. One of the deaths reported in the maternal mortality reports 
describes postpartum cardiac failure exacerbated by oxytocin in a woman with aortic 
stenosis who required manual removal of the placenta [57]. There is a time and preferably 
an elective decision, when conversion to general anaesthesia has to be made because of 
clinical deterioration.  
Each patient must be serially assessed during pregnancy by cardiological investigations, 
including non-invasive Doppler echocardiography and in some cases cardiac 
catheterisation. The case for general anaesthesia is made on the basis that the avoidance of 
sympathetic blockade which occurs with regional anaesthesia decreases the risk of 
significant hypotension following a reduction in systemic vascular resistance. In 
pregnancy hypotension will compromise not only the maternal myocardium but also the 
placental blood flow to the foetus. One disadvantage of general anaesthesia is the 
sympathetic nervous system response to intubation, which can generate tachycardia and 
hypertension, leading to sudden fluctuations in cardiac output. This can be controlled by 
induction with a cardio-stable drug followed by a short acting opioid (e.g. alfentanil). 
Volatile anaesthetic agents also have a direct myocardial depressant effect but this is dose 
related. In obstetrics, their concentration is limited because of their relaxant effect on the 
myometrium.  
Postoperatively monitoring should continue and it is advised that women with significant 
cardiac disease should be nursed in a high-dependency unit on the labour ward and cardiac 
monitoring continued into the puerperium because maternal deaths occur, not 
uncommonly, 3–5 days postpartum [17]. Postoperative analgesia does not govern the choice 
of technique for anaesthesia. Patient-controlled analgesia provides satisfactory analgesia 
after general anaesthesia [58] and by whichever route opioids are administered, respiratory 
monitoring is required. 
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4.2 Regional anaesthesia debates 
Congenital aortic stenosis has been considered a relative contraindication to pregnancy 
because of the high maternal mortality (17%) previously reported [59], although this figure 
has been disputed [60]. The underlying pathophysiology is well known The need to 
maintain afterload has been extrapolated to suggest that regional analgesia and anaesthesia 
are contraindicated in pathological states producing a fixed cardiac output. 
Authoritative sources state ‘high subarachnoid or extradural blockade is contraindicated in 
patients with cardiovascular disease nevertheless It is possible to provide safe regional 
anaesthesia for Caesarean section in women with aortic stenosis, but certain conditions must 
be met. 
Firstly, it is essential to identify these women as early as possible in the antenatal period. 
There is no place for assessing the woman with aortic stenosis a few minutes before she is 
due to be delivered. Secondly, it is important to make clear written and dated management 
plans for anaesthesia and delivery in the patient’s records. These plans should include 
provision for emergency delivery and should be amended as necessary during the course of 
the pregnancy. Regular revision of management plans is important, since deterioration in 
cardiac status during pregnancy increases maternal risk.  
Use of the wedged supine position, or of lateral tilt to ensure displacement of the uterus off 
the aorta and inferior vena cava, is mandatory during anaesthesia for Caesarean section. It is 
important to remember that the tilted or wedged position is a compromise between the full 
lateral position which prevents aortocaval compression and the supine position that the 
obstetricians would prefer to facilitate surgery. Maintaining the full lateral position until the 
obstetrician is ready to perform skin incision reduces the risk of haemodynamic instability 
due to aortocaval compression. 
Ultimately there is, of course, no randomised controlled data comparing carefully managed 
regional anaesthesia with ‘cardiac’ general anaesthesia for Caesarean section in women with 
aortic stenosis. All the arguments for and against both techniques are based on anecdotal 
case reports and assessment of theoretical risks. Multidisciplinary antenatal care of these 
women is important and should involve senior obstetricians, anaesthetists and cardiologists 
and regular assessment of cardiac function. Anaesthetic plans for delivery should include 
provision for the use of invasive monitoring in the peri- and postoperative period and for 
high-dependency care postoperatively. Both general and regional anaesthesia have 
significant risks, but incremental induction of either epidural or spinal anaesthesia should 
be considered a reasonable alternative to general anaesthesia for Caesarean section in the 
women with aortic stenosis. 
5. References 
[1] Roberta L Hines,Katherine E Marschall, Stoelting's Anesthesia and Co-Existing Disease 5th 
ed. 2008, Philadelphia: Churchill livingstone. 
[2] Rick A. Nishimura.Aortic Valve Disease. Circulation, 2002. 106: p. 770-772. 
[3] Kennedy KD, Nishimura RA,Holmes DR et al.Natural history of moderate aortic stenosis. J 
Am Coll Cardiol, 1991. 17: 313. 
[4] Braunwald E (Ed), A Textbook of Cardiovascular Medicine (5th Ed) “Valvular heart disease” in 
Heart Disease1997, Philadelphia WB Saunders Co. 1007-1076. 
[5] Ross J JR,Braunwald E.Aortic Stenosis. Circulation, 1968. 38 (suppl V): 61. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
80
decrease in preload caused by haemorrhage or associated with regional anaesthesia can 
produce cardiogenic shock. An increase in preload can precipitate pulmonary oedema. 
These are acute changes, but they may complicate a more chronic left ventricular 
hypertrophy which ultimately progresses to congestive cardiac failure. Control over left 
ventricular preload is less precise with regional techniques because ventilation cannot be 
manipulated as would be possible with IPPV and filling pressures are less predictable 
because they depend on fluid load and altered sympathetic nervous system responses. A 
segmental nerve block from the lowest sacral segment to T4 is necessary by any route to 
ensure adequate pain relief during Caesarean section and this invariably produces 
extensive sympathetic block [54]. Moreover, the risk of hypotension cannot be eliminated. 
Obstetric anaesthetists are agreed that in severe aortic stenosis tachycardia must be 
prevented, adverse therapeutic events must also be anticipated. If ephedrine is chosen as 
the vasoconstrictor, it has α and ß effects with a resultant tachycardia which is 
undesirable in a patient with aortic stenosis. Phenylephrine might be a better choice 
although it is a pure α agonist [55]. A multidisciplinary approach may be very beneficial 
in mothers with severe aortic stenosis. The cardiac surgery team in such cases is present 
during the caesarean section and may take over in case of an emergency [56]. 
Regardless of the anaesthetic used, blood loss reduces blood volume and to counteract this 
the uterus contracts and releases additional blood into the circulation. This process is 
augmented by the use of oxytocin after delivery to ensure uterine contraction and prevent 
postpartum haemorrhage. One of the deaths reported in the maternal mortality reports 
describes postpartum cardiac failure exacerbated by oxytocin in a woman with aortic 
stenosis who required manual removal of the placenta [57]. There is a time and preferably 
an elective decision, when conversion to general anaesthesia has to be made because of 
clinical deterioration.  
Each patient must be serially assessed during pregnancy by cardiological investigations, 
including non-invasive Doppler echocardiography and in some cases cardiac 
catheterisation. The case for general anaesthesia is made on the basis that the avoidance of 
sympathetic blockade which occurs with regional anaesthesia decreases the risk of 
significant hypotension following a reduction in systemic vascular resistance. In 
pregnancy hypotension will compromise not only the maternal myocardium but also the 
placental blood flow to the foetus. One disadvantage of general anaesthesia is the 
sympathetic nervous system response to intubation, which can generate tachycardia and 
hypertension, leading to sudden fluctuations in cardiac output. This can be controlled by 
induction with a cardio-stable drug followed by a short acting opioid (e.g. alfentanil). 
Volatile anaesthetic agents also have a direct myocardial depressant effect but this is dose 
related. In obstetrics, their concentration is limited because of their relaxant effect on the 
myometrium.  
Postoperatively monitoring should continue and it is advised that women with significant 
cardiac disease should be nursed in a high-dependency unit on the labour ward and cardiac 
monitoring continued into the puerperium because maternal deaths occur, not 
uncommonly, 3–5 days postpartum [17]. Postoperative analgesia does not govern the choice 
of technique for anaesthesia. Patient-controlled analgesia provides satisfactory analgesia 
after general anaesthesia [58] and by whichever route opioids are administered, respiratory 
monitoring is required. 
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4.2 Regional anaesthesia debates 
Congenital aortic stenosis has been considered a relative contraindication to pregnancy 
because of the high maternal mortality (17%) previously reported [59], although this figure 
has been disputed [60]. The underlying pathophysiology is well known The need to 
maintain afterload has been extrapolated to suggest that regional analgesia and anaesthesia 
are contraindicated in pathological states producing a fixed cardiac output. 
Authoritative sources state ‘high subarachnoid or extradural blockade is contraindicated in 
patients with cardiovascular disease nevertheless It is possible to provide safe regional 
anaesthesia for Caesarean section in women with aortic stenosis, but certain conditions must 
be met. 
Firstly, it is essential to identify these women as early as possible in the antenatal period. 
There is no place for assessing the woman with aortic stenosis a few minutes before she is 
due to be delivered. Secondly, it is important to make clear written and dated management 
plans for anaesthesia and delivery in the patient’s records. These plans should include 
provision for emergency delivery and should be amended as necessary during the course of 
the pregnancy. Regular revision of management plans is important, since deterioration in 
cardiac status during pregnancy increases maternal risk.  
Use of the wedged supine position, or of lateral tilt to ensure displacement of the uterus off 
the aorta and inferior vena cava, is mandatory during anaesthesia for Caesarean section. It is 
important to remember that the tilted or wedged position is a compromise between the full 
lateral position which prevents aortocaval compression and the supine position that the 
obstetricians would prefer to facilitate surgery. Maintaining the full lateral position until the 
obstetrician is ready to perform skin incision reduces the risk of haemodynamic instability 
due to aortocaval compression. 
Ultimately there is, of course, no randomised controlled data comparing carefully managed 
regional anaesthesia with ‘cardiac’ general anaesthesia for Caesarean section in women with 
aortic stenosis. All the arguments for and against both techniques are based on anecdotal 
case reports and assessment of theoretical risks. Multidisciplinary antenatal care of these 
women is important and should involve senior obstetricians, anaesthetists and cardiologists 
and regular assessment of cardiac function. Anaesthetic plans for delivery should include 
provision for the use of invasive monitoring in the peri- and postoperative period and for 
high-dependency care postoperatively. Both general and regional anaesthesia have 
significant risks, but incremental induction of either epidural or spinal anaesthesia should 
be considered a reasonable alternative to general anaesthesia for Caesarean section in the 
women with aortic stenosis. 
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1. Introduction  
The main objective of aortic valve replacement (AVR) is to relieve left ventricular (LV) 
burden and normalized LV mass (LVM). During AVR, many surgeons make final decision 
to select the size of the prosthetic valve based on intraoperative measurement. It is ideal to 
place an aortic prosthesis that is appropriately sized to the patient. However, this is not 
always possible owing to insufficient aortic annular dimensions. Patients receive a 
prosthesis that is too small in relation to their body size have persistent abnormally high 
gradients across the valve and may even show deterioration of symptoms and 
hemodynamics after AVR. Rahimtoola first described the concept of patient-prosthesis 
mismatch (PPM), which was defined as existing “when the effective prosthetic valve area, 
after insertion into the patient, is less than that of a normal valve” 1. The optimal 
prosthetic valve should have several characteristics, including a sufficiently large effective 
orifice area (EOA) with a reduced transvalvular pressure gradient around zero, long-term 
durability, and anticoagulability. There is no optimal, commercially available prosthesis. 
The normal aortic valve has 3.0-4.5 cm2 of EOA, but this is rarely achieved with present 
commercially available prostheses, which means that the result of AVR may be 
suboptimal in many patients. In general, PPM is considered to be present when an 
indexed EOA (IEOA) adjusted for body surface area (BSA) is <0.85 cm2/m2 2-4. Although, 
many studies have shown that PPM adversely affects survival and postoperative cardiac 
function 2-4, many studies contradict these findings 5-12. Thus, there is considerable 
controversy regarding the effects of PPM on survival and postoperative recovery of 
cardiac functions. Patients with a small aortic annulus is still challenging and usually 
require several surgical measures to minimize the PPM, such as use of supra-annular 
implantation technique, high-performance prostheses, aortic annular enlargement, or the 
Ross procedure. The surgical strategy is determined based on the individual patient’s 
conditions, including the size of the aortic annulus, patient’s age, BSA, preoperative 
activity level, and ventricular function. Avoiding the risk of severe PPM defined as an 
IEOA <0.70 cm2/m2, which may prevent symptom resolution and regression of left 
ventricular hypertrophy and may adversely affect late cardiac events and survival, must 
always be considered by taking appropriate surgical strategies, but, it is more important 
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1. Introduction  
The main objective of aortic valve replacement (AVR) is to relieve left ventricular (LV) 
burden and normalized LV mass (LVM). During AVR, many surgeons make final decision 
to select the size of the prosthetic valve based on intraoperative measurement. It is ideal to 
place an aortic prosthesis that is appropriately sized to the patient. However, this is not 
always possible owing to insufficient aortic annular dimensions. Patients receive a 
prosthesis that is too small in relation to their body size have persistent abnormally high 
gradients across the valve and may even show deterioration of symptoms and 
hemodynamics after AVR. Rahimtoola first described the concept of patient-prosthesis 
mismatch (PPM), which was defined as existing “when the effective prosthetic valve area, 
after insertion into the patient, is less than that of a normal valve” 1. The optimal 
prosthetic valve should have several characteristics, including a sufficiently large effective 
orifice area (EOA) with a reduced transvalvular pressure gradient around zero, long-term 
durability, and anticoagulability. There is no optimal, commercially available prosthesis. 
The normal aortic valve has 3.0-4.5 cm2 of EOA, but this is rarely achieved with present 
commercially available prostheses, which means that the result of AVR may be 
suboptimal in many patients. In general, PPM is considered to be present when an 
indexed EOA (IEOA) adjusted for body surface area (BSA) is <0.85 cm2/m2 2-4. Although, 
many studies have shown that PPM adversely affects survival and postoperative cardiac 
function 2-4, many studies contradict these findings 5-12. Thus, there is considerable 
controversy regarding the effects of PPM on survival and postoperative recovery of 
cardiac functions. Patients with a small aortic annulus is still challenging and usually 
require several surgical measures to minimize the PPM, such as use of supra-annular 
implantation technique, high-performance prostheses, aortic annular enlargement, or the 
Ross procedure. The surgical strategy is determined based on the individual patient’s 
conditions, including the size of the aortic annulus, patient’s age, BSA, preoperative 
activity level, and ventricular function. Avoiding the risk of severe PPM defined as an 
IEOA <0.70 cm2/m2, which may prevent symptom resolution and regression of left 
ventricular hypertrophy and may adversely affect late cardiac events and survival, must 
always be considered by taking appropriate surgical strategies, but, it is more important 
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to consider whether the benefits of avoiding PPM overcome the drawbacks of other 
complicated measures in each individual patient. 
2. General consideration 
2.1 Left ventricular-aortic pressure gradients 
Gradients are minimal after AVR with aortic and pulmonary autograft or allograft but are 
present after mechanical or bioprosthetic AVR in virtually all patients. Their magnitude 
varies greatly, determined primarily by the characteristics of the prosthesis itself, the size 
of the prosthesis relative to the size of the patient, and the cardiac output (whether the 
study was done during rest or exercise). Smaller-sized stented bioprostheses and 
mechanical prostheses can result with residual transvalvular gradients. In clinical, 
conventional mechanical prostheses and bioprostheses larger than the 21-mm size can 
provide satisfactory performance in most adults. On the other hand, the small resting 
gradients associated with conventional 19-mm prostheses may become 30 to 50 mmHg 
during periods of increased cardiac output. However, in patients with small body size, 
when the patient’s body surface area is less than 1.5 m2, (with their smaller cardiac 
output) conventional 19-mm devices may perform satisfactorily. The relationship between 
peak left ventricular-aortic gradient and prosthesis size was mainly dependent on the 
patient’s BSA. 
3. Definitions of PPM 
In general, PPM is considered to be present when an IEOA is <0.85 cm2/m2 2-4. IEOA has 
been reported as an index that correlates with the severity of PPM 2-6. In present chapter, 
mild to moderate PPM is defined as when an IEOA of ≥0.70cm2/m2 and <0.85 cm2/m2, and 
severe PPM is defined as when an IEOA of less than 0.69 cm2/m2.  
3.1 Effect of PPM on valve related event and survival 
Blais et al. reported the results of 2981 patients who underwent AVR with a stented 
bioprosthesis 3. According to the literature, patients with an EOAI <0.75 cm2/m2 was a 
significant risk factor for increased operative mortality and valve related deaths during 
the follow-up period. Medalion et al. reported the long-term results of 892 patients who 
underwent AVR 7. Moderate PPM had no influence on survival, but advanced age, 
chronic obstructive pulmonary disease, chronic renal failure, and smoking were 
significant risk factors. Urso et al. showed improvement in postoperative NHYA class 
and regression of LVMI during long-term follow-up in patients who underwent AVR 
with a 19-mm mechanical valve 12. We also showed that PPM with an EOAI ≥0.75 
cm2/m2 but <0.85 cm2/m2 has no effect on operative, short-term, and long-term survival 
and the effect of PPM with an IEOA <0.75 cm2/m2 on survival appeared to decrease over 
time 11. Surviving patients with an IEOA <0.75 cm2/m2 showed good long-term survival. 
Although, the effect of PPM on postoperative valve related event and late survival could 
not be definitively determined due to lack of a radomised large population and long-
term follow-up study, in some patients with mild to moderate PPM could be tolerable in 
patients with preserved LV function without any impact on overall survival.  
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3.2 The significance of IEOA 
Recently, aortic valve stenosis has become the leading type of valvular heart disease in 
developed countries, and such stenosis is no longer caused by rheumatic fever but is due 
to aging. Consequently, the age of candidates for AVR have increased markedly and 
have more risk factors and complications. These findings suggest that surgery becomes 
more complicated. Moreover, most patients with aortic stenosis have calcific aortic valve 
sclerosis, which typically becomes clinically significant in seventh or eighth decade of 
life. Therefore, the incidence of patients with a small aortic annulus with calcification is 
also increasing, especially in Japan. This may result in increasing number of patients 
with PPM after AVR. Some previous studies have reported that the risk factors for AVR 
patients with aortic stenosis developing PPM postoperatively are female gender and 
advanced age 2-4, 10. Aortic annular enlargement procedures should achieve the optimal 
measurements to prevent PPM, but these procedures lengthen the cardiopulmonary 
bypass and cross clamp times, increasing the surgical risks. Several reports demonstrated 
that aortic annular enlargement is related to increased operative mortality 15. In such 
circumstance, surgery should be restricted to the minimum necessary. The EOA of 
commercially available prosthetic valves was only 49 - 66% that of a normal aortic valve 
1-9. PPM patients have significantly higher persistent pressure gradients across the valve 
prosthesis than patients without significant PPM. It is well recognized that the 
transvalvular pressure gradient increases exponentially with a decrease in prosthetic 
valve EOA 4. A small decrease in EOA results in a relatively large increase in the 
transvalvular pressure gradient. Several reports demonstrated that PPM increases LV 
workload due to the residual pressure gradient, which prevents regression of LVM and 
increases operative mortality and valve-related events 1-6. The definition of the threshold 
degree of severe PPM that must be avoided due to an adverse effect on survival is 
important. Tasca et al. reported that there was a positive correlation between LVM and 
IEOA, and patients with an IEOA <0.80 cm2/m2 showed inadequate regression of LVM 
after AVR. Moreover, an inadequate regression of LVM positively affected the rate of 
valve-related events after AVR and patients with an IEOA <0.70 cm2/m2 showed 
regression of indexed LVM; LVMI (LVM adjusted for BSA), but LVMI increased again 
during the follow-up period 6. This phenomenon suggests that AVR contributes to 
decreasing the pressure gradient across the valve to less than that of the preoperative 
state. Decreased workload to the left ventricle can lead to regression of LVMI in the 
postoperative acute phase. However, LV workload remains high after AVR due to 
persistent PPM, which may increase LVM again during the follow-up period. On the 
other hand, many studies have been reported that mild to moderate PPM appears to 
have little or no effect on postoperative recovery of cardiac function, late cardiac events 
and survival5-12. Such degree of PPM may be acceptable in not only elderly patients but 
also younger patients7. We also reported that the postoperative peak pressure gradient 
across the prosthesis was significantly higher in patients with PPM than in patients 
without PPM, but postoperative cardiac function, including LV function, LVMI, and 
NYHA class, improved in all patients despite having PPM; the degree of improvement in 
cardiac function in patients with PPM compared favorably to that in patients without 
PPM 11. Avoiding the risk of severe PPM, must always be considered, but, it is more 
important to consider whether the benefits of avoiding PPM overcome the drawbacks of 
other complicated measures in each individual patient. There is controversy about 
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applying a unified standard for avoiding PPM to every patients requiring AVR 
regardless of their age and preoperative condition. The current perception of PPM based 
on the value of IEOA may need to be reconsidered for select populations. Based on these 
findings, IEOA ranges from 0.70 cm2/m2 to 0.75 cm2/m2 may be a lower tolerable 
threshold limit 5-11.  
3.3 Optimal surgery for patients with advanced age 
In general, elderly patients have decreased physiological reserve, and unexpected 
bleeding could occur during the operation due to tissue fragility, which may result in 
difficulty achieving hemostasis. In such circumstances, surgery should be restricted to 
the minimum necessary to obtain improved performance. Elderly patients with a short 
stature, in a relatively inactive, if the patient’s LV function remains preserved, then it is 
not necessary to replace the valve with a larger prosthesis to ensure an IEOA ≥0.85 
cm2/m2, or even to perform additional aortic root enlargement. PPM with an IEOA <0.85 
cm2/m2 and ≥0.70 cm2/m2 could be tolerable without any impact on overall survival5-11.  
4. Introduction of high-performance prostheses 
4.1 Prosthetic performance 
In contrast to other risk factors, PPM can be largely avoided with the use of a prospective 
strategy at the time of operation. Determine patient’s BSA and estimate the minimum 
required prosthetic size for patient. Confirm the indicated sizer pass through the patient’s 
aortic annulus. Currently, high-performance mechanical or bioprosthetic valves that have a 
larger EOA than those of corresponding labeled sizes of conventional prostheses have been 
introduced 13, 14. These valves have a low incidence of PPM without performing annular 
enlargement, especially in the small valve sizes. In recent years, patients who require AVR 
are becoming older and thus have more risk factors and complications. In such 
circumstances, operative invasiveness should be minimized, and there is a tendency to 
perform isolated AVR with a high-performance prosthesis instead of performing aortic 
annular enlargement. However, there are several drawbacks and advantages in high-
performance prostheses. Stentless prosthesis can avoid PPM with excellent hemodynamics, 
but implantation of this prosthesis is more complicated than that of standard AVR. SJM 
Regent valve has a larger EOA than the corresponding same-labeled size of SJM standard 
valve. On the other hand, the thickness of the external sewing ring of SJM Regent valve is 
very thin, so that considerable concern might exist about the fit between the external sewing 
ring and the native aortic annulus. Making an appropriate choice with regard to the 
prosthesis is important. 
Table 1 shows currently available several types of high-performance mechanical prostheses, 
which includes the conventional type of St. Jude Medical Standard aortic valve (Medtronic, 
Minneapolis, MN, USA) for comparison; St. Jude Medical Hemodynamic Plus; St. Jude 
Medical Regent; and ATS AP 360 (ATS Medical Inc, Minneapolis, MN, USA). For each type 
and size of prosthetic valve, the estimates of the prostheses’ EOAs were obtained from the 
manufacturers’ instructions.  
The spectrum of biological valve substitutes for the small aortic annulus includes stented 
and stentless porcine valves, stented pericardial valves, aortic or pulmonary homografts, 
and pulmonary autografts. Table 2 shows currently available several types of high-
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performance bioprostheses, which includes the conventional type of Carpentier-Edwards 
Perimount aortic valve (Edwards Lifesciences, Irvine, CA, USA) for comparison; Carpentier-
Edwards Perimount Magna; Mosaic Porcine Bioprosthesis (Medtronic, Minneapolis, MN, 
USA); and Freestyle Aortic Root Bioprosthesis (Medtronic). For each type and size of 




Size (mm) 16 17 18 19 20 21 22 23 25 
SJM Standard 1.00 1.30 1.60 1.80 
SJM HP 1.00 1.30 1.60 
SJM Regent 1.30 1.70 2.00 2.50 2.60 
ATS AP360 1.20 1.50 1.70 2.10 
Results are the effective orifice area (cm2) 
SJM, St. Jude Medical; HP, Hemodynamic Plus; 
ATS, ATS Medical      
Table 1. Effective orifice area of each high-performance mechanical prosthesis 
 
Prosthesis 
Size (mm) 19 21 23 25 27 29 
CEP 1.28 1.69 1.87 1.89 
CEP Magna 1.58 1.90 2.07 2.33 
Mosaic 1.20 1.30 1.50 1.80 2.00 2.10 
Freestyle-s 1.10 1.40 1.60 2.00 2.40 2.70 
Freestyle-f 1.20 1.40 1.70 2.10 2.40 2.70 
Results are the effective orifice area (cm2) 
CEP, Carpentier-Edwards Perimount 
Freestyle-s, Freestyle subcoronary 
Freestyle-f, Freestyle full root 
Table 2. Effective orifice area of each high-performance bioprosthesis 
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5. Surgery for small aortic annulus 
Ideally, a patient with a small aortic annulus should be identified preoperatively, so that 
alternative measures, such as an aortic root-enlarging procedure or a selection of high-
performance prosthesis, might be considered. Occasionally, the precise size of the aortic 
annulus cannot be determined until the time of operation. 
5.1 Supra-annular implantation 
One-size up prosthesis implantation can be allowed using supra-annular position or single 
suture technique. Other approach to the slightly smaller aortic annulus is to implant 
prosthesis at a slight angle to the plane of the annulus 16. After the sutures are placed in the 
annulus for a supra-annular position, they are passed through the sewing ring and lowered 
into place so that the sewing ring is below the left and right coronary arteries but angled 
upward at the noncoronary sinus. The left and right annulus sutures are tied first, thereby 
securing the sewing ring to the annulus below the left and right coronary ostia. The sutures 
that correspond to the noncoronary annulus are tied last, allowing the valve to ride slightly 
above the annulus in this region.  
5.2 Aortic root enlargement  
Annular enlargement procedures are alternatives for those patients in whom a prosthesis 
being implanted is too small in relation to body size (at least 19-mm cannot be implanted). 
Although, Manouguian’s or the Nicks procedure for annular enlargement may increase 
operative risks, these procedures can allow larger prosthesis implantation in patients with 
small aortic annulus 15. Among surviving patients, aortic annular enlargement improved 
long-term outcome. Recently, with the introduction of high-performance prostheses and 
changes in the patient’s age group, the need for aortic annular enlargement has decreased 
dramatically in our clinical practice.  
5.3 Nicks procedure 
Nicks et al. reported a technique for the enlargement of a small aortic root by an operation 
whereby the small aortic root has been enlarged by insertion of a Dacron fabric gusset that 
it will accommodate a larger sized prosthesis 17. In many cases, enlarging the annulus by 
2-4 mm may be sufficient. One technique associated with minimal increase in morbidity is 
to create a posterior annular split at noncoronary cusps, leaving the anterior mitral leaflet 
and the left atrium intact. The aortic incision is carried downwards posteriorly through 
the noncoronary aortic sinus across the aortic annulus as far as the origin of the mitral 
valve, just above the confluence of the intervalvular trigone, left atrial wall, and mitral 
annulus. A tongue of Dacron fabric is sutured down to the fibrous origin of the mitral 
annulus.  
5.4 Manoughian procedure 
Manoughian et al. reported when greater annular enlargement is desired, a posterior 
incision is made at the commissure between the left and noncoronary cusp and extended 
through the annulus and the intervalvular trigone into the center of the anterior mitral 
leaflet 18. The free edge and body of the anterior leaflet remain intact. The left atrium, which 
is entered at its attachment with the aortic root, can be opened further to facilitate exposure. 
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An elliptical patch is used to close the defect in the anterior mitral leaflet. Interrupted 
horizontal mattress sutures are placed in the annulus and also through the patch. The 
prosthesis is thus seated, using the patch as part of the annulus. The incision in the left atrial 
wall is closed by continuous sutures by incorporating the atrial edges as the patch is sutured 
to the defect in the anterior mitral leaflet. The superior portion of the patch is incorporated 
into the aortotomy closure. Mitral regurgitation due to distortion of the anterior mitral 
leaflet may occur. 
5.5 Konno procedure 
Patients with congenital aortic stenosis have associated hypoplasia of the aortic annulus. In 
such cases, valvotomy is of limited value, and standard AVR is unfeasible because of the 
narrow aortic root. In such cases, Konno procedure is indicated 19. The procedure consists of 
a longitudinal incision in the aortic septum placed in the midportion of the two coronary 
ostia, a vertical incision in the outflow tract of the right ventricle to join the septal incision, 
AVR with prosthetic valve, and patch reconstruction of the outflow tracts of both ventricles 
by means of two layers of a fusiform Dacron patch.  
5.6 Stentless bioprosthesis 
The stentless porcine bioprosthesis has become increasingly popular, because stentless 
xenograft valves have several advantages over the traditional stent mounted tissue 
valves. Notably, stented xenograft valves are intrinsically obstructive due to the space 
occupied by the stent and sewing ring. For a given external diameter, the internal 
diameter of the stentless valve is 2 to 4 mm larger than a stent mounted xenograft valve 
due to lack of a stent. This translates to an ability to place a bioprosthesis with a greater 
EOA, reduce mean transvalvular gradients, and results in greater regression of LV 
hypertrophy compared to the stented bioprosthesis. An increased understanding of the 
functional anatomy of the aortic root has reinforced the concept of the dynamic 
relationships among the valve cusps, annulus, sinus of Valsalva, and sinotubular 
junction. The use of a stentless valve maintains these interactions resulting in improved 
hemodynamic performance. Stentless valves can be implanted in the subcoronary 
position, as an aortic root replacement, or as a root inclusion. Although, subcoronary 
implantation, aortic root replacement, and root inclusion are similar to techniques, 
implantation of a stentless xenograft aortic valve is technically more difficult than a 
stented valve but easier than an allograft used in the subcoronary position. Two valves 
approved for use by the United States Food and Drug Administration are the Toronto 
SPV (St. Jude, Minneapolis, MN) and the Freestyle valve (Medtronic, Minneapolis, MN). 
The Toronto SPV is comprised of the valve and supporting aortic wall only, and is 
designed as a subcoronary implant. 
5.7 Apicoaortic bypass 
Surgical relief of LV outflow tract obstruction may be difficult to achieve by conventional 
methods. Creation of a LV “vent” was accomplished by the anastomosis of a valved 
conduit graft from LV apex to the abdominal aorta 20. A median sternotomy incision is 
made and extended into the linear alba after the decision is made to insert the conduit. 
The supraceliac aorta is exposed and clamped while the anastomosis is performed. 
During temporary cardiopulmonary bypass a plug of myocardium is removed from the 
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5. Surgery for small aortic annulus 
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apex of the left ventricle. The rigid inlet tube attached to a sewing ring and fabric graft is 
sutured to the ventricular ostium. The graft passed into the abdomen through  
an incision in the diaphragm and the composite conduit is anastomosed end to end 
fashion.  
5.8 Ross procedure 
The Ross Procedure is a type of specialized aortic valve surgery where the patient's diseased 
aortic valve is replaced with his or her own pulmonary valve 21. The pulmonary valve is 
then replaced with cryopreserved pulmonary allograft. In children and young adults, or 
older particularly active patients, this procedure offers several advantages over traditional 
aortic valve replacement with manufactured prostheses. Longevity of the pulmonary 
autograft in the aortic position is superior to bioprostheses such as porcine valves, which 
tend to degenerate after only a few years in patients under 35 years of age. Furthermore, 
anticoagulation is not required as with mechanical valves. Thus, individuals can lead an 
active life without the risks associated with anticoagulation therapy. This is especially 
important for women of child bearing age needing aortic valve replacement, as 
anticoagulation is contraindicated in pregnancy. However, lifelong follow-up for 
pulmonary autograft, implanted allograft, and the ascending aortic diameter must be 
required. 
6. Conclusions 
PPM with an IEOA <0.70 cm2/m2 should always be avoided. This degree of PPM adversely 
affects operative mortality and postoperative recovery of cardiac functions. However, in 
some cases, PPM with an IEOA <0.85 cm2/m2 and ≥0.70 cm2/m2 could be acceptable in 
patients with preserved LV function without any impact on overall survival. The current 
perception of PPM may need to be reconsidered with respect to the unified standard 
regardless of each patient’s condition. On the other hand, introduction of high-performance 
prostheses reduces the incidence of PPM without performing annular enlargement, 
especially in the small valve sizes. Making an appropriate choice, including the surgical 
strategy and the prosthesis, based on each individual patient’s preoperative condition is 
very important.  
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1. Introduction 
Aortic valve replacement (AVR) is the treatment of choice for the majority of symptomatic 
adults  with aortic valve stenosis. Despite improvements in bioprosthesis durability and 
reduction of complication rate (both thrombotic and hemorrhagic) of mechanical prosthesis, 
the ideal valve prosthesis is still elusive. 
The hemodynamic performance of the native cardiac valve still outrivals that of prosthesis. In 
a way, any implanted cardiac prosthesis valve is stenotic compared to its native counterpart. 
The concept of patient-prosthesis mismatch (PPM) was first described by Rahimtoola in 
1978. According to this author, PPM exists whenever the effective orifice area (EOA) of an 
implanted prosthesis is inferior to the normal human valve (Rahimtoola, 1978). It can thus 
be said that, in this situation, the implanted prosthesis is stenotic compared to the normal 
native valve. On echocardiographic evaluation, those patients show a high transprothetic 
gradient despite a normal prosthetic valve function. The smaller the prosthetic valve EOA 
and the larger the patients body surface area, the more severe will be the mismatch and the 
observed gradient. Thus, the most useful definition and quantification of PPM is the ratio 
EOA/body surface area (EOA indexed to body surface area). 
The prevalence of moderate PPM varies in different studies from 20 to 70% of cases whereas 
severe PPM is present in 2 to 11% (Pibarot and Dumesnil, 2006). PPM is thus a frequently 
encountered hemodynamic problem after aortic valve replacement. 
2. Definition of the patient-prosthesis mismatch 
Theoretically, an observed high transprosthetic gradient can result from two distinct 
situations. First, a “pathologic” obstruction can result from malfunction of the prosthesis: the 
motion of a mechanical prosthesis can be hindered by thrombus or pannus while deterioration 
of a bioprosthesis can result in rigidification of its leaflets. Besides, endocarditis can cause 
obstructive vegetation masses limiting leaflet motion. Second, a “physiologic” obstruction 
exists when the normally functioning prosthetic valve has too small EOA to accommodate the 
cardiac output without generating too much of a gradient. In all cases, a component of 
perivalvular obstacle must be excluded before blaming the prosthesis. 
Patient-prosthesis mismatch is present when the effective orifice area (EOA) of a prosthetic 
valve is too small in relation to the body size of the patient. The hemodynamic consequence is 
the higher than expected gradient observed through a normally functioning prosthetic valve. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
94
[22] Ross DN. Replacement of the aortic and mitral valves with a pulmonary autograft. 
Lancet 1967;2:956-8. 5 
Patient-Prosthesis Mismatch After  
Aortic Valve Replacement 
Wauthy Pierre and Malekzadeh-Milani Sophie G.  
Brugmann University Hospital,Brussels,  
Belgium 
1. Introduction 
Aortic valve replacement (AVR) is the treatment of choice for the majority of symptomatic 
adults  with aortic valve stenosis. Despite improvements in bioprosthesis durability and 
reduction of complication rate (both thrombotic and hemorrhagic) of mechanical prosthesis, 
the ideal valve prosthesis is still elusive. 
The hemodynamic performance of the native cardiac valve still outrivals that of prosthesis. In 
a way, any implanted cardiac prosthesis valve is stenotic compared to its native counterpart. 
The concept of patient-prosthesis mismatch (PPM) was first described by Rahimtoola in 
1978. According to this author, PPM exists whenever the effective orifice area (EOA) of an 
implanted prosthesis is inferior to the normal human valve (Rahimtoola, 1978). It can thus 
be said that, in this situation, the implanted prosthesis is stenotic compared to the normal 
native valve. On echocardiographic evaluation, those patients show a high transprothetic 
gradient despite a normal prosthetic valve function. The smaller the prosthetic valve EOA 
and the larger the patients body surface area, the more severe will be the mismatch and the 
observed gradient. Thus, the most useful definition and quantification of PPM is the ratio 
EOA/body surface area (EOA indexed to body surface area). 
The prevalence of moderate PPM varies in different studies from 20 to 70% of cases whereas 
severe PPM is present in 2 to 11% (Pibarot and Dumesnil, 2006). PPM is thus a frequently 
encountered hemodynamic problem after aortic valve replacement. 
2. Definition of the patient-prosthesis mismatch 
Theoretically, an observed high transprosthetic gradient can result from two distinct 
situations. First, a “pathologic” obstruction can result from malfunction of the prosthesis: the 
motion of a mechanical prosthesis can be hindered by thrombus or pannus while deterioration 
of a bioprosthesis can result in rigidification of its leaflets. Besides, endocarditis can cause 
obstructive vegetation masses limiting leaflet motion. Second, a “physiologic” obstruction 
exists when the normally functioning prosthetic valve has too small EOA to accommodate the 
cardiac output without generating too much of a gradient. In all cases, a component of 
perivalvular obstacle must be excluded before blaming the prosthesis. 
Patient-prosthesis mismatch is present when the effective orifice area (EOA) of a prosthetic 
valve is too small in relation to the body size of the patient. The hemodynamic consequence is 
the higher than expected gradient observed through a normally functioning prosthetic valve. 
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
96
The clinical significance of  PPM is diversely appreciated in the literature. For some authors, 
the consequences are minimal whereas for others, more severe PPM can even affect 
postoperative survival. This discordance is due in fact to different ways of evaluating EOA. 
As a whole, studies based on an in vivo evaluation of the indexed EOA tend to report 
clinical implications (Blais et al., 2003, Kulik et al., 2006, Ruel et al., 2006, Ruel et al., 2004, 
Tasca et al., 2006). In the contrary, the in vitro evaluation of the indexed EOA tends to 
underestimate clinical implications of PPM (Koch et al., 2005). 
The transvalvular gradient (TVG) is determined by the hydraulic equation: 
 TVG=Q2/(kxEOA2)  (1) 
Q stands for flow and k is a constant. 
This equation shows that the transvalvular gradient is directly related to the square of 
transvalvular flow and inversely related to the square to the valve EOA (Effective Orifice 
Area of the valve). The flow is dependent on cardiac output which is at rest related to body 
surface area (BSA).  
Mismatch can occur in aortic position and in mitral position. We will focus on the aortic 
PPM.  
There is a large body of evidence that the best variable to evaluate transvalvular gradient at 
rest and during exercise is the indexed EOA: EOA is divided by the body surface area 
(Dumesnil and Pibarot, 2011, Pibarot et al., 2000, Zoghbi et al., 2009, Bleiziffer et al., 2007). 
This indexed EOA is the key factor used to define mismatch. Pibarot showed that the 
relation between transvalvular gradient and indexed EOA is curvilinear and that the 
gradient increases exponentially when the indexed EOA is inferior to 0.8 to 0.9 cm2/m2 
(Pibarot and Dumesnil, 2000). The relation of the transvalvular gradient and indexed EOA 
are curvilinear at rest (Figure 1) and in stress conditions (Figure 2). 
 
 
Fig. 1. Curvilinear relation of the gradient and indexed EOA at rest. 
 




Fig. 2. Curvilinear relation of the gradient and indexed EOA at stress. 
Based in this chart, PPM is considered present if indexed EOA (iEOA) is < 0,85 cm2/m2. It is 
graded moderate if the iEOA stands between 0,65 and 0,85 cm2/m2 and severe if less than 
0,65 cm2/m2 (Pibarot and Dumesnil, 2000, Pibarot and Dumesnil, 2006). 
3. Identification of PPM 
Patient-prosthesis mismatch has several major clinical impacts described below and these 
impacts increase proportionally with the severity of PPM (Blais et al., 2003, Milano et al., 
2002).  It is thus important to quantify the severity of this hemodynamic situation. 
PPM can be diagnosed and quantified on echocardiography when iEOA is measured. It can 
also be predicted or estimated at the time of surgery by using the projected EOA derived 
from in vivo studies and available for each type and size of prosthetic valve as illustrated in 
Table 1. 
Echocardiography is the gold standard for the non invasive evaluation of prosthetic valve 
function. It is more demanding to perform and interpret data from a prosthetic valve 
compared to native valve. However, EOA can be calculated on echocardiography and with 
some other useful measurements lead to the diagnosis of PPM. 
The degree of obstruction, the start point of the valve assessment, varies with the type and 
the size of the valve. To some extend every prosthetic valve is at least partly restrictive 
resulting in a mild acceleration though the prosthetic orifice. It may be difficult to 
differentiate obstructive hemodynamic conditions due to valve design from those of mild 
obstruction due to prosthetic dysfunction and from PPM. 
A full echocardiography study is mandatory. The report should include height, weight, 
BSA, blood pressure, age, gender and the type of prosthetic valve implanted. 
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Fig. 1. Curvilinear relation of the gradient and indexed EOA at rest. 
 




Fig. 2. Curvilinear relation of the gradient and indexed EOA at stress. 
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  Medtronic Freestyle 
Prosthesis size 19 21 23 25 27 29 
EOA (cm2/m2) 1,15 1,35 1,48 2 2,32  
BSA (m2)       
1 1,15 1,35 1,48 2,00 2,32  
1,1 1,04 1,23 1,34 1,82 2,11  
1,2 0,96 1,12 1,23 1,67 1,93  
1,3 0,88 1,04 1,14 1,54 1,78  
1,4 0,82 0,96 1,06 1,43 1,66  
1,5 0,77 0,90 0,99 1,33 1,55  
1,6 0,72 0,84 0,92 1,25 1,45  
1,7 0,68 0,79 0,87 1,18 1,36  
1,8 0,64 0,75 0,82 1,11 1,29  
1,9 0,60 0,71 0,78 1,05 1,22  
2 0,57 0,67 0,74 1,00 1,16  
2,1 0,55 0,64 0,70 0,95 1,10  
2,2 0,52 0,61 0,67 0,91 1,05  
2,3 0,50 0,59 0,64 0,87 1,01  
2,4 0,48 0,56 0,62 0,83 0,97  
2,5 0,46 0,54 0,59 0,80 0,93  
Table 1. Indexed EOA by prosthesis sizes. Data from the literature (Blais et al., 2003). 
3.1 2D echocardiography 
The valve should be carefully imaged in 2D  (presence of calcification, thrombus, leaflets 
motion). This can be difficult due to the artifacts created by the valve itself and due to the 
sometimes calcified aorta. Cardiac chambers have to be evaluated with a specific attention to 
the left ventricle (LV). Indeed LV mass, thickness, systolic and diastolic function need to be 
assessed. The aortic root and ascending aorta have to be measured as well as the left 
ventricle outflow (LVO) tract. This measure is important because it is used in the EOA 
measurement. It should be measured in parasternal long axis view or in a modified lower 
parasternal location to avoid the artifacts of the prosthesis. In EOA evaluation, artifacts 
induced by the prosthesis structure are the most frequent source of error. 
3.2 Doppler echocardiography 
The second part of the study is Doppler echocardiography. Several items need to be 
determined in order to rule out or diagnosed PPM: 
1. Peak velocity, gradient and Velocity Time Integral (VTI) of the jet;  
2. Effective Orifice Area; 
3. Doppler Velocity Index; 
4. Evaluation of the importance of pressure recovery phenomenon. 
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3.2.1 Peak velocity, gradient and VTI 
The velocity resemble those of mild native aortic valve stenosis with a maximal velocity 
usually >2m/s. The shape of the velocity contour is triangular with occurrence of the 
maximal velocity in early systole. A different pattern of the flow velocity indicates the 
presence of valve dysfunction. A higher gradient than 3m/sec should prompt further 
investigations.  
The VTI is the contour of the velocity through the valve and is a qualitative but valuable 
index. It is difficult as previously mentioned, to differentiate high flow status from 
obstruction from mismatch. Other indices are than used. 
3.2.2 Effective orifice area 
The aortic EOA is derived with the stroke volume at the LVO, according to the continuity 
equation. This equation shows that in a closed hydraulic system flow is the same at different 
points in the system: 
 EOAPrAV= CSALVOxVTILVO/VTIPrAV (2) 
CSALVO is the cross sectional area of the outflow tract just underneath the valve from the 
parastenal long axis view, assuming a circular geometry. Attention should be given to the 
measure. An error will be amplified by the fact that the radius derived of this measure is 
used in square.  
The VTILVO is the VTI proximal to the valve using pulsed wave Doppler. The sample should 
be located 0,5 to 1 cm below the sewing ring to avoid subvalvular acceleration. 
The VTIPrAV is the VTI across the valve (PrVA: Prosthetic Aortic Valve) using continuous 
wave Doppler. 
The calculated EOA is dependant of the valve size and should therefore be compared to the 
effective EOA available from in vivo measurements for each type and size of valve also 
called projected EOA. 
If calculated EOA is different of 1DSA of the EOA, it is suggestive of dysfunction of the 
prosthesis. 
3.2.3 Doppler velocity index 
The Doppler Velocity Index (DVI) is the ratio of velocity proximal to the valve (VLVO) and in 
the valve (VPrAV). It is independent of the size of the LVO and the valve. It can be 
approximated by the ratio of the respective peak velocities.  
 DVI=VLVO/VPrAV (3) 
DVI is always less than one because flow always accelerates through the valve. If it is < 0,25 
it highly suggestive of significant valve obstruction. 
3.2.4 The pressure recovery phenomenon 
The pressure recovery phenomenon should also be evaluated. The Bernouilli equation 
implies that conversion of pressure to velocity is reversible. When blood flows across a 
stenotic orifice, velocity rises and pressure drops with the lowest pressure and highest 
velocity at the narrowest portion of the jet. When flow widens, flow velocity diminishes 
and pressure increases. This is known as pressure recovery. It is always incomplete 
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because of energy loss due to viscosity and turbulences. The amount of energy lost varies 
with the shape and size of the conduit, and potentially reflect the severity of the stenosis 
(Garcia et al., 2000). The energy lost coefficient (ELC) can be quantified by the following 
equation: 
 ELC= EOAxAA/AA-EOA (4) 
In this equation, AA is the aortic cross-sectional area. 
Pressure recovery can occur in 2 regions: downstream the valve and in the valve. 
Downstream the valve there is an inverse relationship between the size of aortic root and the 
amount of pressure recovery. The importance of the phenomenon is generally small except 
in aorta smaller than 3 cm where the gradient across the valve can be overestimated 
(Baumgartner et al., 1992, Baumgartner et al., 1999). Within the valve, in some cases 
(typically in bileaflet mechanical valves), due the specific design of the valve, this 
phenomenon occurs. The smaller orifice located centrally between the 2 leaflets may give 
rise to a high velocity jet corresponding in localized pressure drops that recovers one the 
central flow reunites with lateral flows. This high gradient can be interpreted and lead to 
overestimation of the gradient across the valve and underestimation of the EOA 
(Baumgartner et al., 1992). This is more frequent in smaller valves. Usually it is not a 
problem because normal gradients expected through each valve exist as for the EOA, and 
are reported in the literature (Zoghbi et al., 2009). 
With all these data, PPM can be diagnosed. Some very clear algorithms exist in the literature 
guiding the clinician in his search for PPM (Pibarot and Dumesnil, 2006, Dumesnil and 
Pibarot, 2011, Zoghbi et al., 2009). Based on these observations, we here present in Figure 3 
maybe the most accurate algorithm, used in our unit, from the Dumesnil and Pibarot 
observations (Dumesnil and Pibarot, 2011). 
To summarise this algorithm and concentrate on mismatch, we could resume the sequence 
to infirm or confirm mismatch. If a high gradient is reported, calculation of the EOA should 
be compared to the projected EOA. If it is similar, the EOA should then be indexed to BSA. 
We can than grade the severity of mismatch with cut off points of 0.85 cm2/m2 for 
moderate mismatch and 0,65 cm2/m2 for severe mismatch bearing in mind the pressure 
recovery phenomenon for small aorta. 
Of course one should bear in mind that PPM and prosthesis dysfunction can coexist and 
that evaluation can still be challenging. Other tests can help differentiating these 
conditions:  
 Cinefluoroscopy by imaging the motion of the leaflets in mechanical valve; 
 Transesophagial echocardiography to have better images of the valve including 
thrombus, endocarditis and leaflets; 
 Computerized tomography to image pannus, calcifications and motion of the leaflets. 
Anatomic orifice area can be determined by CT. It is different than EOA, being too 
optimistic and cannot replace EOA; 
 Exercise testing can be useful. Some patients are symptomatic but echocardiography is 
equivocal at rest. The presence of PPM or dysfunction of the valve is associated with 
marked increase in gradients and pulmonary artery pressure on exercise test. Although 
precise cut points are not available it is likely that a rise in mean gradient >15 mmHg is 
significant as for native valves (Pibarot et al., 1999). Stress test can be particularly 
helpful in elderly patients who may claim to be asymptomatic by self limitation. 
 




Fig. 3. Decisional algorithm to identify the origin of a abnormally hight transvalvular gradient. 
4. Prediction of PPM 
As previously said PPM can be estimated or predicted by using the projected EOA available 
for each valve type and size. 
The predicted EOA measures coming from in vivo studies are well correlated with 
postoperative gradients and clinical outcomes (Pibarot and Dumesnil, 2006, Blackstone et 
al., 2003, Dumesnil and Pibarot, 2006, Koch et al., 2005). 
At this stage it is important to point out that the indexed EOA derived from in vivo 
postoperative measures is the only parameter valid to predict PPM and postoperative 
gradients (Dumesnil and Pibarot, 2011, Zoghbi et al., 2009). It is thus the only one to be 
used. 
The indexed geometric orifice area (GOA) a static manufacturing measure based on ex vivo 
measurements is considerably different than the iEOA. The way it is measured varies from 
one type of prosthesis to the other, it always overestimates the EOA being too optimistic. 
For similar values on indexed GOA, peak and mean gradients can double between 
pericardial valves and homograft’s (Koch et al., 2005). 
The same issue is raised by the EOA measured in vitro by manufacturers. It is also always 
too optimistic and overestimates the EOA derived from in vivo measurements. 
Both GOA and in vitro indexes correlate poorly with postoperative gradients. Within the 
literature some authors are still using GOA and manufacturers data. This is one of the 
reasons why some detrimental effects of PPM remain partly controversial till today. 
Using the indexed in vivo EOA, PPM in not infrequent. Prevalence of moderate PPM 
varies in the literature from 20 to 70% and severe PPM prevalence is estimated between 2 
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to 11% (Pibarot and Dumesnil, 2000, Blais et al., 2003, Milano et al., 2002, Tasca et al., 
2005). 
The PPM prediction at the time of surgery is a key issue. Indeed anticipated it can be 
avoided. Amongst all the risk factor of mortality in AVR, this is the only factor we can 
avoid. 
5. Clinical implications 
PPM has various adverse clinical effects. As for the native aortic valve stenosis, clinical 
impact of PPM increases proportionally with its severity. The consequences of PPM on 
clinical status depend both on severity of the mismatch and on patient characteristics. 
Numerous studies report PPM as a risk factor for postoperative mortality and morbidity.  
As previously described PPM is not rarely encountered (prevalence of moderate PPM 20 to 
70%, severe PPM 2 to 11%). It is noticeable that the frequency of severe PPM has decreased 
over the last couple of years due to the awareness of its detrimental effects, thanks to the 
useful prevention strategies at the time of surgery and thanks to the new generations of 
prosthetic valves with more favorable haemodynamics. 
There is now a strong body of evidence that PPM has an impact on functional class, 
regression of left ventricular hypertrophy, left ventricular function, coronary flow reserve, 
rate of valve degeneration and more importantly, mortality (Tasca et al., 2005, Flameng et 
al., 2010). Over time it has become clear that the impact of PPM depends greatly on the 
clinical condition of the patients. 
5.1 Mortality 
Considering the most important outcome, mortality, we have to distinguish early and 
late mortality. The impact of PPM on early mortality is more important than on late 
mortality given that the left ventricle is more vulnerable during early postoperative 
period to any hemodynamic burden imposed. Early mortality is significantly increased if 
PPM is severe or if moderate PPM is associated with left ventricular dysfunction (left 
ventricular ejection fraction (LVEF) < 40%) (Blais et al., 2003, Pibarot and Dumesnil, 2006, 
Urso et al., 2009). Blais et al showed in a study in 1265 patients undergoing AVR that 
mortality was 5% in patients with moderate PPM and normal left ventricular function, 
was 16% in patients with moderate PPM and depressed left ventricular function and was 
67% if PPM was severe and combined with left ventricular dysfunction (Blais et al., 
2003). 
There are still controversies regarding late mortality. Several studies reported that PPM is an 
independent factor of mortality after AVR (Blais et al., 2003, Tasca et al., 2006), other 
concluded that PPM did not affect mortality (Blackstone et al., 2003, Koch et al., 2005).  The 
different conclusions may result from the heterogenous populations that have been studied 
and the way to predict PPM (GOA or in vitro EOA). Indeed PPM clinical relevance varies 
with the patient characteristics. Mohty et al summarizes the impacts of PPM on late 
mortality in different subgroups of patients: moderate PPM increases mortality if left 
ventricular function is reduced (LVEF <50%) but not with normal ventricular function. 
Severe PPM increases mortality in patients younger than 70 years old, with a reduced left 
ventricular function or BMI < 30 Kg/m2 (Mohty et al., 2009). 
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Blackstone and Howell have used different parameters to define mismatch (GOA, in vitro 
EOA). Blakstone in a very large study showed no effect of PPM on mortality but population 
characteristic is not well defined (Blackstone et al., 2003). 
Some other studies demonstrated that PPM has no impact on mortality in the elderly 
(Monin et al., 2007). The relationship between age and PPM can be explained by the 
cardiac index requirement varying with age. Indeed younger people are more active and 
have a higher basal metabolic state compared with older patients. Another potential 
explanation is the longer exposure to PPM for the younger patients. Finally if we 
consider patients implanted with a bioprosthetic valve, the deterioration of the valve is 
likely to appear faster in younger people who are more prone to calcifications. These 
patients will have less “EOA reserve” if PPM is present. Higher gradient and stenosis 
will tend to develop faster with the combination of degeneration and PPM (Flameng et 
al., 2010). 
Interaction between PPM and BMI should be emphasized. PPM impact on patients with a 
BMI< 30 kg/m2 reflects more probably that EOA should not be indexed with BSA but with 
a fat-free index in these obese patients. iEOA overestimates the prevalence and severity of 
PPM in this subgroup of patients. 
Logically patients with reduced left ventricular function will not tolerate the increased 
burden secondary to PPM regardless of its severity (Blais et al., 2003, Kulik et al., 2006, Ruel 
et al., 2006). 
5.2 Left ventricular hypertrophy, function and coronary flow reserve 
PPM has also an impact on the left ventricle. Controversies remain about the role of 
PPM on the regression of the left ventricular hypertrophy. After relief of the stenosis, 
reduction of the left ventricular hypertrophy will occur whatsoever and the impact of 
the PPM on the degree of regression of left ventricular mass remains unknown. It is 
know recognized that the presence of systemic hypertension, metabolic syndrome, 
decreased vascular compliance results in an increase of the afterload of the ventricle 
that will not be relieved after surgery. The degree of muscular hypertrophy  
and interstitial fibrosis (which is not reversible) does not depend only on residual 
gradient: left ventricular hypertrophy regression is multifactorial and not only related 
to PPM. 
As described earlier PPM has a significant impact on mortality if present with concomitant 
left ventricular dysfunction. The improvement of LV function is correlated with the 
increased EOA after surgery. This has been shown for surgery but also for percutaneously 
implanted aortic valve. Indeed recently LV function has been compared in patients 
surgically implanted and percutaneously implanted. LV function improved faster after 
transcatheter implantation mainly to the larger iEOA observed after transcatheter 
implantation leading to smaller gradient and better haemodynamic (Jilaihawi et al., 2010, 
Clavel et al., 2009).  
One of the main goals of aortic valve replacement is restoration of the myocardial reserve. A 
persistent significant gradient across the valve affects coronary reserve recovery. 
Independently of the regression of the left ventricular mass, postoperative coronary 
vasodilatory reserve varies proportionally to the iEOA and thus to PPM (Rajappan et al., 
2003). 
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Blackstone and Howell have used different parameters to define mismatch (GOA, in vitro 
EOA). Blakstone in a very large study showed no effect of PPM on mortality but population 
characteristic is not well defined (Blackstone et al., 2003). 
Some other studies demonstrated that PPM has no impact on mortality in the elderly 
(Monin et al., 2007). The relationship between age and PPM can be explained by the 
cardiac index requirement varying with age. Indeed younger people are more active and 
have a higher basal metabolic state compared with older patients. Another potential 
explanation is the longer exposure to PPM for the younger patients. Finally if we 
consider patients implanted with a bioprosthetic valve, the deterioration of the valve is 
likely to appear faster in younger people who are more prone to calcifications. These 
patients will have less “EOA reserve” if PPM is present. Higher gradient and stenosis 
will tend to develop faster with the combination of degeneration and PPM (Flameng et 
al., 2010). 
Interaction between PPM and BMI should be emphasized. PPM impact on patients with a 
BMI< 30 kg/m2 reflects more probably that EOA should not be indexed with BSA but with 
a fat-free index in these obese patients. iEOA overestimates the prevalence and severity of 
PPM in this subgroup of patients. 
Logically patients with reduced left ventricular function will not tolerate the increased 
burden secondary to PPM regardless of its severity (Blais et al., 2003, Kulik et al., 2006, Ruel 
et al., 2006). 
5.2 Left ventricular hypertrophy, function and coronary flow reserve 
PPM has also an impact on the left ventricle. Controversies remain about the role of 
PPM on the regression of the left ventricular hypertrophy. After relief of the stenosis, 
reduction of the left ventricular hypertrophy will occur whatsoever and the impact of 
the PPM on the degree of regression of left ventricular mass remains unknown. It is 
know recognized that the presence of systemic hypertension, metabolic syndrome, 
decreased vascular compliance results in an increase of the afterload of the ventricle 
that will not be relieved after surgery. The degree of muscular hypertrophy  
and interstitial fibrosis (which is not reversible) does not depend only on residual 
gradient: left ventricular hypertrophy regression is multifactorial and not only related 
to PPM. 
As described earlier PPM has a significant impact on mortality if present with concomitant 
left ventricular dysfunction. The improvement of LV function is correlated with the 
increased EOA after surgery. This has been shown for surgery but also for percutaneously 
implanted aortic valve. Indeed recently LV function has been compared in patients 
surgically implanted and percutaneously implanted. LV function improved faster after 
transcatheter implantation mainly to the larger iEOA observed after transcatheter 
implantation leading to smaller gradient and better haemodynamic (Jilaihawi et al., 2010, 
Clavel et al., 2009).  
One of the main goals of aortic valve replacement is restoration of the myocardial reserve. A 
persistent significant gradient across the valve affects coronary reserve recovery. 
Independently of the regression of the left ventricular mass, postoperative coronary 
vasodilatory reserve varies proportionally to the iEOA and thus to PPM (Rajappan et al., 
2003). 
  




PPM is also associated with a number of other adverse outcomes with variable clinical 
importance: reduced quality of life, reduced exercise capacity (Bleiziffer et al., 2008), more 
important residual mitral regurgitation (Unger et al., 2010), the risk of early degeneration of 
bioprosthetic valve with stenotic lesions (Flameng et al., 2010) and increased risk of 
hemorrhagic complication due to the acquired abnormalities of the Von Willebrand factor 
(Vincentelli et al., 2003). 
6. Prevention of patient-prosthesis mismatch 
Aortic valve replacement has become a simple and safe procedure through the time. 
Nowadays, this procedure can be accomplished with a low mortality and morbidity rate. 
However, there is no zero risk aortic valve replacement surgery nowadays.  In this 
particular setting, it appears that patient-prosthesis mismatch emerges as a prominent risk 
factor for postoperative mortality and morbidity, and one of the few that can be acted upon. 
A strategy of prevention of PPM is thus of the upmost importance. Severe PPM (EOA<0,65 
cm2/m2) must be avoided in all patients. Moderate PPM only justifies an aggressive 
prevention strategy in the most susceptible patients: 
1. Patients younger than 65 years of age; 
2. Athletes; 
3. Patients with preexistent systolic dysfunction of the left ventricle with left ventricular 
ejection fraction less than 40%; 
4. Patients with severe left ventricular muscle hypertrophy. 
To the contrary, moderate PPM could be neglected in low exposed patients including: 
1. Obese patient where the cardiac output is not directly proportional to the BSA; 
2. Older patients. 
The EOA of the prosthesis to be implanted must thus be more than 0,85 cm2/m2 
(compilation of the body surface area of the patients is prerequired). 
6.1 The choice of the prosthesis 
Compared to a bioprosthesis, mechanical valves present a better EOA at the same 
prosthesis size. Intraoperatively, it is important to consider the EOA of the prosthesis that 
can fit the aortic root. A type of prosthesis with the largest EOA for a given nominal 
diameter should be chosen. Not all available models of prostheses for a given aortic root 
configuration have the same size: a size 23 model of one manufacturer may fit the same 
aortic root configuration as a size 21 model of another. Stentless bioprostheses claim 
better hemodynamic parameters than their stented counterparts. Also, recent generation 
bileaflet mechanical prostheses offer better EOA for a given nominal external diameter. 
On Table 2 and Table 3, the EOA and iEOA of o bioprosthesis and a mechanical valve are 
reported. We can see that mechanical valves presents better hemodynamic parameters 
than bioprosthesis. 
6.2 The surgical technique 
Surgical implantation technique also allows implantation of a larger prosthesis. The 
simplest way to achieve this goal is to choose a supraannular rather than annular 
technique (Fig. 4).  
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 Carpentier-Edwards Perimount 
Prosthesis size 19 21 23 25 27 29 
EOA (cm2/m2) 1,1 1,3 1,5 1,8 1,8  
BSA (m2)       
1 1,10 1,30 1,50 1,80 1,80  
1,1 1,00 1,18 1,36 1,64 1,64  
1,2 0,92 1,08 1,25 1,50 1,50  
1,3 0,85 1,00 1,15 1,38 1,38  
1,4 0,79 93,00 1,07 1,38 1,38  
1,5 0,73 0,87 1,00 1,20 1,20  
1,6 0,69 0,81 0,94 1,12 1,12  
1,7 0,65 0,76 0,88 1,06 1,06  
1,8 0,61 0,72 0,83 1,00 1,00  
1,9 0,58 0,68 0,79 0,95 0,95  
2 0,55 0,65 0,75 0,90 0,90  
2,1 0,52 0,62 0,71 0,86 0,86  
2,2 0,50 0,59 0,68 0,82 0,82  
2,3 0,48 0,56 0,65 0,78 0,78  
2,4 0,46 0,54 0,62 0,75 0,75  
2,5 0,44 0,52 0,60 0,72 0,72  
Table 2. Eoa and iEOA of a performant bioprosthesis (Blais et al., 2003). 
 
 St Jude Medical Regent 
Prosthesis size 19 21 23 25 27 29 
EOA (cm2/m2) 1,5 2 2,4 2,5 3,6 4,8 
BSA (m2)       
1 1,50 2,00 2,40 2,50 3,60 4,80 
1,1 1,36 1,82 2,18 2,27 3,27 4,36 
1,2 1,25 1,67 2,00 2,08 3,00 4,00 
1,3 1,15 1,54 1,85 1,92 2,77 3,69 
1,4 1,07 1,43 1,71 1,78 2,57 3,43 
1,5 1,00 1,33 1,60 1,67 2,40 3,20 
1,6 0,94 1,25 1,50 1,56 2,25 3,00 
1,7 0,88 1,18 1,41 1,47 2,12 2,82 
1,8 0,83 1,11 1,33 1,39 2,00 2,67 
1,9 0,79 1,05 1,26 1,32 1,89 2,53 
2 0,75 1,00 1,20 1,25 1,80 2,40 
2,1 0,71 0,95 1,14 1,16 1,71 2,29 
2,2 0,68 0,91 1,09 1,14 1,64 2,18 
2,3 0,65 0,87 1,04 1,09 1,56 2,09 
2,4 0,62 0,83 1,00 1,04 1,50 2,00 
2,5 0,60 0,80 0,96 1,00 1,44 1,92 
Table 3. Eoa and iEOA of a performant bileaflet mechanical valve (Blais et al., 2003). 
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Fig. 4. Illustration of the benefit to implant the prosthesis in a supraannular technique. 
A more aggressive, and more potentially beneficial technique, consist to associate aortic 
valve replacement and enlargement of the aortic root and annulus. The Manouguian 
technique inserts a widening patch in the left-non coronary commissure and allows 
implantation of a prosthesis one to two sizes larger (Manouguian and Seybold-Epting, 1979). 
Unfortunately, the presence of important aortic root calcifications limits the application of 
this technique. Briefly, an oblique aortotomy is performed and aimed to descend at the left-
non coronary sinus, through the aorto-mitral transition (Figure 5). 
 
 
Fig. 5. Illustration of the transannular incision realized in the Manouguian technique. 
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A widening patch is then implanted to close this incision (Figure 6) and the prosthesis is 
























Fig. 6. Illustration of the enlarging patch reconstruction of the incision. 
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Fig. 6. Illustration of the enlarging patch reconstruction of the incision. 
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The Figure 7 shows the significant oversizing allowed by the technique compare to the 
initial prosthesis size matched to the initial annulus. The aortotomy is closed with the 
enlargement patch after the implantation of the aortic valve prosthesis. 
During this procedure, the incision in the aortoventricular membrane must be carefully 
performed and not extended to deep in the mitral annulus, the anterior mitral leaflet and the 
left atrium. The reconstruction patch may in this particular setting interfere with the hinging 
portion of the anterior mitral leaflet. 
 
 
Fig. 7. Illustration of the realized oversizing allowed by the Manouguian technique. 
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The overall surgical strategy that we proposed is illustrated in the Figure 8. The first 
possibility to match the implanted valve to the patient is to realize a supraannular 
implantation. If this surgical technique is insufficient, we should consider an alternative 
second choice in the prosthesis strategy, ie a bileaflet new generation of mechanical 
prosthesis (an old patient with atrial fibrillation…). The last possibility is to realize a 
Manouguian enlargement of the aortic annulus, if possible. 
 
 
Fig. 8. Surgical strategy to avoid a patient-prosthesis mismatch. 
It should be mentioned that some patients present with a hypoplastic aorto-ventricular 
junction. Most of them are referred to surgery during childhood. In such situation, a radical 
enlargement of both the aortic valve annulus and the left ventricular outflow tract should be 
performed. The anterior technique, first described by Konno in 1974 (Konno et al., 1975), 
consists in a wide opening of the aortic valve annulus and of the interventricular septum 
with an oblique incision at 5mm to the left side of the right coronary ostium. This technique 
is far more complex than the Manouguian technique and may lead to severe complications, 
particularly an iatrogenic ventricular septal defect or atrioventricular block. 
7. Conclusions 
Patient-prosthesis mismatch is probably the most frequently encountered hemodynamic 
problem after aortic valve replacement. All the patients are not equally exposed to this 
problem and clinical consequences may be variable from one to another. However, the 
consequences may lead to an increased mortality and worsen symptomatic improvements 
after the aortic valve replacement. Though, prevention of this mechanism is the key point in 
symptomatic patients that should be operated on. Indexed EOA of the implanted valve should 
be systematically calculated from reference values of the EOA of the prosthesis, and surgical 
strategies adapted to allow implantation of prosthesis with iEOA matched to the patient. 
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1. Introduction 
Atrial fibrillation (AF), the most commonly encountered arrhythmia in clinical practice, is 
associated with significant morbidity and mortality. Of great significance are heart failure 
and stroke.1 With increased incidence and prevalence of AF, it represents a growing clinical 
and economic burden. AF is also a progressive disease secondary to continuous structural 
remodeling of the atria because of AF itself, to changes associated with ageing and to 
deterioration of underlying heart disease. Current management aims at preventing the 
recurrence of AF and its consequences and includes risk assessment and prevention of 
stroke, control of ventricular rate and rhythm control therapies including antiarrhythmic 
drugs and catheter or surgical ablation. 
2. Classification 
The nomenclature used to classify AF has been diverse. AF can be acute (first detectable episode 
whether symptomatic or not) or chronic (paroxysmal, persistent, and long-standing persistent), 
or finally permanent. According to a consensus document2, paroxysmal AF is defined as at least 
two episodes that terminate spontaneously within 7 days. Persistent AF is defined as lasting 
more than 7 days, or lasting less than 7 days but necessitating pharmacologic or electrical cardio 
version. Permanent AF is defined as lasting more than 1 year. 
These definitions apply only to episodes that last at least 30 seconds and have no identifiable 
reversible cause, such as acute pulmonary disease or hyperthyroidism. Both paroxysmal 
and persistent atrial fibrillations are potentially recurrent arrhythmias. Paroxysmal atrial 
fibrillation may become persistent with time; and both paroxysmal and persistent AF may 
become permanent. 
The term “lone atrial fibrillation” refers to AF in young people (aged under 60) in whom no 
apparent cause can be identified. 
3. Pathophysiology 
The exact mechanisms by which cardiovascular risk factors predispose to AF are not 
understood fully but are under intense investigation. Catecholamine excess, hemodynamic 
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stress, atrial ischemia, atrial inflammation, metabolic stress, and neurohumoral cascade 
activation are all purported to promote AF. Although the precise mechanisms that cause AF 
are incompletely understood, AF appears to require both an initiating event and a 
permissive atrial substrate. AF results from multiple re-entrant electrical wavelets that move 
randomly around the atria. These wavelets are initiated by electrical triggers, commonly 
located in the myocardial sleeves extending from the left atrium to the proximal 5-6 cm 
portions of the pulmonary veins3. Other sites in the left and right atria and in the proximal 
superior vena cava may less frequently trigger atrial fibrillation4, 5. Once triggered, the atrial 
tissue harbors these wavelets and promotes re-entry, thus facilitating persistence of the 
arrhythmia. A period of AF initially induces electrophysiological changes (“electrical 
remodeling”) followed by structural changes (“structural remodeling”), which facilitate its 
persistence- hence the phrase "atrial fibrillation begets atrial fibrillation"6, 7. 
 
Common causes of Atrial Fibrillation 
Cardiovascular 
 
 Rheumatic heart disease 
 Hypertension 
 Coronary artery disease 
 Congestive heart failure 
 Non rheumatic valvular heart disease   
 Sick sinus syndrome 




 Congenital heart disease 
Non-cardiovasular 
 
 Endocrine disorders 
(e.g.,Hyperthyroidism) 
 Respiratory causes (e.g., pneumonia, 
pulmonary thromboembolism) 
 Alcohol and drug use 
 
Atrial fibrillation with poor ventricular rate control can cause electrical and structural 
remodeling of the ventricle, leading to ventricular dilatation and impairment of systolic 
function, known as “tachycardia induced cardiomyopathy”. 
Stroke and thromboembolism are a major cause of mortality and morbidity associated with 
AF, and the underlying pathophysiological basis of this is a prothrombotic or 
hypercoagulable state, in association with abnormalities of blood flow (atrial stasis, for 
example) and endothelial or endocardial damage. 
The concept of primary prevention of AF with interventions targeting the development of 
substrate and modifying risk factors for AF has emerged as a result of recent experiments 
that suggested novel targets for mechanism-based therapies.  
Upstream therapy refers to the use of non-antiarrhythmic drugs that modify the atrial 
substrate- or target-specific mechanisms of AF to prevent the occurrence or recurrence of the 
arrhythmia. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) may be effective in AF prevention in patients with hypertension, left 
ventricular hypertrophy, and congestive heart failure, as well as in post myocardial 
infarction patients with depressed left ventricular function8. Also statins and omega-3 
polyunsaturated fatty acids, and possibly corticosteroids. Animal experiments have 
compellingly demonstrated the protective effect of these agents against electrical and 
structural atrial remodeling in association with AF. The key targets of upstream therapy are 
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structural changes in the atria, such as fibrosis, hypertrophy, inflammation, and oxidative 
stress, but direct and indirect effects on atrial ion channels, gap junctions, and calcium 
handling are also applied. Although there have been no formal randomized controlled 
studies (RCTs) in the primary prevention setting, retrospective analyses and reports from 
the studies in which AF was a pre-specified secondary endpoint have shown a sustained 
reduction in new-onset AF with ACEIs and ARBs in patients with significant underlying 
heart disease (e.g. left ventricular dysfunction and hypertrophy), and in the incidence of AF 
after cardiac surgery in patients treated with statins. 
4. Management of AF 
AF management creates a high economic burden because of the concomitant presence of 
heart failure, coronary artery disease, hypertension, and the need for frequent 
hospitalizations. Expensive antiarrhythmic drugs and interventional procedures are other 
important factors that raise the costs of AF care. 
Four major aspects should be considered in the AF management9: 
i. Symptom control by slowing ventricular response during paroxysmal or persistent AF 
and long-term rate control in permanent AF 
ii. Cardioversion to sinus rhythm 
iii.  Maintenance of sinus rhythm after successful cardioversion 
iv.  Prevention of complications and thromboembolic events. 
Rhythm versus Rate Control 
In order to prevent the complications and symptoms of AF two main strategies exist.  
1. Rhythm control: converting the patient’s rhythm to sinus and maintaining the sinus 
rhythm. 
2. Rate control: slowing the ventricular response rate without insisting on conversion to 
sinus rhythm.  
The initial therapy after onset of AF should always include adequate antithrombotic 
treatment and control of the ventricular rate. The goal is to control the ventricular rate 
adequately whenever recurrent AF occurs. 
From a theoretical point of view, converting AF into sinus rhythm is the best option. 
Nonetheless; the most important trials reported in the existing literature thus far have 
mentioned no significant difference in terms of quality of life and other outcomes between 
the two strategies. It seems that the side effects of antiarrhythmic agents (pro-arrhythmia) in 
the long term, poor efficacy of drugs in the maintenance of sinus rhythm, and inappropriate 
discontinuation of anticoagulants in the patients who still have AF episodes can interfere 
with good results in the rhythm-control arm27.  Therefore, many experts believe that rhythm 
control with safe antiarrhythmic drugs or catheter ablation will play an important role in the 
AF management.  
The main agents for slowing ventricular response in AF are beta blockers, calcium channel 
blockers, and digoxin28. Beta-blockers and calcium channel blockers are first-line agents for 
rate control in atrial fibrillation. These drugs can be administered either intravenously or 
orally. They are effective at rest and with exertion. Caution should be exercised in patients 
with reactive airway disease who are given beta-blockers. Digoxin is sometimes used in the 
acute setting but does little to control the ventricular rate in active patients. As such, it is 
rarely used as mono therapy. The therapeutic window for digoxin as mono therapy for rate 
control is narrow and would typically yield toxic levels. Thus, there may be circumstances 
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orally. They are effective at rest and with exertion. Caution should be exercised in patients 
with reactive airway disease who are given beta-blockers. Digoxin is sometimes used in the 
acute setting but does little to control the ventricular rate in active patients. As such, it is 
rarely used as mono therapy. The therapeutic window for digoxin as mono therapy for rate 
control is narrow and would typically yield toxic levels. Thus, there may be circumstances 
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that this drug is used as adjunctive therapy to beta-blockers or calcium channel blockers. 
Caution should be exercised in elderly patients and those with renal failure receiving 
digoxin. Digoxin is indicated in patients with heart failure and reduced LV function.  
Amiodarone has a Class IIa recommendation from the ACC/AHA/ESC for use as a rate 
controlling agent for patients who are intolerant of or unresponsive to other agents. Caution 
should be exercised in those not receiving anticoagulation as amiodarone can promote 
cardioversion. 
Criteria for rate control vary with patient age but usually involve achieving ventricular 
rates between 60 and 80 bpm at rest and between 90 and 115 bpm during moderate 
exercise.  
The potential benets of strict (resting heart rate <80 bpm, heart rate <110 bpm during 
moderate exercise) versus lenient (resting heart rate 110 bpm) rate control were addressed in 
the RACE II  trial of  patients with permanent AF29.  The RACE II study shows that 
lenientrate control <110 bpm is not inferior to strict-rate control <80 bpm. As lenient-rate 
control is generally more convenient, requiring fewer outpatient visits and examinations, 
lenient-rate control may be adopted as a reasonable strategy in patients with permanent AF. 
In the AFFIRM study, there was no survival difference between rate-control and rhythm-
control strategies. In addition, the lower risk of adverse drug effects in the rate-control arm 
conferred some advantages in this arm. A post-hoc analysis of the AFFIRM data proved that 
there was no significant benefit in the rhythm-control group versus the rate-control group in 
patients with AF and left ventricular dysfunction30. The RACE study showed that for the 
prevention of cardiovascular mortality and morbidity in AF, rhythm control was not superior to 
rate control31. In the PIAF trial, clinical outcomes were similar between the rate-control group 
and the rhythm-control group but exercise tolerance was better in the rhythm-control arm32. 
However rhythm-control strategy is more popular than the rate-control strategy worldwide. 
Symptom control and quality of life generally are better when sinus rhythm is restored and 
maintained. Treatment analysis from the AFFIRM study42 showed that the presence of sinus 
rhythm was associated with a 47% reduction in mortality and that the use of AAD was 
associated with a significant increase in mortality of 49%, suggesting a potential benefit of 
sinus rhythm maintenance in a non-pharmacological manner.  
We hope that with the advent of new drugs for both rhythm control and anticoagulation, 
maintenance of sinus rhythm after cardioversion can be a more realistic goal. 
4.1 Cardioversion to sinus rhythm 
As a result of atrial remodelling, the longer the duration of AF the less successful is the 
cardioversion. Predictors of recurrence of AF include long standing atrial fibrillation 
(duration greater than three months), heart failure, structural heart disease, hypertension, 
increasing age (over 70), and increased left atrial size10.  
Although left atrial size is related to the duration of AF, a left atrial diameter greater than 6.5 
cm is associated with an increased risk of recurrence11. 
Cardioversion carries a 5-7% risk of thromboembolism without anticoagulation and a 1-2% 
risk after conventional anticoagulation12. Prolonged anticoagulation is not needed when 
patients present within 48 hours of onset of AF. Such patients may be safely cardioverted 
irrespective of whether heparin has been administered since presentation. Administration of 
heparin is recommended to all patients with an acute presentation, however, to allow 
flexibility in subsequent management of the arrhythmia13. 
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For stable patients, in whom the onset of AF is uncertain or greater than 48 hours, 
anticoagulation for a minimum of three weeks before cardioversion is recommended, to 
allow resolution of potential thrombi. As atrial mechanical activity may not resume 
concurrently with electrical activity, anticoagulation should be continued for at least four 
weeks after cardioversion. 
An alternative approach is to use transoesophageal echocardiography to exclude atrial 
thrombi before cardioversion is attempted. The presence of an atrial thrombus necessitates 
four to six weeks of anticoagulation before cardioversion. Even with this strategy, 
anticoagulation should be continued for at least four weeks after cardioversion. 
4.2 Pharmacological cardioversion 
Pharmacological cardioversion should be reserved for haemodynamically stable patients 
with symptoms.  In general, class I and class III antiarrhythmic agents are commonly used 
for pharmacological cardio version and maintenance of sinus rhythm. In AF episodes 
lasting less than 48 hours cardio version rate for class IC and III drugs is approximately 
60-80%14. 
In a randomised trial comparing flecainide, propafenone, and amiodarone for 
cardioversion of recent onset AF, conversion to sinus rhythm occurred in 90%, 72%, and 
64% of patients respectively15. Class IC drugs (flecainide and propafenone) should be 
avoided in patients with underlying ischaemic heart disease or impaired left ventricular 
function. Amiodarone can be used in such patients, although the time to conversion can 
range from days to weeks. 
Ibutilide is a class III antiarrhythmic agent that can convert AF to sinus rhythm more rapidly 
than can procainamide or sotalol. It has been shown that ibutilide has no significant 
advantage compared with amiodarone for the conversion of AF but severe hypotension was 
not seen with ibutilide23. For acute AF, conversion to sinus rhythm with ibutilide is about 
59%, but there is 1.7% risk of polymorphic ventricular tachycardia with this drug. As a 
result, it is advised to keep the patients receiving ibutilide under monitoring for at least 24 
hours after the infusion of this drug24. 
Dofetilide is another class III antiarrhythmic drug that can be used for maintaining sinus 
rhythm in congestive heart failure patients with AF. The DIAMOND CHF trial showed that 
it could reduce hospitalization due to heart failure. Heart failure worsening was reduced by 
25%.25Dofetilide is known to be more effective in patients with persistent AF compared with 
those with paroxysmal AF, and significant proarrhythmic adverse effects can occur even 
with close monitoring. 
Vernakalant is an atrial-selective drug treatment for atrial fibrillation which affects Na+ and 
several K+ channels in the heart. Vernakalant is most often used intravenously to stop 
recent-onset AF. A long-term oral preparation, however, is in development. Several placebo-
controlled studies have shown vernakalant to be effective in eliminating AF in about 50% of 
patients with limited side effects16, 17. In these studies, vernakalant was most effective for 
treatment of recent-onset AF, but rarely effective at all for long-standing AF. Common side 
effects of vernakalant include nausea, sneezing and dysgeusia. The FDA has recommended 
vernakalant as an intravenous treatment for recent-onset AF. 
The ‘Pill-in-the-poket’ approach may be used in selected, symptomatic patient with 
infrequent episodes of AF. Oral propafenone (450-600mg) or flecainide (200-300mg) is taken 
when symptoms of AF occur18. 
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4.3 Electrical cardioversion 
Synchronised external direct current cardioversion is a safe procedure with success rates of 
70-90%19. It is used acutely in patients who are haemodynamically compromised or 
electively as an alternative to pharmacological cardioversion. Electrical cardioversion is 
usually done under conscious sedation. If this is unsuccessful, adjunctive antiarrhythmic 
treatment with class III agents such as dofetilide, sotalol, and amiodarone can help to restore 
sinus rhythm. 
4.4 Maintenance of sinus rhythm 
Class III antiarrhythmic agents have an important role as a part of cardioversion strategy 
and maintaining sinus rhythm. Amiodarone, which is the hallmark drug in this group and 
most frequently used antiarrhythmic drug for AF treatment, is a relatively safe and effective 
drug but frequent adverse effects like thyroid dysfunction, pulmonary fibrosis, 
dermatological changes, and ophthalmic involvement have been reported with its long-term 
use20.  
Dronedarone is a benzofuran-derivate of amiodarone with the same electropharmacological 
profile36 but without side effects on the pulmonary system21. It has a shorter half-life than 
amiodarone (1 - 2 days). The recommended oral dose of dronedarone is 400 mg twice a day 
with meals. The ANDROMEDA study was terminated prematurely because of increased 
mortality due to the worsening of heart failure in the dronedarone group. Therefore, 
dronedarone is contraindicated in patients with moderate to severe heart failure26. The 
major adverse cardiac effects of dronedarone are bradycardia and QT prolongation. 
Torsades de pointes have been reported22.  Cases of rare but severe hepatic injury associated 
with use of dronedarone reported. Periodic monitoring of  liver-function test should be done  
especially in the first six months of treatment.  
Dronedarone was approved by the American FDA in March, 2009, for sinus-rhythm 
maintenance in patients with a history of atrial fibrillation/flutter with ejection fraction 
greater than 35%. 
4.5 Reduction of thromboembolic risk 
Atrial fibrillation can predispose clot formation in the left atrium and consequently ischemic 
stroke and extra cranial thromboembolism33. When stroke occurs in association with atrial 
fibrillation, patients have a greater mortality and morbidity, longer hospital stays, and 
greater disability than those without AF. If AF persists for two days, left atrium thrombosis 
could be seen in 5 - 14% of patients34. It might, subsequently, become fragmented and 
embolize to the peripheral atrial system35. 
Pooled data from trials comparing antithrombotic treatment with placebo have shown 
that warfarin reduces the risk of stroke by 62% (95% confidence interval 48% to 72%) and 
that aspirin alone reduces the risk by 22% (2% to 38%). Overall, in high risk patients, 
warfarin was better than aspirin in preventing strokes, with a relative risk reduction of 
36% (48% to 72%). The risk of major haemorrhage with warfarin was twice that with 
aspirin36. 
Anticoagulation treatment needs to be tailored individually for patients on the basis of age, 
comorbidities, and contraindications. In patients with valvular heart disease or high-risk 
individuals (according to the CHADS2 or CHA2DS2VASC  scoring), warfarin is the drug of 
choice. In low-risk conditions, aspirin can be used37. 
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Oral anticoagulation therapy with warfarin proved superior to clopidogrel plus ASA for 
prevention of vascular events in AF patients. Treatment with clopidogrel plus ASA was 
associated with bleeding risk similar to treatment with warfarin38. In the ACTIVE-A trial, AF 
patients for whom oral anticoagulation with warfarin was considered unsuitable, the 
addition of clopidogrel to ASA reduced the risk of major vascular events, especially stroke, 
and increased the risk of major hemorrhage39. 
Dabigatran is a new, potent, direct and competitive inhibitor of thrombin. Its half-life is 12 to 
17 hours, and it does not require regular monitoring.  AF patients receiving Dabigatran 110 mg 
twice daily had similar rates of stroke and systemic embolism compared with those using 
warfarin, but with lower rates of major bleeding. At a dose of 150 mg twice daily, the rate of 
stroke and systemic embolism is lower but the rate of major bleeding is similar to warfarin40. 
Apixaban, a novel factor Xa inhibitor, was tested in the AVERROES trial in patients 
unsuitable for warfarin therapy and at increased risk of stroke. The trial was stopped 
prematurely because of clear benefit in favor of apixaban, compared to aspirin41. 
4.6 Non-pharmacological therapy 
Many non-pharmacological treatments have been developed for the management of AF and 
some even afford a possible “cure”. 
4.7 Radiofrequency catheter ablation 
The past decade has witnessed radiofrequency catheter ablation of AF evolve from an 
experimental procedure to an important treatment option for many patients with AF. 
Randomized controlled trials now confirm that left atrial ablation is superior to 
antiarrhythmic drug therapy in maintaining sinus rhythm over time52- 54. 
Curative catheter ablation techniques initially attempted to mimic the lesions created by the 
surgical Maze procedure, resulting in limited success with a substantial complication rate. In 
1998, Haissaguerre et al. first demonstrated that pulmonary veins (PVs) provided focal 
firings triggering the occurrence of paroxysmal AF3. They showed that as many as 94% of 
such triggers originated from the PVs and that the elimination of these foci by 
radiofrequency (RF) energy applications in the PVs could cure the paroxysmal form of AF, 
which became the cornerstone of curative ablation of AF. However, it turned out that high 
recurrence rates of AF and late development of PV stenosis were often associated with this 
procedure43. Subsequently, a more advanced technique attempting to isolate the PV muscle 
sleeves form the left atrium evolved. 
Among various procedures to isolate the PV muscle sleeves from the LA initially employed 
by several investigators, two approaches predominated: namely, segmental ostial ablation at 
sites where localized conductions between the PV and the LA were electrophysiologically 
identified44, and anatomically guided circumferential PV ablation encircling individual 
PVs45. 
Presently, almost all centers empirically isolate all four PVs not at the ostium but outside the 
tubular portion of the PV to avoid the risk of venous stenosis and improve procedural 
efficacy. Because the PV is funnel-shaped with a large proximal end (referred to as the 
antrum), which blends into the posterior wall of the LA, isolation of the PV and the 
surrounding antral tissue has become the current goal of this procedure. 
In order to eliminate the substrate for maintaining AF, the efficiency of two additional 
adjunctive ablation strategies  of PV isolation have been described. The linear lesions are 
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made at the roof between the contralateral superior PVs (roof line) and at the isthmus 
between the mitral valve and the left inferior PV (mitral isthmus line) 46, 47. This concept 
improved the AF-free ratio from 69 to 87% in paroxysmal AF cases, although epicardial RF 
applications were required in 60% of cases to achieve the mitral isthmus block. 
Currently, the most popular method for AF substrate modification in the atrium is to apply 
RF energy and create lesions targeting the areas with complex fractionated atrial 
electrograms (CFAEs) 48. CFAEs are believed to represent slow conduction or pivot points 
where wavelets turn around at the end of arcs of functional blocks. Although the concept of 
this method is well accepted, its role in ablation strategies has not yet been fully established. 
CFAE ablation targets only the substrate to perpetuate AF, and only modest efficacy of this 
method alone for chronic AF has been reported so far49. More recently, CFAE ablation has 
been achieving a general consensus as one of the combination strategies for modifying AF 
substrates. 
Ablation treatment is successful in approximately 60% to 70% of patients that 10% to 40% of 
patients require a second ablation procedure, and that 10% to 15% still need antiarrhythmic 
drugs50.  
Success rates for catheter-based ablation are lower in patients with persistent atrial 
fibrillation than in those with paroxysmal AF. In addition, the chances of a successful 
outcome are lower in those with marked dilation of the left atrium. Oral and colleagues51 
reported 75% recurrence rate in patients with persistent AF, compared with 29% in patients 
with paroxysmal AF.  
4.8 Ablation strategy for chronic atrial fibrillation 
Multiple strategies of various procedures, including PV isolation, anatomy- or electrogram-
guided left-atrial ablation, linear ablation and thoracic vein isolation, have been developed. 
Each strategy performed alone has been shown to yield similar rates of outcome (50–70% 
success), suggesting the various co-existing targets and factors as the modifiers of the AF 
substrates. Haïssaguerre et al. developed stepwise multifaceted ablation method for chronic 
AF, which could integrate different (electrogram- and anatomy based) approaches55-57. They 
combined the approaches of PV isolation, electrogram-based ablation targeting CFAEs, 
linear ablation at the LAroof and the mitral isthmus and right atrial ablation (in some cases). 
Up to now, no single strategy is uniformly effective in patients with persistent and long-
standing persistent AF. 
4.9 Indication for catheter ablation 
Catheter ablation should generally not be the first-line therapy for atrial fibrillation. The 
primary indication for it is symptomatic atrial fibrillation that is refractory to at least one 
class 1 or class 3 antiarrhythmic drug  or the inability of a patient to tolerate these drugs. 
Another indication is in patients in whom rapid atrial fibrillation is determined to be the 
cause of tachycardia-mediated cardiomyopathy resulting in heart failure, reduced ejection 
fraction, or both. Studies have been performed in which catheter ablation was used as first-
line therapy. The expert consensus committee2 recognized this but did not fully support the 
practice. The decision to proceed with catheter ablation must be individualized on the basis 
of the risk of complications, the likely benefits, and the likelihood of success.  
Recent guidelines have class I recommendation for ablation in selected patients with 
significantly symptomatic paroxysmal AF and failed treatment with an antiarrhythmic drug 
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and have normal or mildly dilated left atria, normal or mildly reduced LV function, and no 
severe pulmonary disease, when performed in experienced centers.   
An absolute contraindication to catheter ablation is left atrial thrombus. Because of the risk 
of dislodging an existing thrombus during the procedure and causing a stroke, patients with 
persistent atrial fibrillation who are in atrial fibrillation at the time of the procedure should 
undergo trans esophageal echocardiography to screen for thrombus. 
4.10 Complications of RFA 
The most common complication associated with catheter ablation of AF is symptomatic or 
asymptomatic pulmonary vein stenosis (defined as a >70% reduction in lumen diameter), 
with an overall incidence of 1.6%. Somewhat less common are cardiac tamponade (0.7%), 
pericardial effusion (0.6%), periprocedural stroke (0.3%), and periprocedural transient 
ischemic attack (0.2%). The overall mortality rate is 0.7%58. 
It is clear that catheter ablation is more effective than AAD therapy in treating AF. However 
because of associated complication catheter ablation of AF should be considered after a 
patient has failed attempts at treatment with 1 or more AAD. 
4.11 The surgical maze procedure 
Surgeons were the first ones to treat AF effectively and reverse it to sinus rhythm. James Cox 
described a series of surgical procedures known as Cox-Maze technique. The maze procedure 
is based on the concept that a critical mass of atrial tissue is needed to allow multiple waves of 
depolarisation to spread. This surgical approach was directed to divide both right and left atria 
by a series of cuts and sutures to redirect the electrical impulse to close-end paths. This 
operation also included the exclusion of both atrial appendages and the isolation of the four 
pulmonary veins and the posterior wall of the left atrium. Nowadays, cryotherapy, bipolar 
radiofrequency, and ultrasounds are the most used energy sources. 
Although very effective, with over 91% patients maintaining sinus rhythm at 10 years, few 
surgical groups performed the Cox-Maze procedure due to the aggressiveness of it, with 
long suture lines and prolonged myocardial ischemic times59,60. Preoperative AF is 
associated with worse survival rates after valvular or coronary surgery.  Furthermore, 
patients with successful maze procedures have shown better long-term survival rates, 
higher freedom from stroke, and thromboembolic events, improved ventricular ejection 
fraction and exercise tolerance. All the above factors have expanded the indications for the 
surgical treatment of concomitant AF to most patients with coronary or valvular surgery.  
In addition, minimally invasive approaches have been described in the last five years with very 
good results for isolated paroxysmal or persistent AF. Nevertheless, prospective randomized 
trials are necessary to confirm their long-term results, compared to catheter ablation. 
4.12 Pacing for atrial fibrillation 
Atrial-based pacing, in either single- or dual-chamber mode, reduced the incidence of AF in 
several prospective multicenter studies62-67. More recently, a variety of preventive atrial 
pacing strategies, including continuous overdrive pacing, pacing in response to atrial 
premature beats, postmode switch and postexercise pacing therapies, were developed to 
reduce the burden of AF among patients with known atrial tachyarrhythmias68-73. 
However, the magnitude of AF prevention due to dedicated preventive pacing algorithms 
and the identication of responder candidates remains unclear74-76.  
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significantly symptomatic paroxysmal AF and failed treatment with an antiarrhythmic drug 
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patients with successful maze procedures have shown better long-term survival rates, 
higher freedom from stroke, and thromboembolic events, improved ventricular ejection 
fraction and exercise tolerance. All the above factors have expanded the indications for the 
surgical treatment of concomitant AF to most patients with coronary or valvular surgery.  
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4.12 Pacing for atrial fibrillation 
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and the identication of responder candidates remains unclear74-76.  
 
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
122 
4.13 Atrioventricular node ablation  
Atrioventricular (AV) node ablation provides highly effective control of ventricular rate in 
patients with AF. Catheter ablation of AV node is a palliative but irreversible procedure and 
is therefore reasonable in patients in whom pharmacological rate control, or rhythm control 
with drugs and/or ablation therapy has failed. In such patients, AV node ablation improves 
quality of life and renders mortality similar to death rates in the general population. It is 
reasonable to assume that patients with LV systolic dysfunction may require biventricular 
pacing after AV node ablation to prevent deterioration of LV function. In patients without 
LV dysfunction, it is not established at present whether biventricular pacing is needed: some 
data suggest that biventricular pacing may be beneficial,77 while others demonstrate similar 
benefits with right ventricular pacing. 
4.14 Obliteration of the left atrial appendage 
The left atrial appendage (LAA) is considered the main site of atrial thrombogenesis.Thus, 
occlusion of the LAA may therefore be an effective way to reduce thromboembolic risk. 
Surgical closure is recommended only as an adjunctive procedure in patients undergoing 
mitral valve surgery. However devices have been developed that allows percutaneous LAA 
closure via the transeptal approach. This may be appropriate for patients who are not 
suitable for anticoagulation78. Further trials are needed to evaluate its long term safety and 
efficacy. 
4.15 Rheumatic valvular heart disease and atrial fibrillation 
AF is frequently associated with rheumatic valvular heart disease (RVHD). Valvular heart 
disease is one of risk factors for development of AF. The frequency of RVHD has decreased 
in developed but RVHD constitutes a significant burden on  healthcare in developing 
countries. 
The risk of thromboembolism in patients with RVHD and AF is high.  The stroke risk 
increases 17-fold if patients have rheumatic heart disease and AF, compared with age-
matched controls79. AF worsens hemodynamics in patients with RVHD as absent atrial kick 
and irregular ventricular rhythm lead to a fall in cardiac output. 
Results of randomized trials evaluating strategies for heart rate control or rhythm control is 
not necessarily acceptable for patients with RVHD and AF, because the majority of patients 
in these trials were non-RVHD. In patients with RVHD and AF, the maintenance of sinus 
rhythm can be expected to improve mortality and QOL. It is suggested that in RVHD and 
AF if there is no significant valvular compromise necessitating intervention and if the left 
atrium size is not more than 6.0 cms, rhythm control with amiodarone facilitated by 
electrical cardioversions should be the strategy82. If attempts to maintain SR fail over one 
year’s time, rate control measures should suffice In young patients and those with RVHD 
but no significant valve compromise, restoring and maintaining SR should be attempted. 
Patients receiving mechanical valve replacement need to continue anticoagulant therapy. It 
is unclear whether or not the maintenance of sinus rhythm influences clinical outcome for 
thromboembolism in these patients. However, the maintenance of sinus rhythm is 
important patients receiving tissue valve replacement, or balloon intervention, because they 
are likely to discontinue anticoagulant therapy.  
If AF persists, electrical and pharmacologic cardioversion are effective in restoring sinus 
rhythm, and the administration of antiarrhythmic drugs may be effective in preventing 
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AF80. However, once AF has developed in patients with RVHD, these drugs may not be 
effective in restoring sinus rhythm because of the pathological changes that develop in the 
atrium and predispose to AF.  
Surgery for AF should be utilized for patients with associated RVHD undergoing valve 
surgery. The probability of spontaneous conversion to SR after isolated mitral valve surgery 
is less than 10%. Patients who return to SR after mitral valve replacement or repair 
demonstrate better survival and freedom from adverse events.  
After the success of the Cox maze III procedure in treating AF, several surgeons began to 
add the maze procedure as an adjunct to mitral valve surgery to treat both problems81. 
Successful restoration of SR has been achieved in 70-96% of patients. 
5. Conclusion 
Recent developments in pharmacological and non-pharmacological therapy have opened a 
new horizon in management of AF.  Cure of AF has, however become a realistic goal albeit 
in limited number of patients and will remain a challenge for years to come. 
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Novel Alternative Therapies for the Treatment  
of Severe Aortic Stenosis 
Javier Gualis, Alejandro Diego, Antonio de Miguel and Mario Castaño 
Complejo Hospitalario Universitario de León, 
Spain 
1. Introduction 
Aortic stenosis is the most common valvular disease among the occidental population and it 
is one of the most important causes of morbidity and mortality in developed countries. It 
has an incidence of 4% among over 80 years old patients (Charlson E et al.,2006). Its 
evolution is generally slowly progressive from asymptomatic/mild aortic stenosis to the 
symptomatic/severe form when survival is dramatically reduced as well as quality of live is 
importantly impaired. (Iung B et al., 2003) 
All along natural history of this disease, patients will consult several times to specialists in 
order to adjust medical treatment and perform the indicated diagnostic tests. Occasionally 
in-hospital admittance will be unavoidable and this will necessarily arise into economic 
resources consumption, that might be assumed by actually over-the-edge and almost 
bankrupted socio-sanitary policies, at least in the most of developed countries (Varadarajan 
P, 2006; Pai RG, 2006).   
Over more tan 40 years, standard treatment for severe symptomatic aortic stenosis has been 
focused in surgical replacement of the affected valve for a mechanical prosthesis. To achieve 
this replacement, patient must mandatorily undergo several risky procedures as general 
anesthesia, median sternotomy, and aortic arch clamping and cardioplegic solution infusion 
in order to maintain cardiac arrest in diastole during the intervention, with the 
indispensable cardiopulmonary bypass pumping. (Kvidal P et al,. 2000) 
Hence, standard surgical therapy has inherent morbi-mortality risks itself that must be 
carefully evaluated, so this therapy may be not suitable for a subpopulation of candidates 
because of an excessive high-risk profile. These patients must then admit the natural history 
of this disease with a terribly poor mid-term prognosis and elevated economic expenses for 
the system. (Alexander KP et al., 2000) 
Socio-sanitary policies need to organize the diagnostic and therapeutic procedures in this 
cohort of patients in order to obtain the necessary balance that allow an adequate treatment 
with risk minimization achieving the best possible results with the lowest expenses, 
optimizing the efficiency in the management of these complex pathology. 
In this moment, several therapeutic alternatives are being studied with the aim of the risk 
reduction in the management of patients with severe aortic stenosis and surgical high-risk 
profile. These therapies do not pretend to become a substitution of the standard surgical 
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therapy but a way to reduce the burden of complication and morbidity in the subgroup of 
patients that cannot be eligible for standard surgery. (Rodés-Cabau et al., 2008) 
The present chapter is dedicated to a detailed description of the different therapeutic 
procedures that are being developed nowadays as an alternative to standard surgical 
treatment. Special surgical new techniques as low-profile mechanical prosthesis, biological 
prosthesis (both stented and stentless), homograft and Ross technique (pulmonary autograft 
in aortic position and homograft in pulmonary position) will not be commented in this 
chapter. 
2. Aortic valvuloplasty 
Aortic balloon valvuloplasty is a classical procedure firstly performed in the late fifties and 
still in use for children affected of congenital aortic stenosis with acceptable results. Its use 
in degenerative or rheumatic aortic stenosis has been abandoned in the last decades due to 
its prohibitive mid-term restenosis rates. With good results limited to the first days after 
procedure, generally approved indications for severe aortic stenosis has been displaced 
towards a bridging therapy between a critical clinical situation and a surgical replacement 
that is delayed for any cause. Other previous indications, as palliative therapy among 
patients that reject surgery, previous to non-cardiac surgery or low gradient aortic stenosis 
with severely reduced left ventricle ejection fraction are losing their sense with the 
introduction of transcatheter aortic valve implantation, but all the way this novel therapy 
requires aortic valve balloon dilatation previously to device implantation, balloon 
valvuloplasty is not only out of danger of disappear but be clearly reinforced, redirected 
towards its implication in the TAVI procedure process. (Vahanian A et al., 2004). 
3. Transcatheter aortic valve implantation: TAVI 
Andersen performed first experimental studies of transcatheter aortic valve implantation in 
the early nineties (Andersen et al., 1992). Afterwards, in year 2000, Bonhoeffer did the first 
in-human implantation of a percutaneous prosthesis in pulmonary position (Bonhoeffer P et 
al., 2000) , but it was not until 2002 when Dr. Alain Cribier performed successfully the first 
implantation in a patient affected of severe symptomatic aortic stenosis rejected for surgery, 
obtaining an excellent initial clinical result that led to a fast spreading of the technique and 
implementation of the devices (Cribier A ,. 2002). From this moment on, the development of 
valvular programs to perform catheter-based aortic stenosis treatment have been increasing 
exponentially worldwide. 
In a summarized way, the procedure consists of the implantation of a biological prosthesis 
anchored in a metallic stent over the diseased and stenotic native valve using a 
percutaneous arterial and/or venous access or a transapical access after performing a 
minithoracotomy. All of these ways to access the aortic valve have the intention to avoid the 
median sternotomy and the cardiopulmonary bypass with its implicit risks. 
First procedures were performed via catheterization of the femoral vein and accessing the 
right heart and then the aortic valve in an anterograde way through a transseptal puncture. 
Although this kind of procedure is still performed in selected patients, now the most 
frequently used technique is the retrograde method through arterial access described by 
Webb in 2005, using preferably femoral site of puncture, though subclavian or even 
ascending aorta itself can be performed to reach the aortic valve (Webb JG et al., 2006). The 
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transapical technique, described by Lichtenstein in 2006, would require surgical access with 
a minithoractomy and at this moment it is the second preferred method (Lichtenstein SV et 
al., 2006). 
TAVI is a complex technique essentially reserved for very high perisurgical risk patients. It 
is important to emphasize that, due to its complexity, the learning curve of the technique 
must be performed following a strict program that minimize the risk of complications. 
Several groups have compared initial results with those obtained after the first learning 
curve period. Webb et al reported their experience after the first 168 Edwards Sapien 
transcatheter aortic valve implantation, both transfemoral (n=113) and transapical (n=55) 
showing a decrease in 30-days mortality from 14,3% in the first 84 patients to 8,3% in the 
second half of the sample. Of course, not only the experience acquirement but the technical 
advances in the device design have contributed to this results improvement (Webb JG et al., 
2007). In the same line, Grube el al demonstrated a 73% reduction in 30-days mortality (from 
40% to 10,8%) in 102 patients who underwent 18F CoreValve system valve implantation in 
comparison with an older sample treated with the first generation 25F device (Grube E et al 
., 2005). This data suggest that, while improvements in the design of the device and the 
selection of patients keep on growing exponentially, a reduction in the learning curve 
requirements should be expected for the next generation of devices and future centre 
incorporations to this alternative technique.  
Despite this technical improvements, they will never replace the importance of the learning 
curve.  Himbert et al reported that, in relation with the initial experience of a specific centre, 
precisely the learning curve is the most important factor related to in-hospital mortality and 
mid-term survival after this kind of procedures. (Himbert D et al., 2009). 
The most important issue for the generalization of these techniques is the indispensable 
device development carried out by the medical industry. The experimental tests performed 
by the different research and development programs have the goal of optimizing results by 
minimizing complications in the access site, increasing durability, improving flexibility and 
navigability of devices, developing non-traumatic guide-wires and catheters and low-profile 
stents that allow the active fixation of the valve and its homogeneous expansion in order to 
avoid paravalvular leaks and, at the end, improve general clinical results in terms of 
morbidity and mortality.  
There are several devices commercialized, the most used are the Medtronic CoreValve® 
Transcatheter Aortic Valve Implantation System (Medtronic Inc, Minneapolis, USA) and the 
Edwards Sapien® Trancatheter Heart Valve system (Edwards Lifesciences Inc., Irvine, 
USA).  
CoreValve first implantation was reported for Grube et al in 2005 and obtained the CE mark 
in 2007. More than 10.000 devices have been already successfully implanted in more than 34 
countries, and recently a clinical trial has been approved by the Food and Drugs 
Administration to evaluate its results in the USA. At this time, this device is designed for a 
transarterial retrograde approach implantation. This device is made up of a porcine 
pericardium valve fixed to an auto-expandable nitinol stent designed to anchor both the 
outflow tract of the left ventricle and the ascending aorta. It is commercialized in two sizes: 
26mm (indicated for aortic annulus between 20 and 23mm) and 29mm (for annulus between 
23 and 27mm). It is delivered through a 18F sheath so it is intended to be used in patients 
with femoral artery diameters over 6mm.   
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The Core Valve 
The new Edwards Lifescience device, the Sapien-XT valve, can be delivered by an arterial or 
venous access site (anterograde or retrograde technique) as well as by a transapical 
approach; it has the CE mark since 2007 and has the FDA investigational device exemption 
for the PARTNER US trial.  Like the CoreValve system, more than 10.000 devices have been 
implanted all around the world with promising initial results. It is constructed with a bovine 
pericardium valve sewed to a balloon expandable chromium-cobalt stent to be anchored to 
the calcified native aortic annulus. Three sizes are commercialized: 23mm (for aortic annulus 
between 18 and 21mm), 26mm (for aortic annulus between 21 and 25mm) and the recently 
added 29mm size for annulus over 25mm. The femoral sheath is 18F for the smaller size and 
19F for the 26, and the transapical sheath is 22F for the smaller, 24F for the 26mm size and 
26F for the 29mm. No femoral system has been designed yet for the 29mm valve. 
 
 
The Edwards Sapien XT valve 
3.1 Indications 
Initially, these devices were only approved as compassionate therapy for non operable 
patients with severe symptoms (NYHA class IV dyspnea or angina), but after the initial 
results achieved, the indications of these proceedings are extending to any patient with 
symptomatic severe aortic stenosis and specific contraindication for cardiac surgery or very 
high perioperative risk profile. It is reasonable to think that, as the technique is 
consolidating, the screening of patients for TAVI should follow the general 
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recommendations for the management of patients with degenerative aortic stenosis reported 
by the scientific societies. (Vahanian A et al., 2007,2008) 
3.1.1 General indications of aortic valve replacement for aortic stenosis following the 
European Society of Cardiology clinical guidelines 
1. Patients with severe aortic stenosis and presence of any symptoms (Recommendation 
class IB). 
2. Asymptomatic patients with severe aortic stenosis and systolic dysfunction (LVEF 
<50%) not attributable to other cause (IC). 
3. Asymptomatic patients with severe aortic stenosis and exercise test that shows lowering 
of arterial systolic pressure under basal levels (IIaC). 
4. Asymptomatic patients with severe aortic stenosis and severe calcification of the valve 
and a progression of the aortic peak velocity >0,3m/s per year (IIaC). 
5. Patients with low gradient severe aortic stenosis (<40mmHg) with systolic dysfunction 
(LVEF<40%) and contractile reserve (IIaC). 
6. Asymptomatic patients with severe aortic stenosis and exercise test that shows complex 
ventricular arrhythmias (IIbC). 
7. Asymptomatic patients with severe aortic stenosis and left ventricle hypertrophy 
(>15mm) in case of no arterial hypertension (IIbC). 
8. Patients with low gradient (<40mmHg) severe aortic stenosis and systolic dysfunction 
with no contractile reserve (IIbC). 
*Severe aortic stenosis is defined as a valvular area <1cm2 (<0,6cm2/m2 of body surface 
area) or a mean gradient >50mmHg with normal flow situation. Special evaluation is 
required in case of low flow situations.  
3.1.2 Contraindication for conventional aortic valve replacement 
1. High co-morbidity: elderly patients, left ventricle dysfunction, pulmonary 
hypertension, chronic obstructive pulmonary disease, renal failure, cerebrovascular 
disease, peripheral artery disease or any other circumstances evaluated following 
EuroSCORE (European System for Cardiac Operative Risk Evaluation) or STS (Society 
of Thoracic Surgeons) scales that leads to very high-risk profiles.  
2. Excessive technical complexity: multiple re-interventions or porcelain aorta. 
3.1.3 Absence of specific contraindications for transcatheter aortic valve implantation  
In case of aortic valve replacement indication with contraindication for standard surgery or 
very high-risk patient, TAVI should be considered. If TAVI is indicated, because of slightly 
better mid-term clinical results (CITA), transarterial retrograde technique would be the 
preferred technique over the transapical approach, but always after taking into account the 
experience and/or preferences of the center. 
- General contraindications: 
1. Aortic annulus smaller than 18mm or bigger than 27mm. 
2. Bicuspid or unicuspid aortic valve. 
3. Asymmetric severe valve calcification (bulky calcification) that might lead to high risk of 
coronary ostia occlusion during implantation.  
4. Severe symptomatic coronary artery disease not suitable for percutaneous 
revascularization.  
  




The Core Valve 
The new Edwards Lifescience device, the Sapien-XT valve, can be delivered by an arterial or 
venous access site (anterograde or retrograde technique) as well as by a transapical 
approach; it has the CE mark since 2007 and has the FDA investigational device exemption 
for the PARTNER US trial.  Like the CoreValve system, more than 10.000 devices have been 
implanted all around the world with promising initial results. It is constructed with a bovine 
pericardium valve sewed to a balloon expandable chromium-cobalt stent to be anchored to 
the calcified native aortic annulus. Three sizes are commercialized: 23mm (for aortic annulus 
between 18 and 21mm), 26mm (for aortic annulus between 21 and 25mm) and the recently 
added 29mm size for annulus over 25mm. The femoral sheath is 18F for the smaller size and 
19F for the 26, and the transapical sheath is 22F for the smaller, 24F for the 26mm size and 
26F for the 29mm. No femoral system has been designed yet for the 29mm valve. 
 
 
The Edwards Sapien XT valve 
3.1 Indications 
Initially, these devices were only approved as compassionate therapy for non operable 
patients with severe symptoms (NYHA class IV dyspnea or angina), but after the initial 
results achieved, the indications of these proceedings are extending to any patient with 
symptomatic severe aortic stenosis and specific contraindication for cardiac surgery or very 
high perioperative risk profile. It is reasonable to think that, as the technique is 
consolidating, the screening of patients for TAVI should follow the general 
Trends in Degenerative Aortic Disease:  
Novel Alternative Therapies for the Treatment of Severe Aortic Stenosis   
 
133 
recommendations for the management of patients with degenerative aortic stenosis reported 
by the scientific societies. (Vahanian A et al., 2007,2008) 
3.1.1 General indications of aortic valve replacement for aortic stenosis following the 
European Society of Cardiology clinical guidelines 
1. Patients with severe aortic stenosis and presence of any symptoms (Recommendation 
class IB). 
2. Asymptomatic patients with severe aortic stenosis and systolic dysfunction (LVEF 
<50%) not attributable to other cause (IC). 
3. Asymptomatic patients with severe aortic stenosis and exercise test that shows lowering 
of arterial systolic pressure under basal levels (IIaC). 
4. Asymptomatic patients with severe aortic stenosis and severe calcification of the valve 
and a progression of the aortic peak velocity >0,3m/s per year (IIaC). 
5. Patients with low gradient severe aortic stenosis (<40mmHg) with systolic dysfunction 
(LVEF<40%) and contractile reserve (IIaC). 
6. Asymptomatic patients with severe aortic stenosis and exercise test that shows complex 
ventricular arrhythmias (IIbC). 
7. Asymptomatic patients with severe aortic stenosis and left ventricle hypertrophy 
(>15mm) in case of no arterial hypertension (IIbC). 
8. Patients with low gradient (<40mmHg) severe aortic stenosis and systolic dysfunction 
with no contractile reserve (IIbC). 
*Severe aortic stenosis is defined as a valvular area <1cm2 (<0,6cm2/m2 of body surface 
area) or a mean gradient >50mmHg with normal flow situation. Special evaluation is 
required in case of low flow situations.  
3.1.2 Contraindication for conventional aortic valve replacement 
1. High co-morbidity: elderly patients, left ventricle dysfunction, pulmonary 
hypertension, chronic obstructive pulmonary disease, renal failure, cerebrovascular 
disease, peripheral artery disease or any other circumstances evaluated following 
EuroSCORE (European System for Cardiac Operative Risk Evaluation) or STS (Society 
of Thoracic Surgeons) scales that leads to very high-risk profiles.  
2. Excessive technical complexity: multiple re-interventions or porcelain aorta. 
3.1.3 Absence of specific contraindications for transcatheter aortic valve implantation  
In case of aortic valve replacement indication with contraindication for standard surgery or 
very high-risk patient, TAVI should be considered. If TAVI is indicated, because of slightly 
better mid-term clinical results (CITA), transarterial retrograde technique would be the 
preferred technique over the transapical approach, but always after taking into account the 
experience and/or preferences of the center. 
- General contraindications: 
1. Aortic annulus smaller than 18mm or bigger than 27mm. 
2. Bicuspid or unicuspid aortic valve. 
3. Asymmetric severe valve calcification (bulky calcification) that might lead to high risk of 
coronary ostia occlusion during implantation.  
4. Severe symptomatic coronary artery disease not suitable for percutaneous 
revascularization.  
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
134 
5. Active infective endocarditis. 
6. Hypertrophic Obstructive Myocardiopathy.  
- Contraindications for transfemoral access: 
1. Excessive tortuosity of the ilio-femoral axis.  
2. Previous aorto-bifemoral by-pass surgery. 
3. Small iliac or femoral artery diameter (<6-8mm depending on the device). 
4. Severe angulation of proximal ascending aorta or the valvular plane. 
5. Severe atheromatosis of ascending aorta or aortic arch, aortic coarctation, aneurism or 
dissection of descending thoracic aorta or abdominal aorta, specially if wall thrombus is 
present. 
*In case of TAVI indication and contraindication of femoral access, subclavian access 
might be considered. 
**In case of femoral/subclavian access contraindication, transapical access might be 
considered. 
- Contraindications for transapical access: 
1. Previous cardiac surgery on left ventricle apex. 
2. Paricardium calcifications. 
3. Chronic respiratory insufficiency that contraindicates minithoracotomy. 
4. Apical thrombus in left ventricle. 
3.2 TAVI program development 
Before starting a new transcatheter program is essential to proceed with the organization of 
a local heart team that must be formed by two cardiothoracic surgeons, two interventional 
cardiologists, an echocardiographist, an anesthesiologist, two dedicated nurses, and a 
perfusionist. Problem-solving skills and learning ability are essential, as it is the 
collaboration among the different departments and units involved in order to front the 
complications that will arise during the learning curve. 
Because of the elevated costs of the device, the difficulty of the technique and the high-risk 
profile of the candidates, specific learning courses realization is mandatory, as well as 
continuing training all along the team assistance trajectory. Industry demands, for both 
CoreValve and Sapien devices, a 15 procedures period in which the presence of a proctor 
that leads and trains the heart team is recommended before the achieving of the 
accreditation as an independent unit.  
Patient screening must be performed with exquisite care as the success or failure of the 
starting program could depend on the results of the initial cases. We must never forget that 
elective therapy for severe aortic stenosis is still surgical replacement, and only when 
surgery is contraindicated or very risky TAVI can be considered. TAVI indication must be 
established after consensus between the heart team dedicated to this technique and the 
clinical cardiologist responsible of the candidate and not only clinical but economic criteria 
must be taken into account as the elevated expenses that this procedures involve requires 
the proper selection that may lead to optimal clinical long term results, both in terms of 
survival expectancy and quality of live. 
Bullesfeld et al reported that pre-procedure patient functional class, assessed by Karnofsky 
index, was the only in-hospital survival predictor after CoreValve implantation. This fact 
comes to point again the main importance that an exhaustive screening process has in terms 
of late clinical results, and so in terms of efficiency (Bullesfeld L et al., 2009). 
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3.3 Additional diagnostic tests 
Usual imaging complementary tests performed before TAVI are transthoracic 
echocardiography, transesophageal echocardiography, cardiac catheterization and coronary 
angiography and CT-scan and/or C-MRI. In addition to confirmation of aortic stenosis 
severity, detailed basic information is required regarding (Delgado V et al., 2010): 
- Valve morphology (tricuspid or bicuspid, extend of calcification). 
- Annulus diameter. 
- Left ventricular outflow tract (LVOT) morphology. 
- Morphology of the aortic root (sinuses and their relation to extensive valve 
calcification) 
- Distance between coronary arteries and annulus (relation to sinus morphology and 
extensive valve calcification). 
- Size, pathology (complex plaques, aneurysm) and course (kinking) of the entire 
aorta. 
- Size, pathology (calcification) and course (tortuosity) of iliac and femoral arteries. 
The consolidation of transcatheter aortic valve implantation procedures in the common 
practice will be related to the results obtained. Imaging techniques improvements and its 
application during the procedure can help to obtain better results. 3D-Transesophageal 
echocardiography will contribute with valuable information about device positioning, valve 
function and relation between the prosthesis and the coronary ostia and the aortic root. It is 
especially valuable in the assessment of leaflets calcifications that might cause early in-
procedure complications during the valve deployment and will help the operator to find the 
proper positioning at the same time that allows identifying perivalvular leaks and guiding 
corrective manoeuvres in order to gain final prosthetic normal function and optimal 
performance. (Ng AC et al., 2010)  
DynaCT is being introduced in the most advanced hybrid catheterization laboratories, 
adding a new tool that offers incomparable information about aortic root configuration and 
relations among the different structures involved in TAVI procedures, but at this moment, it 
is only available in a very few centres and, however in the next future it may become the 
usual guiding diagnostic tool, it cannot be considered as a standard requirement at this 
moment.  (Kempfert J et al,. 2009) 
3.4 Operating room 
The ideal place to perform these complex techniques is called hybrid operating room or 
hybrid catheterization laboratory, were both, optimal x-ray imaging facilities and surgical 
treatment of the room adequate for cardiopulmonary by-pass, join together in order to 
minimize the risk of complications and adopt the necessary therapeutic measures in case of 
their presentation. The elevated cost of these hybrid rooms and the considerably big space 
that require make them to be out of reach for many centers, so several portable x-ray devices 
are being approved for its use into standard operating rooms. 
3.5 Complications 
Most often complication that may present in the early post-procedure period are: valve 
malposition, peri-prosthesis leak, acute aortic regurgitation and acute lung oedema, device 
embolization, low cardiac output heart failure with hemodynamic support requirements, 
conventional surgery conversion with in-pump connection, vascular access complications 
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5. Active infective endocarditis. 
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present. 
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perfusionist. Problem-solving skills and learning ability are essential, as it is the 
collaboration among the different departments and units involved in order to front the 
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Because of the elevated costs of the device, the difficulty of the technique and the high-risk 
profile of the candidates, specific learning courses realization is mandatory, as well as 
continuing training all along the team assistance trajectory. Industry demands, for both 
CoreValve and Sapien devices, a 15 procedures period in which the presence of a proctor 
that leads and trains the heart team is recommended before the achieving of the 
accreditation as an independent unit.  
Patient screening must be performed with exquisite care as the success or failure of the 
starting program could depend on the results of the initial cases. We must never forget that 
elective therapy for severe aortic stenosis is still surgical replacement, and only when 
surgery is contraindicated or very risky TAVI can be considered. TAVI indication must be 
established after consensus between the heart team dedicated to this technique and the 
clinical cardiologist responsible of the candidate and not only clinical but economic criteria 
must be taken into account as the elevated expenses that this procedures involve requires 
the proper selection that may lead to optimal clinical long term results, both in terms of 
survival expectancy and quality of live. 
Bullesfeld et al reported that pre-procedure patient functional class, assessed by Karnofsky 
index, was the only in-hospital survival predictor after CoreValve implantation. This fact 
comes to point again the main importance that an exhaustive screening process has in terms 
of late clinical results, and so in terms of efficiency (Bullesfeld L et al., 2009). 
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adding a new tool that offers incomparable information about aortic root configuration and 
relations among the different structures involved in TAVI procedures, but at this moment, it 
is only available in a very few centres and, however in the next future it may become the 
usual guiding diagnostic tool, it cannot be considered as a standard requirement at this 
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The ideal place to perform these complex techniques is called hybrid operating room or 
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including vessel rupture, dissection and/or acute occlusion, stroke, myocardial infarction, 
coronary ostia occlusion, atrioventricular block and renal failure.  
Valve malposition and valve embolization:  
Valve malposition and valve embolization are classical complications very related to the 
different teams learning curve and the technical improvements in the deployment devices. 
They have been drastically reduced from initial series (approximately 6%) to the incidence 
reported in the pate trials (approximately 2%). (Walther T et al,. 2007) 
Peri-prosthesis leak: 
Peri-prosthesis leak is due to absence of complete apposition of the device to the aortic 
annulus caused by lack of homogeneous expansion and it is one of the most common 
complications and the most important factor related to post-procedural aortic regurgitation. 
This valve regurgitation, when it is severe, can generate acute hemodynamic instability and 
acute lung oedema (that also may appear after pre-implantation balloon valvuloplasty) and 
it is one of the most important issues to improve in order to achieve a real advance in this 
technique (Cribier A et al., 2006).  
Vascular access complications:  
Vascular access major complications are still over 10% in the majority of the series reported 
despite the results improvements. Experience with the CoreValve system indicates that 
transporter catheter diameter reduction has great impact in the reduction of these 
complications (from over 20% to 5% in the last registries). In addition to this, 22F catheter 
maintenance for Edwards Sapient system lead to a stabilization in the incidence of vascular 
complication despite the operators experience gaining. Anyway, it seems that, at least in the 
SOURCE registry, vascular complications do not determine higher 30-days mortality 
incidence. This suggests that the presence of highly prepared teams with experience in the 
treatment of these vascular complications may limit their impact in peri-procedural 
mortality.  
It is important to advice that not only transfemoral technique is related to access 
complications as transapical access has also been associated with serious access 
complications as ventricular tear or severe bleeding during apex reparation. (Dumont E et 
al,. 2009, Rodés-Cabau J et al,. 2010) 
Stroke: 
Stroke, because of its terrible consequences for the patient, it has been another major concern 
of this technique. Stroke incidence has been kept below 5% in the majority of series; that is 
quite inferior to the expected incidence in an octogenarian population who undergo 
standard cardiac surgery with aortic clamping. This supports the idea that conventional 
aortic replacement surgery with cardiopulmonary by-pass and aortic clamping has a higher 
risk of stroke than these newer techniques despite the necessity of big sized aggressive 
devices that must navigate the aortic arch during implantation. It is important to remark 
here that transapical access avoids the manipulation of these catheters in the aorta and last 
trials have reported a tendency towards a stroke incidence reduction, so many centres have 
given priority to this access when severe aortic atheromatosis or porcelain aorta are present 
(Grube E et al,. 2008; Rodés-Cabau J et al,. 2010). 
Myocardial infarction: 
Assessing the incidence of myocardial infarction as a complication of TAVI is a very difficult 
objective as myocardial infarction definitions are quite variable among different trials and 
registries. Incidence vary from 0,2 to 17,5% depending on the definition given. In terms of 
severity and device-related myocardial infarction, the most important pathophysiological 
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condition that must be watched is the occlusion of a coronary ostium secondary to calcified 
native valve leaflets displacement, much more frequent than ostium jailing phenomenon 
caused by the stent struts. Several groups have remark the importance of adequate 
assessment of the distance between the aortic annulus and coronary ostia to avoid this 
dramatic complication, especially in cases with severe calcifies native valve. Predicting peri-
procedural myocardial infarction secondary to previous coronary disease would be much 
more difficult. Actually approved devices producers recommend the prophylaxis of this 
complication by coronary angiography and eventually percutaneous coronary intervention 
that should be performed at least 48 hours before TAVI. (Kapadia Sr et al,. 2009; Bagur R,. 
2010; Wood D et al,. 2009) 
Atriventricular block: 
Atrioventricular block and need for pacemaker implantation has shown to be related to a 
low positioning of the valve that leads to His bundle conduction system injury. Incidence 
of permanent pacemaker implantation requirements after trancatheter valve 
implantation may vary among registries, but it looks clear that is much more frequent 
after CoreValve implantation in comparison with the Sapien system (10-33% vs <7%. 
(Piazza N et al,. 2008; Grube E et al., 2008). This difference is explained by the design 
characteristics of the CoreValve: the bigger length of the prosthesis favours under-aortic 
annulus anchorage and the nitinol autoexpandable alloy determines an additive 
progressive expansion of the stent after the deployment, with the subsequent risk of 
electric conduction system injury. 
With such a high-risk of AV block, emphasis in the search for predictors that can anticipate the 
need for permanent pacemaker has been done. Jilahihawi et al recently reported the presence 
of previous left-bundle atrioventricular block, a ventricular septum bigger than 17mm or a 
non-coronary leaflet bigger than 8mm as a predictor for pacemaker requirement with a 75% 
sensibility and 100% specificity. (Jilahihawi H et al., 2009) Nevertheless, more studies with 
bigger sample sizes are needed before making definitive recommendations about prophylactic 
measures focused on avoiding this important, although rarely lethal, complication.  
Advances in the knowledge of the aetiology and pathophysiologic generation of the 
atrioventricular block with different transcatheter valves will help to optimize final results. 
Alternative septum membranous anchorage systems that facilitate implantation on the 
native annulus and reduction of the terminal outflow tract cross-section size should be the 
key for improving results.  
Renal failure and haemodialysis requirements:  
Aregger et al evaluated the incidence of renal failure in a 54 patients cohort of CoreValve or 
Sapien implantation (Aregger F et al., 2009). The majority of the patients achieved an 
improvement in the creatinine serum levels after the procedure, but renal failure reached a 
28% and 7,4% required haemodialysis during hospitalization. Bagur et al have recently 
reported a renal failure incidence of 11,7% after the Edwards Sapien device implantation, 
with a 4-fold in-hospital mortality increase (Bagur R et al., 2010). Curiously, in the same 
paper, incidence of acute renal failure among patients with previous chronic renal failure 
was lower in the group of TAVI than in the group of standard surgical valve replacement 
(9,2 vs 25,9%; haemodialysis requirements: 2,5 vs 8,7%). 
3.6 Evidence 
Degenerative aortic stenosis is a pathological process with stable prognosis and well known 
history for years, it can be considered as a “classical” heart disease and it has experimented 
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very few advances during the past decades. Surgical valve replacement has shown itself as 
an excellent therapy and no alternative has arisen until the development of transcatheter 
valve implantation, and it has started its journey as a marginal palliative alternative for non-
operable patients, so virtually no field for multicentre randomized double-blinded clinical 
trial that provide statistically reliable information that can guide evidence-based 
recommendations. Hence, the beginnings of transcatheter aortic valve implantation could be 
described at least as “complicated” and many difficulties have been overcome before 
achieving the minimal necessary strength before reaching the clinical trials era that now we 
are observing. 
After initial heroic implantations performed by Cribier, Grub, Bonhoeffer or Webb, first 
experience was evaluated in several observational multicentre studies like SOURCE, 
REVIVE, REVIVE II and REVIVAL (Kodali SK et al., 2011). This studies reported valuable 
information about feasibility and safety of the technique with promising clinical results, but 
clinical randomized trials are needed before extracting definite conclusions about the true 
clinical benefits of transcatheter aortic valve implantation.  
The SOURCE trial was a post-commercialization study in with the participation of 34 
european centres that included a total of 463 patients with severe symptomatic aortic 
stenosis who underwent transfemoral aortic valve implantation because of severe 
comorbidities that made standard surgical therapy contraindicated or too risky. Immediate 
success of the procedure was achieved in 95,6% and 30-days after procedure survival was 
93,7% in the whole cohort and 88,6% among patients who suffered vascular access 
complications. Other common complications reported were: pacemaker implantation (6,7%), 
aortic regurgitation > grade 2 (3,2%), device malaposition (1,7%) and coronary occlusion 
(0,7%). There was no device embolization event.(Wendler O et al., 2010; Thomas M et al., 
2010)  
After the initial results achieved during the first era and the spreading of the technique, 
major adverse cardiovascular events, in-hospital admittances, post-procedural functional 
class, complications, costs and quality of live are issues that must be contrasted no only 
against medical conservative therapy but also against conventional surgical treatment in this 
subset of high risk patients (but still considered operable). If clinical results still remain 
positive, long term follow-up and durability might be considered in order to extend clinical 
indication to lower risk profile patients. 
After these first promising results it seems to be reasonable to affirm that TAVI is a 
feasible alternative to standard surgery for very high-risk patients, that allows offering 
them better expectative of survival and quality of life than a conservative pharmacological 
strategy. 
In general, multicenter registries have included more than 2000 patients with an overall 
success over 90% and a 30-days mortality <10%, a definite step in order to confirm the 
feasibility, safety and efficacy of this technique as an alternative to surgical standard 
replacement in the subgroup of high-risk or prohibitive risk patients. At this point, direct 
comparison with surgical replacement does not look like a non-reachable objective, at least 
for the subgroup of patients in the frontier of the cardiopulmonary by-pass surgery 
indication (risk high enough to consider alternatives but not so much to be firmly rejected). 
This issue is the aim of the next generation of clinical trials involving TAVI. 
In this way, the PARTNER trial pretends to give the response to these questions that initial 
practice arose. During the first part of this trial, patients with a diagnose of severe 
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symptomatic aortic stenosis and rejected for surgery were randomly assigned into two 
groups: standard pharmacological conservative therapy or transcatheter aortic valve 
implantation. The results of this first step were reported in October 2010 and they showed a 
one-year mortality of 30,7% in the TAVI group vs 50,7% in the conservative therapy arm. 
Differences in hospital admission needs were as well statistically significant (42,5% in the 
TAVI group vs 71,6% in the conservative group) and a benefit in terms of functional class 
was observed too (NYHA class III/IV of 25,2% in TAVI group vs 58% in the 
pharmacological group), however, the incidence of stroke showed to be higher in the TAVI 
group (5% vs 1,1%) so they did vascular complications. (León MB et al., 2010) 
Second part of PARTNER trial is actually on course and will try to compare the results of 
severe symptomatic aortic stenosis patients with very-high risk surgical profile randomly 
assigned into a group of standard surgical valve replacement or TAVI. Clinical events are 
being collected and publications of the results are expected for this year. They probably will 
guide the final clinical recommendations in the management of this complicated subgroup 
of patients. 
Many individual and multicentre trials are on course at this moment trying to evaluate the 
efficiency of TAVI. As it is a novel technique in continuous evolution, European societies 
have recently published the guidelines to define the main endpoints that must be recorded 
in order to perform a conceptual standardization, that may serve as a reference for future 
comparisons among different studies and avoid possible biases.  
A medicine based clinical practice and the rational application of these novel techniques 
(doing the essential exhaustive screening in order to select the best candidates to gain 
clinical benefit) will balance the performing of these promising procedures with more or less 
demonstrated results and the enormous commercial pressure that these devices 
development and researching suffer. We cannot forget the international economic situation 
that we are witnessing at this moment and we must show ourselves with clinical common 
sense enough to ensure maximum efficiency. If this is not guaranteed, exaggerated expenses 
and bad clinical results might lead to fail in the introduction of promising innovations 
before they are really tested. 
As transcatheter aortic valve implantation techniques are spreading, newer indications for 
their use are extending with excellent initial results. That is the case of biological aortic 
prosthesis degeneration after conventional cardiac surgery. The anchoring of the 
transcatheter valve over the degenerated prosthesis seems to be quite safe and facilitate the 
treatment of patients that cannot undergo a surgical reintervention. We must wait until 
large series results to be reported before extract conclusions, but this is an obvious new field 
for the application of TAVI that can give response to an emerging problem as the population 
of developed countries keeps on aging.  
3.7 Mid and long term follow-up results 
There are relatively few data about mid and long-term follow-up results after transcatheter 
aortic valve implantation. The one-year survival after transfemoral implantation has 
reached 80% ore over in the most recent registries like SOURCE. It is interesting to remark 
the late publication in this sense of Webb et al where the majority of deaths that appear after 
30 days are demonstrated to be non-cardiac related. This fact underlines again the main 
importance of making a proper patient selection in order to achieve good long-term results. 
Canadian multicentre experience (Rodés-Cadau J et al., 2010), that included transfemoral 
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symptomatic aortic stenosis and rejected for surgery were randomly assigned into two 
groups: standard pharmacological conservative therapy or transcatheter aortic valve 
implantation. The results of this first step were reported in October 2010 and they showed a 
one-year mortality of 30,7% in the TAVI group vs 50,7% in the conservative therapy arm. 
Differences in hospital admission needs were as well statistically significant (42,5% in the 
TAVI group vs 71,6% in the conservative group) and a benefit in terms of functional class 
was observed too (NYHA class III/IV of 25,2% in TAVI group vs 58% in the 
pharmacological group), however, the incidence of stroke showed to be higher in the TAVI 
group (5% vs 1,1%) so they did vascular complications. (León MB et al., 2010) 
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being collected and publications of the results are expected for this year. They probably will 
guide the final clinical recommendations in the management of this complicated subgroup 
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have recently published the guidelines to define the main endpoints that must be recorded 
in order to perform a conceptual standardization, that may serve as a reference for future 
comparisons among different studies and avoid possible biases.  
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(doing the essential exhaustive screening in order to select the best candidates to gain 
clinical benefit) will balance the performing of these promising procedures with more or less 
demonstrated results and the enormous commercial pressure that these devices 
development and researching suffer. We cannot forget the international economic situation 
that we are witnessing at this moment and we must show ourselves with clinical common 
sense enough to ensure maximum efficiency. If this is not guaranteed, exaggerated expenses 
and bad clinical results might lead to fail in the introduction of promising innovations 
before they are really tested. 
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their use are extending with excellent initial results. That is the case of biological aortic 
prosthesis degeneration after conventional cardiac surgery. The anchoring of the 
transcatheter valve over the degenerated prosthesis seems to be quite safe and facilitate the 
treatment of patients that cannot undergo a surgical reintervention. We must wait until 
large series results to be reported before extract conclusions, but this is an obvious new field 
for the application of TAVI that can give response to an emerging problem as the population 
of developed countries keeps on aging.  
3.7 Mid and long term follow-up results 
There are relatively few data about mid and long-term follow-up results after transcatheter 
aortic valve implantation. The one-year survival after transfemoral implantation has 
reached 80% ore over in the most recent registries like SOURCE. It is interesting to remark 
the late publication in this sense of Webb et al where the majority of deaths that appear after 
30 days are demonstrated to be non-cardiac related. This fact underlines again the main 
importance of making a proper patient selection in order to achieve good long-term results. 
Canadian multicentre experience (Rodés-Cadau J et al., 2010), that included transfemoral 
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and transapical access, demonstrated that the presence of extra-cardiac comorbidities as 
renal failure or chronic obstructive pulmonary disease were two of the most importantly 
late mortality related factors. Finally, with the available data until date, no structural 
damage has been found yet in the mid-term follow up. 
Recent long-term results of a single centre have been reported with the transfemoral 
CoreValve system in 450 patients. Pre-procedure logistic EuroSCORE was over 20% in >90% 
of the cohort. Early in-hospital mortality has been decreasing during last two years until 
stabilization in 6%. Other in-hospital complications have decreased as well with the 
exemption of pacemaker requirements that stabilizes in 39%. Stroke appeared in 1,6% of the 
patients. One-year survival was 60% with the 25F device, 79% with the 21F and 84% with 
the 18F, remarking the critical importance that the design improvement holds.  
Transapical procedures have been related to one-year survival rates <80%, even in recent 
registries as SOURCE, probably due to higher risk basal characteristics of patients selected 
for this approach. Lichtenstein et al reported their initial experience in seven severe aortic 
stenosis patients that presented bad vascular access and severe comorbidities (Lichtenstein 
et al., 2006). Valve was implanted through a minimal thoracic incision and apex puncture 
without cardiopulmonary by-pass. There was no early mortality or valve dysfunction in this 
report. One year later, Walther et al reported their initial experience in a 30 patients cohort. 
Valve implantation was successfully implanted in 29 and one patient required cardiac 
surgery conversion with median sternotomy. After these reports, the possibility for an 
alternative access route when lack of vascular access is present was demonstrated. The same 
late author reported the experience of 4 centres that treated 59 patients with a mean 
EuroSCORE of 24±14% intended for Edwards–Sapien transcatheter heart valve 
implantation. Procedure was performed successfully in 53 patients when 4 patients required 
sternotomy and standard surgery conversion. Early in-hospital mortality was 13,6% and no 
prosthesis dysfunction was observed. (Walther T et al 2007) 
Out of Europe, four American centres also reported their initial experience with the first 40 
Edwards-Sapien implantation tries. The valve was successfully implanted in 35 patients. 30-
days mortality was 17,5% and in a 143 days follow-up 6 more patients died, so Kaplan-
Meier curves showed survival rates of 81,8±6,2% at one month, and 71,7±7,7% at 3 months. 
The PARTNER EU registry included 69 severe aortic stenosis patients with serious 
comorbidities, high-risk surgical profile (mean logistic EuroSCORE 33,8±14,7%) and poor 
vascular access. Technical device implantation success was achieved in 91%. 30-days 
mortality was 18,8%; stroke 2,9%, conversion to standard surgery 2,9% and permanent 
pacemaker 4,4%. On-year survival was 50% and an important improvement in functional 
class was recognized for the majority of patients. 
The largest cohort of transapical Edwards-Sapien implantation is the one in the SOURCE 
registry, with 575 patients. Mean logistic EuroSCORE was 29,2% and primary procedure 
success was reached in 92,8%. Conversion to standard surgery was reported in 3,5%, severe 
aortic regurgitation in 5,9an valve malaposition in 1,4%. 30-days mortality was 10,3%, stroke 
2,9% and permanent pacemaker implantation 7,3%. 
Medical industry has found in TAVI an open door for alternative treatment demands, so 
many companies are promoting research and developing of newer devices at this moment. 
Sadra Lotus, Direct Flow, Sorin Perceval, 3F Endurance Valve, LPI Repositionable, Lutter 
Valve, Heart Leaflet Technologies, Aortech and Artx valves may serve as an example. 
Summarizing, we are now witnessing the beginning of a new era in the development of 
therapies for patients affected of aortic stenosis. The rigorous selection of patients and the 
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rigorous obtaining of clinical data from trials and registries will determine the permanence 
and rising of this highly promising short of therapies. 
4. Sutureless biological aortic valve surgical replacement 
Clinical short and long term results of conventional aortic valve replacement have been 
clearly established along the last decades. At this moment, medical industry is developing a 
new short of biological aortic valve prosthesis that, despite the standard cardiopulmonary 
by-pass and aortic clamping need, they hold the advantage of a sutureless implantation 
system that leads to a faster surgery with less on-pump time with the evident benefits in 
terms of surgical risks. Interesting alternative application of sutureless valves is the redo 
surgery (re-interventions after prosthesis dysfunction). In this short of surgery, as it is 
always complex and risky, reducing aortic clamping time is essential, so these sutereless 
valves may offer an inestimable help by accelerating the valve insertion process. In case of 
biological dysfunctional prosthesis, sutereless valves allow a valve-in-valve implantation 
without the extraction of the previous dysfunctional valve. This procedure is performed by 
deployment of the sutureless valve within the pre-implanted valve stent-annulus, avoiding 
this way the risks involved in prosthesis removal (aortic root and annulus manipulation and 
prolonging clamping time). 
This kind of prosthesis generate very low hemodynamic gradient because they are 
constructed over a low profile metallic stent, with a similar structure to transcatheter-
deployable devices. This advantage improves valve hemodynamics and may contribute to 
ventricular mass regression.  
The commercial bid of this group of prosthesis is based on its capacity to reduce the 
aggression of standard surgery, favouring the realization of progressively less invasive 
surgical techniques (ministernotomy, minithoracotomy, robotic surgery…) and the adding 
value of its contribution on the researching and development of future transcatheter 
devices. 
Sorin´s Perceval and 3F´s Enable are the more promising models at this moment. The 
companies involved in the production of this prosthesis are those who may point the aim of 
this technique: development of newer transcatheter devices or really improve standard 
surgery results.(Shrestha M et al., 2009, Aymard T et al., 2010) 
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5. Apicoaortic conduits 
Surgical aortic valve replacement by median thoracotomy under cardiopulmonary bypass is, 
as mentioned above, the standard therapy for severe aortic stenosis that has proven 
superiority to conservative pharmacological therapy. Many times, however, this treatment 
cannot be performed because of different technical, anatomic or clinical problems that the 
patient may present, as it could be porcelain aorta or tiny aortic annulus. Aortic valve conduits, 
also known as apicoaortic conduits, are a short of devices designed in the sixties to give an 
alternative in these situations. Apicoaortic conduits connect the left ventricle apex with the 
descending thoracic aorta, relieving the intraventricular pressure by allowing the blood flow to 
find a way out of the heart without fighting against the aortic valve resistance. Because the 
operation was technically difficult, it had fallen into disuse, but, with the introduction of 
technically easier and less invasive procedures performed by minithoracotomy, this alternative 
offers clear advantages over standard valve replacement (avoidance of sternotomy, 
cardiopulmonary bypass, cardioplegic cardiac arrest, native valve debridement, conduction 
system injury, aortic cannulation, and aortic cross-clamping) and arises as another option in 
addition to transcatheter aortic valve implantation as alternative therapy for high risk patients. 
This technique offers the possibility to choose from a big variety of valve models and sizes, it  
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has proven long-term efficacy and durability, involves lower peri-procedural stroke risk and 
has no incremented AV block or paravalvular leak risks. As disadvantage, it commonly 
requires cardiopulmonary bypass pump, though some off-pump cases have been reported 
(Vassiliades TA Jr et al 2003; Hirota M et al;  Chahine JH et al., 2009)  
6. Conclusions 
As the developed countries population continues its progressive aging, number of patients 
grows as the majority of cases, with the subsequent increase in co-morbidities and risk profile 
worsening. In the other hand, technical improvements and innovation in newer devices design 
and performance make these alternatives more and more attractive. In this scenario, the data 
reported by big clinical trials as PARTNER may result in a deep revolution in degenerative 
aortic stenosis management, where minimal invasive procedures arise as the procedures of 
choice for this high-risk population. We must wait until definitive publications in this way 
before introducing any change in the clinical practice guidelines, but at this moment we can be 
quite confident about the fact these novel techniques “are here to stay” 
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